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Following both significant advances and setbacks in the past decades of fighting malaria, the end
goal of malaria elimination is now once again within sight. However, this endgame may prove the
most challenging yet, as there are still significant gaps in our understanding of human malaria more
generally and aswe know frompast experience that themalaria parasite is able to rapidly overcome any
challenge thrown at it. Despite the huge international endeavour to understand the genomic basis of
malaria biology, the genome sequences of two of the five humanmalaria parasite species, Plasmodium
malariae and P. ovale, have remained essentially a mystery. Consequently, the implications of these
sequences on aspects such as drug resistance have eludedus. However, even for humanmalaria parasite
species that have been sequenced at large scale, such as P. falciparum, a better understanding of the
impact of genetic variation on drug resistance is needed, especially in light of multidrug resistance in
Southeast Asia. In this thesis, I have, in collaboration with others, explored these different aspects of
human malaria parasites, showing to what extent sequencing data can inform our understanding of
human malaria and aid us in our fight against this devastating disease.
Initially I assembled reference genome sequences for both P. malariae and P. ovale, an analysis of
which I present in Chapter 1. I show that the P. malariae genome is markedly different to other Plas-
modium genomes and relate this to its unique biology. Using additional draft genome assemblies, I
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In Chapter 2, I use the newly assembled P. malariae reference genome in combination with clinical
data to characterize a case of clinical recrudescence of a P. malariae infection, and suggest that drug
resistance may have played a role. To better understand the ability of malaria parasites to acquire drug
resistance, inChapter 3 I harnessed a large dataset ofP. falciparumwhole genome sequenceswith asso-
ciated phenotype data onmefloquine, an antimalarial drug. I show that the current outbreak of mul-
tidrug resistance in Southeast Asia is accompanied by a hyper-sensitization of the parasite population
through the acquisition of a complex genetic architecture of mefloquine sensitivity. Finally, in Chap-
ter 4, by incorporating phenotype data on additional drugs, including chloroquine, artemisinin and
piperaquine, I identify a specific haplotype of the pfcrt gene that displays super-resistance to chloro-
quine and that acts as a genetic backbone to artemisinin resistance and to multidrug resistance in
general.
The approach taken in this thesis is one of extracting new information from layering on additional
data. I begin by comparing genome sequences to each other in Chapter 1, I then layer on clinical
metadata in Chapter 2, I add in phenotype data for one drug in Chapter 3, and finally, in Chapter 4,
I harness phenotype data for multiple drugs. At each level, I identify new biology that both expands
our understanding of human malaria in general and sheds light on the specifics of antimalarial drug
resistance. The contributions made in this work will be of significant importance in the upcoming
end game of malaria elimination.
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...and in summer dysenteries, diarrhoeas, and protracted
quartan fevers frequently seize them, and these diseases
when prolonged dispose such constitutions to dropsies, and
thus prove fatal.
Hippocrates, On Airs, Waters, and Places, 400 BCE
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An Introduction toMalaria
0.1 The Basics ofMalaria
0.1.1 Global Burden ofMalaria
Malaria is a life-threatening disease caused by intra-erythrocytic parasites of the Plasmodium genus.
According to the World Health Organisation (WHO), there were an estimated 216 million clinical
cases of malaria in 2016, resulting in almost half a million deaths368. While malaria is a disease that is
found globally (figure 1), with indigenous cases having been reported in 91 countries across multiple
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Figure 1: Global distribution of P. falciparummalaria in 2010. Figure adapted fromGething et al. 118 .
continents in 201616, the vast majority of these malaria cases (> 90%) occurred in Africa368. This
distribution also coincides with the number ofmalaria fatalities, with 91% ofmalaria fatalities in 2016
being estimated to have occurred on the African continent368.
At the outset of this thesis, there were five recognized species of Plasmodium parasites that infect
humans, including P. falciparum, P. vivax, P. malariae, P. ovale, and the zoonotic P. knowlesi. How-
ever, there had been suggestions that P. ovale may consist of two distinct species, P. o. wallikeri and
P. o. curtisi 339, which would imply the existence of six human-infective malaria parasite species. The
different species differ significantly in terms of their public health impact because of differing levels
of prevalence and disease severity. Subsequently, research efforts and resources have been unequally
distributed across these species, with some human-infective species, such as P. malariae and P. ovale,
having been largely neglected by the research community.
P. falciparum is by far the most well-studied human-infective species. It causes the majority of
malaria-related deaths and is consequently the prime subject ofmostmalaria research. P. falciparum is
found across all malaria-endemic regions (figure 1) and there were an estimated 207million cases of P.
falciparum-associated malaria in 2016368. Most of these P. falciparummalaria cases (>90%) occurred
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in sub-Saharan Africa, where malaria transmission remains very high16. The case fatality rate of P.
falciparum malaria is estimated at about 0.256%, which is about 7-times higher than the estimated
fatality rate of the second most important human-infective species, P. vivax (0.0375% case fatality
rate)368. This high fatality rate is due to the unique propensity of P. falciparum to cause infected red
blood cells to clump together with each other and evenwith uninfected red blood cells. These clumps
can then ‘sequester’ in the host’s microvasculature causing obstruction16. The most severe and fatal
cases ofmalaria are the result of this obstruction happening in the brain, known as cerebralmalaria361.
While P. vivax malaria is less fatal than P. falciparum malaria, it is the most important form of
malaria outside ofAfrica. Therewere an estimated 8.5million clinical cases ofP. vivaxmalaria globally
in 2016368. P. vivax is almost absent from most regions of Africa as the parasite requires the Duffy
antigen on the red blood cell surface for successful invasion, while the human population in Africa
mostly lacks the Duffy antigen220. Some recent studies however suggest that P. vivax may in rare
cases successfully invade Duffy negative individuals217. Outside Africa, P. vivax cases exceed those
of P. falciparum, especially in South America16. P. vivax is less deadly than P. falciparum368, but is
capable of forming a dormant liver stage, called a hypnozoite231. Dormant hypnozoites can result in
malaria relapses many months after the initial infection. This aspect of P. vivax malaria significantly
increases the morbidity associated with it11.
The most recently discovered human-infective species is P. knowlesi, a species that is usually re-
stricted to infectingmacaques. While macaques are the natural host of P. knowlesi, it can be transmit-
ted to humans as a zoonosis16. P. knowlesi has quite a restricted geographical range, as the macaques
it infects are limited to Malaysia. Initially, P. knowlesi infections were misdiagnosed as P. malariae
infections due to their morphological similarity325. P. knowlesi infections are frequently fatal if un-
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treated, as the parasite can propagate quickly within the host leading to high levels of parasitaemia and
consequently severe anaemia72. The case fatality rate of P. knowlesi is thought to be similar to that of
P. falciparum if the infection is not recognized quickly289. While the overall burden of P. knowlesi
infections is not well understood, it seems that infections with the species may be more common in
the Malaysian region than initially thought72,24.
The first Plasmodium species to be viewed under a microscope was P. malariae and was hence
named after the disease. It is widespread and is found throughout most malaria-endemic regions68.
While present in all these regions, P. malariae-associated malaria is relatively benign and is therefore
likely to be under-reported16. Many reported cases of P. malariae result from patients presenting
to the hospital with P. falciparum or P. vivax malaria and then discovering to be co-infected with
P. malariae298. P. malariae infections are however not completely benign, as they may occasionally
result in fatal renal complications178. Furthermore, P.malariae, even though it is not thought to pro-
duce hypnozoites, has the ability to cause recrudescencesmany years after the initial infection318. This
ability to remain hidden in the host for decades is not well understood, but can result in P. malariae
infections being a lifelong disability if not treated.
The final human-infective species is P. ovale, which may possibly consist of two morphologically
indistinguishable subspecies339. P. ovale is found throughout Africa and Asia, but it is conspicuously
absent in South America16. It is not known why P. ovale is not found in South America. Similar to
P. malariae, infections with P. ovale are relatively benign and the species is frequently only reported
in co-infections with P. falciparum and P. vivax 298. Similar to P. vivax, P. ovale forms dormant hyp-
nozoites and can result in malaria relapses years after initial infection67. The species is not well un-
derstood and has only recently been proposed to consist of two separate species, P. o. curtisi and P. o.
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wallikeri 339,250,10. Both of these have been shown to co-occur in the same region249 and even within
the same host110. There have been suggestions that P. o. curtisimay have longer relapse times than P.
o. wallikeri 244, but little else is known to distinguish the two biologically or clinically.
0.1.2 GeneralMalaria Biology
Plasmodiumparasites are eukaryotic organismsbelonging to thephylumofprotozoanparasites known
as theApicomplexa, therebybeing related toother infectious agents such asToxoplasmagondii, causing
toxoplasmosis, Babesia species, the agents of babesiosis, Cryptosporidium parvum, the parasite caus-
ing cryptosporidiosis, and many others292. The Apicomplexa are single-cellular organisms character-
ized by the presence of an invasion-related apical complex, consisting of numerous subcomponents
such as rhoptries andmicronemes189. Another distinguishing feature ofmost species ofApicomplexa,
including the Plasmodium species, is the presence of a unique organelle termed the apicoplast214,
thought to have originated from an ancestral event of secondary endosymbiosis of a red algae resem-
blingChromera196. AllApicomplexa have complex lifecycles, involving several stages ofmultiplication
and changes between haploid and diploid states189, however the Plasmodium lifecycle is particularly
complex due to the obligate need for both a host and a vector to complete its full lifecycle.
Human-infective Plasmodium species rely on both the human host and on a mosquito vector to
complete their lifecycle (figure 2). Species of Plasmodium parasites vary in the specific mosquito
species that are able to transmit them33. Themost commonhumanmalaria vector species aremosquitoes
belonging to the Anopheles gambiae species complex, however over 50 species have been identified as
competent humanmalaria vectors136. When an infectedmosquitobites a human to take a bloodmeal,
hundreds of sporozoites, a haploid and motile stage of the malaria parasite, are injected through the
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mosquito saliva into the human skin285 (figure 2). Upon entering the blood stream, the sporozoites
migrate to the human liver, where they infect hepatocytes and are virtually invisible to the immune
system345. For two days to three weeks following liver infection, a process of rapid asexual multiplica-
tion termed merogony occurs within the infected hepatocytes79. Each of these infected hepatocytes,
now termed a schizont, results in the generation of hundreds-to-thousands of infectivemerozoites285.
In most human-infective malaria parasite species, upon completion of merogony all the infected hep-
atocytes release the merozoites into the bloodstream by budding off vesicles known as merosomes335
(figure 2). Two species of human-infective malaria parasite species, P. vivax and P. ovale, may result
in the formation of a dormant liver stage, termed a hypnozoite175. Hypnozoites can persist for years
within the host and often result in relapses long after the initial infection has been cleared317,210. The
process by which hypnozoites are reactivated is not fully understood210,312, however the result is that
the merozoites within the hypnozoite are released into the bloodstream and thereby restart a blood-
stage infection.
The merozoites that are released into the bloodstream now attempt to invade host erythrocytes
(figure 2). The process by which the merozoites identify and ultimately invade the fast-flowing target
erythrocytes, all the while surviving in a highly hostile environment, is rapid, completed in under a
minute363. Merozoites initially attach to erythrocytes using merozoite surface proteins (MSPs), such
asMSP-171 (figure 3). The parasites thenmakes use of two classes of adhesins, Duffy binding proteins
(DBPs)137 and reticulocyte binding proteins (RBPs, known as Rh proteins in P. falciparum)113. The
adhesins bind to specific host proteins, such as glycophorins48,207,212 in the case of DBPs, and their
differential distribution across species has been suggested to contribute in part to the cell specificity of
the different species113,225, withP. falciparum, P. knowlesi andP.malariae invading normocytes (ma-
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Figure 2: Plasmodium lifecycle overview. Figure reproduced fromMueller et al. 231 .
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Figure 3: Overview of erythrocyte-invasion steps. Figure reproduced fromCowman et al. 71 .
ture erythrocytes) and with P. vivax and P. ovale preferring reticulocytes (young nucleated erythro-
cytes)155,225. Most adhesins are thought to be dispensable individually, however the overall function
they perform is essential to invasion202. In particular, oneRBP inP. falciparum, PfRh5, is essential to
invasion through its binding to humanbasigin74. The PfRh5protein is thought to be tethered as a tri-
partite complex of PfRh5withPfRIPRandCyRPAto theGPI-anchoredPf113360,111, where engage-
ment of the complex with basigin would initiate pore formation between the parasite and erythocyte
membranes363. This essential role played by PfRh5 has therefore made it a prime vaccine target273.
Upon pore formation, a tight junction is formed between apical membrane antigen 1 (AMA1) on the
parasite surface and theRONcomplex that the parasite inserts into the erythrocytemembrane347 (fig-
ure 3). The parasite then utilizes this anchoring to propel itself into the erythrocyte, losing its surface
proteins on the way, and finally sealing the vacuole behind, producing the parasitophorous vacuole
that the parasite resides in intra-erythrocytically71.
Upon completion of invasion, the parasite begins another process of asexual replication within the
red blood cell, known as schizogony. This particular asexual replication cycle lasts approximately 48
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hours inmost species, howeverP.malariae takes 72 hours andP. knowlesi takes only 24 hours to com-
plete it. The cycle is often split into three phases that are morphologically and metabolically distinct:
the ring stage, the trophozoite stage, and the schizont stage (figure 2). The ring-stage, named so by its
appearance when Giemsa-stained, is the initial stage following invasion. The parasite begins feeding
on the erythrocyte’s haemoglobin, catabolising it into a haemderivative (ferriprotoporphyrin IX) that
is then converted into inert haemozoin crystals23. As the parasite grows within the red blood cell, it
eventually morphs into a trophozoite with amore rounded shape, an increased number of ribosomes,
and an enlarged rough endoplasmic reticulum, allowing for increased protein synthesis23. As the par-
asite ramps up its protein production, it eventually undergoes multiple nuclear division, schizogony,
producing between 6 and 32 merozoites that take up most of the intra-erythrocytic space91. The
number of merozoites that a schizont harbours varies by species, with P. malariae and P. ovale gen-
erally having fewer than P. falciparum, which in turn produces fewer merozoites per schizont than
P. vivax (Centre for Disease Control, US). Finally, these newly formed merozoites egress from the
red blood cell through a protease degradation of the parasitophorous vacuole and erythrocyte mem-
brane35. As they egress, the merozoites search for new red blood cells to infect, thereby restarting the
intra-erythrocytic cycle120.
Throughout the intra-erythrocytic cycle, the parasite exports a number of proteins to the red blood
cell surface in order to avoid the host immune system, modifying the morphology of the erythrocyte
in the process78. The malaria parasite has two main methods in which it alters the red blood cell to
avoid detection by the immune system122. Firstly, malaria parasite species express highly variable anti-
genic proteins that may enable long-lasting infections by preventing a unilateral immune response
against any specific surface protein98,306. Using these antigenic proteins to direct the immune re-
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sponse against a subset of infected red blood cells is thought to keep the parasite population from
killing the host, thereby enabling the establishment of a chronic infection102. Secondly, certain pro-
teins that are transported to the erythrocyte membrane are involved in either binding to other red
blood cells247, resulting in a process called rosettingwheremultiple infected and uninfected red blood
cells clump together140, or in binding to the vascular endothelium, enabling the infected red blood
cell to sequester in the microvasculature, thereby avoiding clearance by the spleen270.
It is this intra-erythrocytic cycle that results in the clinical disease symptoms of malaria. The usu-
ally synchronised egress of merozoites from the infected red blood cells results in a strong immune
response that presents itself as a high fever (usually referred to as a paroxysm), leading to the character-
istic tertian fever (every three days for most human malaria species) or quartan fever (every four days
forP.malariae) that is often used to initially diagnose the disease114. P. knowlesi produces a quotidian
fever due to its shorter lifecycle. The continuous feeding on red blood cells can lead to severe anemia
in chronic infections130, as well as splenomegaly from the spleen removing all the infected red blood
cells45. Severe malaria cases involve malaria parasites sequestering in the brain, referred to as cerebral
malaria, which is fatal in almost 20% of cases232. Similarly, malaria infections during pregnancy can
result in parasites sequestering in the placenta, resulting inmiscarriages, low birth weights, andmater-
nal anemia226. The latter two complications are restricted toP. falciparum infections and, whilemost
malaria deaths are due to severe anemia232, they do contribute in part to the highmortality associated
with this species16.
While most infected red blood cells will develop into schizonts that release merozoites to continue
the blood infection, a certain proportion of infected erythrocytes develop into the sexual stage of
the malaria parasite, a process termed gametocytogenesis159 (figure 2). Infected red blood cells that
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undergo gametocytogenesis develop into either male or female gametocytes, known as micro- and
macrogametocytes respectively. The rate of commitment, ie. the proportion of infected red blood
cells that develop into sexual stages, is not fully understood80,2, but certain environmental stressors
such as anemia or drug treatment are known to contribute to higher levels of commitment53. While
most human-infectivemalaria parasite species complete gametocytogenesis within 2 days and produce
round gametocytes, P. falciparum takes a lengthy 10-12 days to complete the process159 and produces
sickle shaped gametocytes (from which the species derives its name).
As a mosquito feeds on an infected host, it may ingest by chance both a male and a female ga-
metocyte as part of its blood meal (figure 2). The change in environment from human blood to
mosquito mid-gut, ie. change in temperature, pH and exposure to xanthurenic acid, causes the ga-
metocytes to mature to gametes34. These haploid gametes then fuse into a diploid ookinete with
meiotic recombination occurring in the process324. Ookinetes traverse the epithelial mid-gut wall to
form oocysts159. Within each oocyst, thousands of sporozoites develop that eventually egress and
travel to the mosquito’s salivary glands via the haemocoel296. The sporozoites remain in the salivary
glands until themosquito takes a new bloodmeal, at which point the sporozoites are injected into the
host to restart a malaria infection324.
0.1.3 GlobalMalaria Eradication Program
Malaria has afflicted humans for thousands of years, andwhile humans fought back against the disease
on a genetic level by developing resistance mutations164, such as that resulting in sickle cell anemia4,
it was in the early 20th century that humankind put up a real fight to eliminate the disease. Malaria
was long known to be common around marshes, with ‘bad air’ (latin: mal-aria) being thought of
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Figure 4: Changes in global malaria endemicity from themid-19th century to the 21st century. The change in endemicity
from ’Before 1946’ to ’1967’ can largely be attributed to the GMEP. Figure reproduced fromKamini et al. 162 .
as the cause of the disease. As the mechanisms of the disease, such as transmission via mosquitoes,
were finally discovered at the turn of the 20th century, control methods including draining marshes,
deploying bed nets and the use of the antimalarial drug quinine led to the elimination ofmalaria from
a number of regions, mostly parts of North America and Europe162 (figure 4). Heartened by success-
ful elimination efforts in a number of countries, together with the advent of the first residual insecti-
cide, dichloro-diphenyl-trichloroethane (DDT), and the synthesis of the highly effective antimalarial
drug, chloroquine, theWHOwas given the mandate in 1955 to direct a global campaign to eradicate
malaria: the Global Malaria Eradication Program (GMEP)237.
The GMEP was a highly ambitious project that aimed for the complete eradication of malaria
within a decade. Based on positive experiences of malaria elimination in a limited number of epi-
demiological settings, the GMEP was based on the concept of complete coverage of in-door residual
spraying (IRS) ofDDT to disrupt transmission101. This complete coverage ofDDTwas advocated at
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the expense of other traditional control interventions, such asmarsh draining and bed nets237. Signif-
icant inroads were initially made, for instance by eradicating malaria from Europe and North Amer-
ica, as well as by significantly reducing the incidence in certain countries such as India (figure 4). In
1963 however, funding for the program began to diminish as the US stopped contributing, resulting
in available resources becoming stretched. The progress of the GMEP began to stall, and, around
1967, certain countries reverted from the post-elimination ‘consolidation phase’ back to the on-going
transmission ‘attack phase’. For example, Sri Lanka (then known as Ceylon) had virtually eliminated
malaria by 1963 leading them to halt their IRS of DDT, which in turn led to a strong resurgence
of malaria in the following years, culminating in large epidemics in 1968 and 1969165. These local
setbacks were exacerbated by the emergence of mosquitoes with resistance to DDT in a number of re-
gions, as well as the discovery of the negative environmental impact of DDT spraying. In addition to
this, the single-minded focus on reducing transmission by usingDDTmeant that the appearance ofP.
falciparum parasites that exhibited chloroquine resistance in pockets of Southeast Asia and in South
America in the 1950’s was not given the attention it deserved237. By the end of the 1960’s, chloro-
quine resistance had spread throughout those regions, eventually reaching East Africa in the 1970’s
and the rest of Africa by the mid 1980’s272. In light of all of these setbacks, and despite the initial
successes of the GMEP, the program was abandoned in 1969 as it became apparent that eradication
was not possible any more.
0.1.4 Current Progress
The abandonment of the GMEP in 1969 is often said to have succeeded in eradicating, instead of
malaria, the job prospects of any aspiring malariologists at the time, as malaria research was largely
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neglected for many years after the campaign was called off237. The WHO recommended a switch to
control efforts in order tomaintain the gains that were made during the GMEP, resulting in resources
being unevenly distributed with a disproportionate amount being designated for regions with very
low levels of malaria. With this approach, almost no gains were made in further reducing the global
limits ofmalaria until a shift in policywith the launch of theRoll BackMalaria (RBM)movement135.
The RBM campaign, launched in 1998, aimed to halve malaria mortality, morbidity, and economic
burden of the disease by 2010235. As opposed to the control efforts that preceded it, the RBMmove-
ment focused resources on areas that were highly endemic for malaria135. The movement was able to
make significant inroads328, and over time additional funding partners joined the effort, such as the
Bill and Melinda Gates foundation. The RBM partnership has now published their current goal of
eliminatingmalaria by 2030 as part of the Action and Investment to defeatMalaria 2016-2030 (AIM)
plan (www.rollbackmalaria.com). This plan of eliminating malaria by 2030 is reminiscent of the am-
bitious aims of the GMEP, and it is on that backdrop that current elimination efforts are taking place.
Over the last two decades, the RBM movement has resulted in almost halving the number of
malaria-associated deaths62,123, and the number of countries that are endemic to malaria have also
continued to decrease over the years (figures 5 & 6)368. This reduction in malaria deaths and preva-
lence can largely be attributed to the use of insecticide-treated bednets (ITN), in-door residual spray-
ing (IRS), and the use of artemisinin-based antimalarial drugs32. However, the WHO has recently
stated in its 2017 World Malaria Report that ‘Progress appears to have stalled.’ and that ‘...in some
countries and regions, we are beginning to see reversals in the gains achieved.’368. While this has to do
with both a stalling in increasing ITNcoverage and a reduction in IRS368, insecticide and antimalarial
drug resistance also play a role and threaten the progress made to date. Pyrethroid-resistance in the
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Figure 5: Overview of changes in malaria endemicity by country in 2016. Figure reproduced from theWHOWorld
Malaria Report 2017 368.
mosquito vector is now widespread and at high frequency throughout most of the malaria-endemic
regions of the African continent, which is coincidentely also where ITNs and IRS are the primary
public health interventions138. While effective alternatives such as piperonyl butoxide (PBO) treated
bednets exist284, they are very slow to be deployed at scale167.
While insecticide-resistance is already harming progress and potentially leading to increased cases
of malaria, the threat of antimalarial drug resistance also looms on the horizon. The front-line anti-
malarial drug treatment for the last two decades has been artemisinin combination therapies (ACTs),
deployed across all malaria-endemic regions for the treatment ofP. falciparummalaria368, while other
drugs such as chloroquine are occasionally still used for non-falciparummalaria378. Due to the short-
acting half-life of artemisinin, it is usually administered with a long-acting partner drug such as piper-
aquine or mefloquine, with the intent of slowing down the acquisition and spread of resistance to
the drugs134. This is based on the idea that the parasites that are able to survive the short-acting
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Figure 6: Global distribution of antimalarial drug resistance in P. falciparum (top and bottom-right), as well as change in
the number of cases and deaths attributed to P. falciparum from 2010 to 2015 (bottom-left) . Figure reproduced from
Ashley et al. 16 .
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artemisinin, either by being resistant or by being in a lifecycle stage that is unaffected by the drug,
would subsequently be cleared by the longer-acting partner drug302. Despite these precautions, par-
asite resistance to artemisinin was first reported in 2008 in Western Cambodia243 and has subse-
quently been observed throughout the Southeast Asian region84,15,351 (figure 6). The slow-clearing
artemisinin-resistant parasites were initially still cleared by the partner drug, which is piperaquine in
these particular countries, however in recent years these resistant parasites appear to also have acquired
resistance to piperaquine, leading to cases of complete treatment failure185,187. The threat that now
overshadows current control efforts is the possibility of these multidrug resistant parasites spreading
to Africa, where most malaria cases occur but no resistance to artemisinin has yet to be reported374.
The current situation is in many ways analogous to that of chloroquine resistance during the time
of the GMEP, where tragically chloroquine resistance ended up spreading from Southeast Asia to
Africa, leading to innumerous deaths. We are, as the WHO says368, ‘at a crossroads’. With compla-
cency and a reduction in funding, a reenactment of the failed GMEP may be on the cards, however
with continued effort by all stakeholders involved, we may learn from history and avoid losing the
ground that we have gained. Many things are different now to the way they were in the 1960’s, as our
understanding of malaria has increased tremendously. We also have one very special new tool in our
toolkit, the topic of which this thesis is about, namely genomics.
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0.2 Malaria Genomics Introduction
0.2.1 The Road to SequencingMalaria Parasites
Sequencing technologies have advanced at a rapid pace over the last two decades and there have been a
number of breakthroughs that have transformed our ability to characterize malaria parasites on a ge-
nomic level that have led up to this. An important development early on in enabling genetic studies of
Plasmodium parasites was the adaptation of P. falciparum to continuous in vitro culture348, opening
up an endless supply of parasites to experiment on. The ability of P. falciparum to infect normocytes
enabled this culturing and is what has prevented, for instance, P. vivax from being cultured, as it is
restricted to reticulocytes, which are difficult to obtain in the lab313. Recently, P. knowlesi has been
successfully adapted to continuous in vitro culture224 and is now often used as a proxy for P. vivax
as they are more closely related to each other than to P. falciparum97. Attempts to culture either P.
ovale and P. malariae have until now been unsuccessful67,68.
For species that cannot be cultured in vitro, such as P. vivax, as well as to study clinical samples or
understand local population structure, advances have been made in collecting and preparing samples
for sequencing directly from the field. The main limitation had previously been the low amount of
parasite DNA that can be extracted from a sample compared to the high abundance of host (ie. hu-
man) DNA. Indeed, within a whole blood sample from a patient with a 1% parasitaemia, there will
be roughly 10 times more parasites than white blood cells (WBC) but due to the human genome be-
ing 300 times larger than the parasite genome, only approximately 5% of the DNA material will be
of parasite origin21. To circumvent this problem, protocols have been developed to deplete WBC21
from samples or to enzymatically degrade the host DNA262. Another obstacle has been the low yield
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ofDNA from field samples, especially for the samples with low parasitaemia levels. PCR-based whole
genome amplification (WGA) protocols, some especially designed for the low-GC biased P. falci-
parum genome, are now commonly used to amplify the amount of DNA in those samples264,263.
Furthermore, both problems of lowDNAyield and high abundance of host DNAhave recently been
tackled using a unifiedmethod called selectivewhole genome amplification (sWGA),whichmakes use
of specially designed primers that bind to sequence motifs that are significantly enriched in the para-
site genome compared to the host genome188. These different advancements nowmake it possible to
perform whole genome sequencing of malaria parasites directly from dried blood spots (DBS)261.
The advances in preparing the parasite DNA for sequencing have been complemented by the rapid
advances in sequencing technologies over the last twodecades. Thefirst typeof sequencing technology
to be widely used for Plasmodium sequencing was capillary-based ‘Sanger’ sequencing, an expensive
technology that produced long sequencing reads of up to 1kb (kilobase) in length and had a very low
rate of sequencing errors305. Sanger sequencing was used for many of the original reference genome
sequencing projects, including among others the human genome153, the P. falciparum genome115,
and the Anopheles gambiae genome144. While the technology has fallen out of favour in recent years
due to the high costs associated with it, it is still sometimes used for confirmation of highly polymor-
phic regions due to its low error rate.
In the mid 2000’s, massively-parallel ‘next generation’ sequencing (NGS) technologies were devel-
oped that had shorter reads but significantly higher throughput at a much lower cost than Sanger
sequencing, with innovators in the area including Solexa (acquired by Illumina)28, 454 (acquired by
Roche)88, and SOLiD sequencing by Life technologies316. The fierce competition in the area drove
innovation and sequencing costs dropped by four orders ofmagnitude between 2007 and 2012314. Il-
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lumina now dominates themarket for short-read sequencingwith a range of different sequencingma-
chines. These short-read sequencers produce sequencing reads of up to 300bp (base pairs) in length.
The short reads have proven very useful in aligning themback to reference genome sequences to study
genetic variation (see below), however using them to perform de novo genome assemblies has proven
challenging315.
The original Sanger sequencing reads enabled genome sequences to be assembled via an ‘overlap-
layout-consensus’ method, using greedy assembly softwares such as the TIGR assembler340 or the
Celera CAP3146, a method which required an all-against-all pairwise similarity check comparison be-
tween all the input reads. These methods therefore scaled exponentially with the number of input
reads, causing data storage and run-time memory requirement problems with the huge volume of
short reads coming from the NGS sequencers. This meant that new approaches had to be developed
to handle this huge volume of data, a problem for which there is no efficient solution233. Graph-
based assembly tools formalize the problem by treating reads as strings and then attempting to find
the minimal superstring that contains all the strings using the concept of a string-graph234. Many
assemblers utilizing a string graph prune the graph for spurious connections to speed up the assem-
bly process, but still tend to scale suboptimally with the volume of read input. An innovation was
the development of a method similar to a string-graph, but based on k-mers (read fragments of size
k) that are connected in a so-called de Bruijn graph. This k-mer based approach is able to scale well
with the volume of input reads, as identical k-mers are collapsed into a single node in the de Bruijn
graph278. Assemblers employing a k-mer-based approach include among others Velvet379, ABySS323
and SOAP-denovo206. Hybrid assemblers utilizing a combination of these approaches also exist, such
as the MaSuRCA assembler383. By fragmenting the reads, k-mer based approaches have difficulties
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handling repetitive regions. These difficult regions can frequently be overcome using paired end (PE)
sequencing, where two reads originate from the same original sequencing template with a certain gap
(known as the fragment size) between them. Standalone software, such as SSPACE37, is able to use
these paired reads to ‘scaffold’ assembly gaps caused by repetitive regions, thoughmost assemblers also
have in-built scaffolding processes.
In addition to the short-read sequencers by Illumina, in recent years a number of long-read sequenc-
ing machines have been developed by companies such as Pacific Biosciences (PacBio)95and Oxford
Nanopore Technologies (ONT)183. The former is based on optical reading of polymerase-mediated
synthesis in real time using fluorescently labelled nucleotides95, while the latter utilizes the flow of
ions that a DNAmolecule emits when it moves through a nanometre-scale pore in order to infer the
nucleotide sequence183. Hence, both technologies do not require template amplification, leading to
the generation of large sequencing reads often exceeding 10kb in length, with some reads from the
ONT almost reaching 1Mb (megabase)156. While the throughput for both technologies is still below
that of the high-throughput Illumina sequencers, they are making rapid progress314. Both technolo-
gies are also known to have high rates of sequencing errors (>10%), which are fortunately randomly
distributed in PacBio (and can therefore be corrected forwith sufficient coverage), butmay be for now
more systematic for ONT314. On the other hand, the ONT sequencer, known as the minION, has
the added advantage of being extremely portable, being the size of a USB stick, which has made it an
extremely valuable tool for sequencing samples in the field141. The long reads generated by these se-
quencing technologies are uniquely useful for performing de novo genome assemblies as they are able
to span large homopolymer tracks and other repetitive regions279. With the reduction in throughput
and increased read length, specialised long-read assemblers are often based on string-graphs, including
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HGAP59 or HINGE160 for example, though k-mer-based approaches also exist, such as CANU172.
Finally, hybrid assemblers that can use short reads and long reads together have also recently been
developed, with examples including HySA100 and the updatedMaSuRCA assembler384.
0.2.2 P. falciparum Genome Sequencing
In1996, a consortiumof genomecentres and funderswas established to sequence the complete genome
sequence of P. falciparum142. This multi-year project eventually completed in 2002 with a slew of
publications117,41,132,116,148 describing the 23Mb genome sequence of P. falciparum clone 3D7115.
The extremely low GC content of the genome sequence (<20% GC) caused both experimental and
computational difficulties, such as DNA fragments not being stable in Escherichia coli and large AT
repeats causing difficulties in the assembly process142. While the first version of the P. falciparum
reference genomewas published in 2002, there has been continuousmaintenance and curation of the
genome sequence and annotation by the Wellcome Sanger Institute in the UK, with the current ver-
sion, 3.1 (released in August 2015), having added the 35kb apicoplast genome sequence for instance.
The 3D7 reference genome sequence together with the curated annotation is publicly available and
searchable through GeneDB (www.genedb.org) and PlasmoDB (www.plasmodb.org).
The≈23.3MbP. falciparum 3D7 reference genome sequence consists of 15 contigs,making up the
14 chromosomes and the apicoplast genome sequence, but missing the correspondingmitochondrial
genome sequence115. The current assembly is of very high quality, with no sequencing gaps and with
the chromosome sequences extending from telomere to telomere. The chromosomes range in size
from chromosome 1 (≈0.64Mb) to chromosome 14 (≈3.29Mb)115. The overall AT content of the
genome is extremely high with 82% AT, though this is unevenly distributed with higher levels in the
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‘core’ region of the genome and lower levels in the ‘subtelomeric’ regions where the percentage of GC
is higher. This uneven distribution of GC content in P. falciparum is predominantly due to the high
GC content of the subtelomeric var genes. Exactly defining where the subtelomeric regions end and
where the core begins has remained debatable, but recent work using multiple long-read assemblies
has attempted to resolve this using gene orthologies255. The current 3D7 genome annotation lists
5,432 genes, with 36% (1,964/5,432) of them being annotated as unknown function, reflecting the
amount ofPlasmodium specific biology thatwe still do not fully understand. However, this compares
with 60% of genes having unknown function upon the initial publication of the genome in 200285,
showing to an extent the progress that has beenmade in understandingPlasmodium genetics over the
last 15 years.
0.2.3 Sequencing Other Plasmodium Species
While P. falciparum was the first human malaria parasite species to be sequenced, P. vivax and P.
knowlesi have also had reference genome sequences assembled and annotated for themover time51,266.
The firstP. vivax reference genome sequencewas published in 2008, originating from a strain (termed
Sal1) isolated in 1972 from a patient in El Salvador51. While a breakthrough at the time, the P. vi-
vax Sal1 reference genome sequence was less contiguous than the P. falciparum 3D7 genome, with
thousands of contigs that could not be assigned to chromosomes and with the 14 core chromosome
regions being split across 30 contigs51,20. Additionally, the gene annotation of the SAL1 genome was
notmanually curated by the original authors and therefore over time began to lag in accuracy to other
curated Plasmodium reference genomes. It was in 2016, that a new P. vivax reference genome was
published (PvP01) which managed to consolidate the 14 chromosomes to 14 contigs, reduced the
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amount of unassigned contigs to 226, and brought the gene annotation up to date with the other
reference genome sequences20. The P. vivax PvP01 assembly spans 29Mb of sequence and has a GC
content of 39.8%, which is significantly higher than P. falciparum. P. vivax also exhibits an uneven
GC content between the core and the subtelomeres, though in P. vivax this does not appear to be
linked to a particular gene family. Conversely to P. falciparum, P. vivax has a higher level of AT in the
subtelomeres and a lower level in the core regions of the chromosomes51, referred to as an ‘isochore’
structure. The subtelomeres in P. vivax are much larger than those in P. falciparum and mostly ac-
count for the difference in genome size between the two assemblies (29.0Mb vs. 23.3Mb)20. Due to
the larger genome size, the P. vivax PvP01 assembly with 6,642 genes has many more genes than the
P. falciparum 3D7 reference. Most of these additional genes are located in the subtelomeric regions
of the PvP01 reference and belong to large multigene families. While there are major differences in
the structure and gene content of the subtelomeric regions, the core regions of the P. vivax genome
share a large amount of synteny with those in P. falciparum, with most core genes being positionally
conserved51.
Shortly after the publication of the P. vivax Sal1 reference genome, the genome sequence of the
zoonotic P. knowlesi was published266. The 23.5Mb genome of P. knowlesiH strain was slightly less
discontiguous than the originalP. vivax Sal1 assembly, but still consisted of 715 contigs, 511 of which
couldn’t be assigned to any of the 14 chromosomes266. With 5,188 genes, P. knowlesi has fewer genes
than either P. falciparum and P. vivax. The P. knowlesi genome also differs from the latter two by
having multiple intrachromosomal regions with high GC content that contain tandemly repeating
telomeric sequences (heptad sequence GGGTT[T/C]A)266. Besides these species-specific regions,
much of the P. knowlesi genome was again highly syntenic to the other sequenced human malaria
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parasite species266. Very recently, an updated P. knowlesi genome was published using PacBio long
reads, reducing the number of contigs down to 28180.
Up until the beginning of this project, neither the genomes of P. malariae nor P. ovale had been
sequenced, leaving the number of sequenced human malaria parasite species at three out of five. In
2016 however, draft genomes for both species (including the two P. ovale subspecies) were published
by Ansari et al. 10 . An analysis of these draft genomes is presented in Chapter 1. Finally, besides the
human-infectivePlasmodium species, a number of genome sequences have beenpublished for rodent-
infective, primate-infective, and avian-infective species.
Rodent-infective malaria parasite species have long been used experimentally as models of human
malaria, with a number of these species having been adapted to passaging through laboratory mice73.
Around the same time as the completion of the P. falciparum genome project, the complete genome
of the rodent-infectiveP. yoeliiwas published52. Other rodentmalaria genome sequences followed for
P. berghei and P. chabaudi 131, with improved versions published in 2014256. All these rodent malaria
genomes are small in size, with many below 20Mb, and have GC contents of≈30%256. The genomes
are extremely collinear in the core regions and nucleotide-sequence identity between the genomes is
very high at≈90%171.
Other primate-infective Plasmodium species have been sequenced in order to get a better under-
standing of the evolutionary history of humanmalaria parasites and to see how the latter have adapted
specifically to infect humans. The first primate-infective species to be sequenced was P. cynomolgi,
which infects simian monkeys, and which appears to resemble P. vivax closely both phenotypically
and genetically341. Following this, the chimpanzee-infective P. reichenowi was sequenced259. Due to
being very similar morphologically, it was long thought that P. reichenowi was the closest extant rel-
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ative to P. falciparum, which was supported by the genome sequences of the two species being more
alike each other than to any other sequenced Plasmodium species, forming the so-called ‘Laverania’
subgenus . Recently however, genome sequences for a number of Plasmodium species in the Lavera-
nia subgenus have been published, shedding light on the Plasmodium phylogeny (see below)258, con-
cluding thatP. falciparum likely originated froma gorilla-infective species calledP. praefalciparum200.
The genome sequences of theseLaverania species resemble that ofP. falciparum in terms of gene con-
tent and structure258, clearly distinguishing them from the species in the P. vivax clade, as well as the
rodent malaria parasites.
0.2.4 Population Genomics ofMalaria
As the cost of sequencing continued dropping and sample collection methodologies improved, the
number ofmalaria parasite whole-genome sequences kept increasing rapidly, enabling the study of ge-
netic variation across time and space. This enables for instance the identification of gene flowbetween
populations, tracking of changes in parasite population due to control interventions, and pinpointing
of drug resistance mutations when they emerge. The first study to look at multiple different P. falci-
parum genome sequences examined 16 samples359, in 2012 a study looked at 227 samples209, while
the current Pf3k dataset, an international collaboration to sequenceP. falciparum samples fromacross
the globe, includes 2512 P. falciparumwhole-genome sequences (www.malariagen.net). For P. vivax,
the first study to look at multiple whole genome sequences was only published in 2012 and looked at
four sequences239, while more recent studies have included hundreds of samples147,274. Finally, even
for the less studied P. knowlesi, multiple whole genome sequences have been analysed281.
In order to analyse these large datasets, software and numerous specialised methodologies have
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been developed. The initial step is to map all samples against a reference genome sequence, thereby
producing an alignment of the sample reads to the reference genome, ie. determining which region of
the genome each sequencing read corresponds to. Most mapping software is based on either hashing
algorithms, such as MAQ193 and Stampy205, or on the so-called ‘Burrows-Wheeler transform’ data
compression algorithm242, including Bowtie179 or BWA191. When running these tools, parameters
are set to determine the leniency with which the reads are mapped, ie. how different the read can be
from the reference sequence whilst still being aligned. The mapping software then provides metrics
such as the proportion of reads that mapped and whether they were properly paired (in case of paired
sequences), which can be used as metric for the quality of the sample and sequencing data. The type
of information that can be garnered from viewing aligned reads includes getting an idea about the
general coverage of the genome, ie. whether all the regions of the genome are covered andwhether the
coverage is evenly distributed, and also highlights the general level of similarity of the sample and the
reference genome by pinpointing discrepancies between the sequences such as sample contamination
or SNPs (figure 7). Sample reads that do not map to the reference genome can also be of interest
depending on the reason they didn’tmap, such as in cases of highly polymorphic regions, ie. toomany
differences between sample reads and reference genome, or if the sample has novel genetic elements not
found in the reference sequence, as is often the case with antigenic gene families. Based on themanual
inspection of read mapping, samples may be excluded from further analysis if they are deemed to be
of low quality, a judgment that can be made based on overall coverage or evidence of contamination
for instance.
Once the final sample set is determined, genotypes, and consequently SNPs, need to be called from
themapped reads242. The fundamental concept behind SNP-callers is to look at the allele distribution
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Figure 7: Showing an example Artemis 300 view, with reads from two samples (black and blue respectively) mapped to a
reference genome sequence (bottom). While both samples have even coverage, the black sample appears to have higher
levels of coverage than the blue sample (indicated by the height of the bars, ie. howmany reads are stacked on top of each
other). Redmarks indicate discrepancies between the sequence reads and the reference sequence. Consistent marks that
are present in all reads covering a speci c part of the reference sequence are likely SNPs, examples of which can be seen
in the blue sample. Inconsistent redmarks are potentially sequencing errors.
in the sequenced reads for a specific base call and to calculate the probability of that position being
a specific allele. By using multiple samples, such as for GATK215, the additional information of the
general distribution of alleles for that base position can be used, whereas linkage-disequilibrium gives
another independent source of information for certain SNPs that are difficult to call242. Following
SNP-calling, SNPs are filtered both by sample, ie. certain samplesmay have a high proportion ofmiss-
ing calls, andby base position, as certain SNPsmaybe in highly polymorphic regions and the SNPcalls
may therefore be unreliable242. SNP filtering can often be done using in-built functions in the SNP
calling softwares, such as in GATK where best practices for filtering SNPs have been published215.
The filtered SNP set can then be used for a number of analyses, such as looking at nucleotide diversity,
positive or negative selection acting on genes, or looking at SNPs that segregate between populations
for example. Such analyses have already yielded significant insights into the genetic basis of malaria.
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0.3 Insights Gained fromMalaria Genomics
0.3.1 Subtelomeric Gene Families
One of the early insights from sequencing different Plasmodium species was the observation that
each newly sequenced genome appeared to contain an abundance of genes of unknown function that
were specific to that species. These large species-specific gene expansions often cluster into ‘gene fam-
ilies’, meaning that the genes in the same family share higher levels of nucleotide similarity and gene
structure with each other than with other genes in the genome157,173. The similarity in sequence
and gene structure of genes in the same gene family suggests that they likely originated from an an-
cestral expansion event and subsequently began to diversify157. In most Plasmodium species, these
gene families are often restricted to the highly recombinogenic subtelomeric regions of the genome309,
though there are exceptions such as instances of chromosome-internal gene clusters inP. knowlesi and
P. falciparum. Between individuals of the same species, these subtelomeric gene families vary tremen-
dously both in number and in nucleotide similarity, due to significant amounts of recombination in
the subtelomeric regions. This high amount of variation in sequence, genomic location, gene pres-
ence/absence, and, paradoxically, non-specificity due to high levels of nucleotide similarity between
gene family members in the same genome, make these genes incredibly difficult to study using con-
ventional population genetics approaches25. Being able to confidently map sequencing reads to these
genes is rare and calling reliable SNPs from these alignments is consequently very difficult. In order to
be able to make sense of these gene families, they are often assembled de novo from either unmapped
reads or from reads mapping to the subtelomeric regions and the resulting arsenal of genes can then
be compared between individuals using comparative genomics approaches173,20.
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Even before the sequencing of the first P. falciparum genome, research into the so-called var genes
and their role in antigenic variationwas on-going336,26. Wenowknow that eachP. falciparum genome
contains approximately 60 var genes and a number of var pseudogenes. Close evolutionary relatives
ofP. falciparum, such asP. reichenowi and otherLaverania species, also have var gene repertoires, but
none of the other human-infective species does. The var genes encode the P. falciparum erythrocyte
membrane proteins (PfEMP1), which are transported to the red blood cell surface361. At any point
in time only one var gene is expressed310, with the switching between vars thought to potentially
be mediated by a highly conserved var gene known as var2csa352. It is believed that by switching
between different var genes, the parasite is able to evade the host immune system361. The PfEMP1
proteins are thought to bind to a number of host proteins, such as complement receptor 1 (CR1)299
and heparan sulfate58, and that this binding may lead to rosetting66, ie. agglutination of infected red
blood cells, which in turn may result in cases of cerebral malaria50. In addition to cerebral malaria,
expression of var2csa leads to PfEMP1 binding to chondroitin sulfate A (CSA) in the placenta of
pregnant women65, resulting in placental malaria304. Due to the involvement of var genes in causing
severe malaria, they have been extensively studied.
In addition to var genes, the P. falciparum genome also contains members of other gene families,
including etramp genes, phist genes, and rif genes. The latter are now thought to be part of a large
gene family present in all sequenced Plasmodium species, the pir (Plasmodium interspersed repeat)
genes157,76. The pir genes also have species specific names, such as vir in P. vivax, kir in P. knowlesi,
and cir in P. chabaudi for example. The number of pir genes varies significantly between species, with
P. relictum (an avianmalaria species) for instance only having 4 copies38, while P. falciparum has 227,
and the newly assembledP. vivax P01 genome appears to have an astounding 1,212 pir genes20, in line
30
with the 1,373 pirs in the closely related P. cynomolgi genome269. While the pir genes between species
appear to be related to each other, and likely have a single common ancestor, the pir repertoire of each
species is distinct, suggesting that they expanded in a species specific manner76. The exact function
of pir genes is not known, though it was originally thought that the large number of genes and high
variability between the genes may imply a role in antigenic variation, similar to var genes. Studies in
P. vivax found a role of pir-encoded proteins binding to endothelial cells30, while studies in P. falci-
parum suggested an involvement in rosetting through binding to red blood cells belonging to blood
group A121. Work in mouse models with P. chabaudi suggests that pir genes may be involved in viru-
lence and in establishing chronic infections depending on the type of pir genes being expressed329,44.
While their biological function is still under investigation, the sheer abundance of pir genes across all
sequenced Plasmodium species perhaps indicates important, yet to be discovered, roles.
0.3.2 Plasmodium Phylogenetics
Disentangling the evolutionary relationship between Plasmodium species has been a difficult chal-
lenge and the inferred evolutionary tree has been revised numerous times293. In part, this is due to
the complexity of Plasmodium genetics, where different parts of the genome tell different evolution-
ary stories133, as well as the large differences in GC content between the species skewing relationship
estimates112. Early phylogenies often relied on small parts of the genome, such as 18S rRNA or the
cytochrome B locus of the mitochondrion for example293. This, together with the fact that many key
Plasmodium species hadn’t been discovered yet, led to a number of conclusions that have now had to
be revised293. Some of the biggest questions in Plasmodium phylogenetics relate to the evolutionary
origin of the human-infective species, with a lot of work having been done on both P. falciparum and
31
P. vivax.
The hypothesis of the origin of P. falciparum has been revised a number of times. It was initially
thought that the particularly high virulence of P. falciparum indicated that it had jumped into hu-
mans very recently from birds362. This bird-origin hypothesis was however rejected when a number
of primate-infective Plasmodium species were discovered and described as P. falciparum-like (P. re-
ichenowi), P. malariae-like (P. rhodaini), and P. vivax-like (P. schwetzi), due to their morphological
similarities291. The rRNA sequencing of the chimpanzee-infective P. reichenowi, showed the close
relationship of the species to P. falciparum and it was suggested that the two species shared a com-
mon ancestor up to the event of humans diverging from chimpanzees, at which point they began to
co-evolve in parallel with their newly diverged hosts97. However, this hypothesis therefore suggested
thatP. falciparum had co-evolvedwith humans formillions of years, whichwas at odds with its highly
virulent nature. It was onlywhen additional species ofPlasmodiumwere discovered in other primates
that the phylogeny around P. falciparum became clear291. Extensive sampling of primate-infective
species revealed that P. falciparum likely originated from a Gorilla-infective species now termed P.
praefalciparum200. Further sequencing confirmed the close similarity of P. praefalciparum to P. fal-
ciparum258,181 andhighlighted a number of key genetic changes thatmayhave enabled the host switch
fromGorillas to humans338. Furthermore, the close genetic similarity of the two species suggests that
the host switch occurred relatively recently, with estimates ranging from10,000338 to 50,000258 years,
which is in line with the high virulence of P. falciparum.
While the origin of P. falciparum is now generally accepted to be a host switch from Gorillas to
humanswith the closest extant relative beingP. praefalciparum258, the evolutionary origin ofP. vivax
is still contested. Specifically, the debate centers around whether P. vivax has an African or an Asian
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origin. For many years, the consensus was that P. vivax likely originated in Southeast Asia from a
cross-species transmission event of a macaque parasite229,239. This hypothesis was supported by the
observation that the closest known relative of P. vivax was for a long time the macaque-infective P.
cynomolgi 341 and that most of the other close relatives of P. vivax are other simian-infective species
such as P. simiovale or P. knowlesi 204. This out-of-Asia hypothesis however cannot account for two
important facts. The first is that natural resistance to P. vivax is widespread throughout Africa in
the form of Duffy-negativity54, ie. P. vivax struggles to infect erythrocytes lacking the duffy antigen.
The second is that humans only arrived in Asia 60,000 years ago216 while P. vivax likely diverged
from macaque-infective species much longer ago than that229,239. The recent discovery of great apes
infectedwithP. vivax throughoutAfrica has further convoluted this out-of-Asia story bynecessitating
an importation of P. vivax from Asia to Africa to account for this observation286. This discovery of
P. vivax in African great apes has however strengthened the out-of-Africa hypothesis, proposing that
P. vivax originated from a host-switch from African great apes into humans and then subsequently
spread to Asia, before essentially disappearing from humans in Africa due to humans evolving Duffy-
negativity75. This hypothesis is further supported by the recent sequencing of a chimpanzee-infective
Plasmodium species that now appears to be the closest relative of P. vivax 204, known as P. vivax-like.
The main problem with the out-of-Africa proposal is the phylogenetic placement of P. vivax and its
chimpanzee-infective relative within the clade of Asian monkey-infective species. The question of
out-of-Asia versus out-of-Africa is therefore still ongoing.
While the evolutionary origin of P. falciparum and P. vivax has been extensively studied and de-
bated, it is not surprising that little is known about the evolutionary origin ofP.malariae andP. ovale.
As both species only result in relatively benign forms of malaria, it is often believed that both species
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have been infectinghumans for a very long time. This is further supportedby the ability ofP.malariae
to persist in its host for many decades318, suggesting that it has exquisitely adapted to humans over a
long period of time. Little is known about their host range, however it is believed that theNewWorld
monkey-infective P. brasilianum could potentially be P. malariae. The limited phylogenetic studies
that have been performed with P. malariae and P. ovale place both of them closer to P. vivax than
to P. falciparum112,204,14, though the exact placement of both species is still contested. Both species
usually formoutgroups toP. vivax and theAsian primate-monkey infective species, though published
phylogenies differ in terms of placing P. malariae112 or P. ovale204 as the furthest outgroup. A study
based on the apicoplast, placed P. ovale as a sister taxa to the rodent-infective species and P. malariae
as an outgroup to that clade, suggesting a potential host switch from humans to rodents14. These
phylogenies all have in common that both P. ovale and P. malariae significantly differ from other
studied Plasmodium species and it has therefore been difficult to accurately determine their phyloge-
netic relationship to these. Full genome information will enable both species to be more accurately
placed within a phylogeny.
0.3.3 Genetics of Antimalarial Drug Resistance
During the GMEP, chloroquine resistance emerged and spread across the globe. Since then, P. fal-
ciparum has managed to evolve resistance to almost every drug that has been thrown at it36 (figure
8). Using advances in sequencing, it has become possible to study the genetic basis of chloroquine
resistance as well as the genetic basis of antimalarial resistance to other drugs deployed since then. The
fundamental idea in identifyingmutations or other genetic variants thatmay be involved in providing
resistance to specific drugs essentially consists of comparing sensitive and resistant parasites and then
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Figure 8: Showing the timeline of different antimalarial drugs being deployed and the timing of the rst resistance to the
drugs being detected. Figure reproduced fromBlasco et al. 36 .
seeing what differs between them. This procedure therefore consists of two important parts, the first
being the process of determining the level of resistance of the parasites to be studied, and the second
being the method used to compare these parasites.
For the first part, there are generally two different ways of assessing the level of resistance of par-
asites. The first consists of using treatment outcomes, where parasites are sampled before treatment
and after treatment. Those that are sampled after treatment are likely to be the resistant ones, while
those before treatment are a combination of resistant and sensitive parasites. A comparison between
these groups of parasites would then pinpoint certain genetic variants that are either significantly en-
riched or significantly depleted in the resistant population compared to the baseline population. A
more common method of ascertaining the level of resistance of parasites is to perform either in vitro
or ex vivo drug testing to measure their 50% inhibitory concentration (IC50) value358. These IC50
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values are a quantitative estimate of how much of a drug is needed to kill 50% of the parasites and
are estimated by fitting a dose response curve after exposing parasites to a range of different drug con-
centrations. Compared to the binary outcome of the simple before and after counting method, IC50
values are quantitative estimates and therefore provide a higher level of resolution, though they can
be laborious to measure in the first place. For certain drugs, such as artemisinin, IC50 values have not
been accurately associated with the actual clinical response to the drug, and alternative measures have
been developed such as the ring-stage survival assay (RSA)13.
Once estimates of drug resistance have been obtained for studied samples, analytical methods need
to be employed to pinpoint the genetic variants that are most strongly associated with the observed
drug phenotype. An important method that has only recently become amenable to be used in Plas-
modiumdue to the large number of sample phenotypes andwhole genome sequences that are required
for statistical confidence, is performing genome-wide association studies (GWAS)275. GWAS studies
perform statistical association tests for every SNP in the genome with the tested phenotype358. Due
to the large number of tests that this entails (many thousands depending on the amount of SNPs),
the number of false positives, ie. associations that are significant by chance, will often times outnum-
ber the true positives154. To account for this, GWAS studies adopt multiple testing corrections and
thereby require associations to be exceedingly significant to reach ‘genome wide significance’358. To
achieve this, either the underlying effect of a variant on a phenotype has to be very large, or a signif-
icant number of samples have to be examined to provide sufficient statistical confidence145. GWAS
studies can also be obfuscated by other factors, such as underlying population structure, which can
be a major problem in Plasmodium221, and choice of study population, where the genetic basis of re-
sistance may differ between populations358. Finally, not all resistance phenotypes are associated with
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Table 1: Antimalarial Drugs and their GeneticMarkers
Antimalarial Drug Genetic Markers References
Chloroquine crt,mdr1,mrp 364,81,105,321,158,288,354
Mefloquine mdr1 (SNPs & CNV),mspdbl2 370,89,282,319,230,353,320,354
Piperaquine plasmepsin 2/3 (CNV), exonuclease,mdr1 (SNPs & CNV) 6,92,354,8,372
Artemisinin kelch 13,mdr1 (SNPs & CNV) 89,319,13,221,213,334,354
Lumefantrine mdr1 (SNPs & CNV),mspdbl2 319,353,354
changes in SNP frequencies, other underlying resistancemechanismsmay be responsible, such as gene
copy number amplifications or epigenetic changes, though GWAS analyses can be adapted for those
purposes.
Before the advent of GWAS, drug resistance genes in P. falciparum were initially identified using
homology, such as for the multidrug resistance protein 1 (mdr1) gene involved in mefloquine resis-
tance105,369 or the dihydropteroate synthase (dhps)349 and dihydrofolate reductase-thymidylate syn-
thase (dhfr)277,276 genes that are respectively involved in sulfadoxine and pyrimethamine resistance.
An alternative method was by using genetic linkage information following selection experiments358,
leading to the identification of the chloroquine resistance transporter (crt) gene responsible for chloro-
quine resistance364,81. These initial findings have subsequently been recapitulated by GWAS stud-
ies267,358, with crt andmdr1 being significantly associated with resistance to a number of antimalarial
drugs, including chloroquine and mefloquine230. Other GWAS studies have subsequently identi-
fied novel genes associated with resistance to amodiaquine, quinazoline, quinine, halofantrine, meflo-
quine, lumefantrine, piperaquine and artemisinin365,353,8,372,57,221,342. See table 1 for a list of selected
antimalarial drugs and the genes with which they have been associated358.
Pinpointing the genetic basis of artemisinin resistance and piperaquine resistance have been impor-
tantbreakthroughs inhandling the current crisis ofmultidrug resistance inSoutheastAsia. Artemisinin
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resistance, as characterised by a reduction in the speed of parasite clearance, has been linked to mu-
tations in the propeller domain of the kelch 13 gene219,221,13, and piperaquine resistance is strongly
associatedwith a copynumber amplification of the plasmepsin 2 and plasmepsin 3 genes8,372 (aswell as
with a SNP in an exonuclease gene, which is in strong linkage with the plasmepsin 2/3CNV8). While
artemisinin resistancehas been shown tohave emergedmultiple times in SoutheastAsia342, onepartic-
ular lineage, KEL1, outperformed others and eventually combined with the PLA1 lineage, associated
with piperaquine resistance9. This multidrug resistant KEL1/PLA1 lineage is the main agent of the
current outbreak ofmultidrug resistance in Southeast Asia9,150, having spread fromWesternCambo-
dia to other countries149, including Thailand, Laos, and Vietnam6,149,307,346. Knowing the genetic
basis of thesemultidrug-resistant P. falciparum parasites now enables us to better track them andmay
even help us in deciding how to best fight them next.
0.4 Thesis Overview
Malaria is a complex disease made up of a multitude of different interlinking factors. Perspectives on
the field ofmalaria research will vary significantly from person to person, ranging from parasitologists
to entomologists, clinicians to bioinformaticians, and even from sociologists to economists. In this
thesis, I have attempted to outline and explore a number of key gaps in our understanding of malaria,
specifically from the perspective of a computational parasitologist with an interest in evolutionary
biology. As a result of this narrow focus, little attention is given to otherwise very important aspects
of malaria research, such as vector control or vaccine development. Throughout this thesis, the main
leading question that guides the work is: ‘What can genomics tell us about humanmalaria parasites?’
(figure 9).
38
Figure 9: Showing an overview of the thesis structure, with the guiding question in red.
As discussed above, genomics has already taught us a lot about the biology of the malaria parasite,
however there is still a lot to be learned. Genomics has the ability to shed light both on the distant
past, through constructing phylogenies and identifying evolutionary adaptations, as well as on recent
events, by tracking outbreaks of drug resistance and diagnosing hospital infections. While there may
be a temporal disconnect between the timescales of these applications of genomics, they do intersect
and influence each other. In this thesis, I will attempt to delve into both the ancient and the recent,
and showcase the intersections between them. To do this, I will identify important problems in both
realms, explorations of which I will then apply in the other (figure 9).
One of themost surprising gaps in our understanding of the evolutionary history of humanmalaria
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parasites is the lack of reference genome sequences for two of the five human malaria parasites, P.
malariae and P. ovale. We know little about their phylogenetic relationship to other Plasmodium
parasites and even less about the genes that phenotypically distinguish these species from the more
virulent human-infective ones. With the rapid advances in sequencing and sample preparation over
the last two decades, obtaining sufficient sequencing data to assemble reference genomes for both
species should now be possible. Not only would these genome sequences enable us to answer impor-
tant evolutionary questions about these species, but it would also open up the possibility of studying
recent cases of treatment failure or co-infections in these species from a genomic perspective.
On the scale of recent evolutionary events, the current rise ofmultidrug resistance in SoutheastAsia
necessitates a genomic approach to understanding and tracking the problem. While KEL1/PLA1
parasites have become resistant to both artemisinin derivatives and piperaquine, little is known in
terms of their specific response to other antimalarial drugs, such as mefloquine. Analysing whole
genome sequences of KEL1/PLA1 parasites with associated mefloquine IC50 values using a GWAS
approach, will answer important questions relating to the individual response ofKEL1/PLAparasites
to mefloquine and the likely sustainability of mefloquine in the field longer term. Notably, the large
number of whole genome sequences collected as part of the Pf6 dataset over the last two decades will
then enable us to take a historical perspective of multidrug resistance in the region and beyond.
One additional leitfaden throughout this thesis is that of layering data, where, at the beginning of
the thesis, I look solely at genome sequences and by the end of it, I amalgamate data ranging from
genotype data to metadata, over to clinical phenotypes (figure 9). In Chapter 1, I assemble reference
genome sequences for both P. malariae and P. ovale, analysing their gene content and relating it to
their unique biology. I also use additional draft genome assemblies to confirm whether P. ovale con-
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sists of two species. In Chapter 2, clinical metadata is layered on to the genome sequences in order to
characterize a case of clinical recrudescence of a P. malariae infection. In Chapter 3, phenotype data
on mefloquine susceptibility is used together with P. falciparumwhole genome sequences and meta-
data to perform aGWASofmefloquine resistance in Southeast Asia. Finally, inChapter 4, phenotype
data formultiple drugs is harnessed, including chloroquine, artemisinin,mefloquine andpiperaquine,
in order to understand the genetic basis of multidrug resistance. At each level, I attempt to identify
new biology that both expands our understanding of humanmalaria in general and sheds light on the
specifics of antimalarial drug resistance.
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Our castle’s strength will laugh a siege to scorn. Here let
them lie till famine and the ague eat them up.
William Shakespeare, Macbeth, 1606 CE
1
Completing the Set of HumanMalaria
Parasite Genomes
1.1 Abstract
Despite the huge international endeavor to understand the genomic basis of malaria biology, there
remains a lack of information about twohuman-infective species: Plasmodiummalariae andP. ovale.
The former is prevalent across all malaria endemic regions and able to recrudesce decades after the
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initial infection. The latter is a dormant stage hypnozoite-forming species, similar to P. vivax. In this
chapter, I present the newly assembled reference genomes of both species, thereby completing the set
of all human-infective Plasmodium species. I show that the P.malariae genome is markedly different
to other Plasmodium genomes and relate this to its unique biology. Using additional draft genome
assemblies, I confirm that P. ovale consists of two species that appear to have diverged millions of
years ago. These genome sequences now provide a new resource to study the genetic basis of human-
infectivity in Plasmodium species and open up otherwise impossible opportunities for developing
diagnostics, drugs and vaccines against these neglected species of malaria parasites.
1.2 Introduction
All known humanmalaria species were described in the early 20thCentury, withPlasmodiummalar-
iae and P. ovale being recognized as distinct species from P. falciparum, P. vivax, and P. knowlesi 166.
Reference genomes have now been published for the latter three115,51,266, with the extent of human
infections caused byP. knowlesi having only been recognized decades after initial discovery60. Analysis
of these reference genomes has revealed the genomic basis of key biological processes, including viru-
lence76, invasion69, and antigenic variation228. The lack of whole genome sequences for P. malariae
and P. ovale has meant that little progress has been made in the understanding of molecular genetics
in these important species.
Infections with P. malariae and P. ovale are frequently asymptomatic298 and often have para-
sitaemia levels undetectable by light microscopy83, making their study in human populations dif-
ficult and potentially thwarting efforts to eliminate them and declare any regions ‘malaria free’40.
This lack of knowledge is especially worrying because the two species are distributed widely across
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all malaria-endemic areas of the world67,68 (figure 1.1 a). P. malariae and P. ovale frequently occur
as co-infections with the two more common species, P. falciparum and P. vivax, and can be present
in up to 5% of all clinical malaria cases298. This equates to roughly 30 million annual clinical cases.
P. malariae infections can lead to lethal renal complications178 and can recrudesce after decades318,
further increasing their socioeconomic costs.
Unraveling the mechanisms that enable P. malariae to persist in the host for decades is critical
for a more general understanding of chronicity in malaria. The genome sequence of P. ovale, the
other hypnozoite-forming species, will facilitate the search for conserved hypnozoite genes and will
conclusively showwhetherP. ovale consists of two cryptic subspecies, as recently suggested339. Finally,
the genetic basis of human-infectivity in malaria parasites can only be fully understood by having
access to the genome sequences of all human-infective species.
Here I present the genome sequences of both these species, including the two recently described339
subspecies of P. ovale (P. o. curtisi and P. o. wallikeri). I update the phylogeny of the Plasmod-
ium genus using whole genome information, and describe novel genetic adaptations underlying their
unique biology. Using whole genome sequencing of additional P. malariae (including two obtained
from chimpanzees, referred to as P. malariae-like) and P. ovale samples, I describe their genetic varia-
tion, aswell as identify genes that are under selection. The data presented here provide the community
with an essential foundation for further research efforts into these neglected species and into under-
standing the evolution of the Plasmodium genus as a whole.
All methods used for this chapter are detailed in Appendix A. This project was a large collaborative
effort with sample collection and sequencing having been performed by a large number of collabora-
tors. All data analyses presented in this chapter are my own work unless specifically noted otherwise.
45
1.3 Plasmodium Co-Infections
Obtaining P. malariae and P. ovale DNA has historically been difficult due to the low level of para-
sitaemia innatural human infections. Using anovelmethodbasedon identifying species-discriminating
mitochondrial SNPs I developed (AppendixA),P.malariae andP. ovalewere found in approximately
2%of allP. falciparum clinical infections fromthe globally sampledPf3Kproject (www.malariagen.net)
(figure 1.1 a) (table 1.1), compared to 4% being co-infections with P. vivax. A number of infections
containing three species were also identified. These P. malariae and P. ovale co-infections are in ad-
dition to the larger number of mono-infections that they cause, which are frequently missed due to
difficulties in confirming a species diagnosis. I used the two P. ovale co-infections with the highest
number of sequencing reads to perform de novo genome assemblies.
1.4 Genome Assemblies
A 33.6 megabase (Mb) reference genome of P. malariae was produced from clinically isolated par-
asites and sequenced using Pacific BioSciences long-read sequencing technology. The assembled se-
quence comprised 14 super-contigs representing the 14 chromosomes, with 6 chromosome ends ex-
tending into telomeres, and a further 47 unassigned subtelomeric contigs containing an additional 11
telomeric sequences (table 1.2). Using existing Illumina sequence data from two patients primarily in-
fected with P. falciparum, sequencing reads were extracted and assembled into 33.5Mb genomes for
both P. o. curtisi and P. o. wallikeri, each assembly comprising fewer than 800 scaffolds. The genomes
are significantly larger than previously sequencedPlasmodium species and, likeP. vivax, have isochore
structures with a higher AT content in the subtelomeres. In addition, a P. malariae-like genome
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Table 1.1: Samples positive for different Plasmodium species in the Pf3k dataset
Country Total Samples P. falciparum P. vivax P. malariae P. ovale P. knowlesi
The Gambia 65 65 0 0 0 0
Guinea 100 100 0 7 3 0
Thailand 148 148 11 0 0 0
Ghana 617 617 5 12 9 0
Cambodia 570 570 50 0 0 0
Mali 96 96 0 1 0 0
Bangladesh 50 50 4 0 0 0
Malawi 369 369 4 4 4 0
Vietnam 97 97 16 0 0 0
Myanmar 60 60 7 0 0 0
Laos 85 85 4 0 2 0
DRCongo 113 113 1 2 1 0
Nigeria 5 5 0 0 0 0
Senegal 137 137 0 0 1 0
Global 2512 2512 102 26 19 0
The first column shows country of origin for the different samples, with the second column showing the total number of samples collected in
that country. The following five columns show the number of these samples that are positive for the different Plasmodium species. All samples are
positive for P. falciparum, which is expected because all the samples were initially identified as P. falciparum infections. I did not see any samples
positive for P. knowlesi.
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Figure 1.1: Prevalence and phylogenetic relationship of P. malariae and P. ovale. a)Worldmap showing presence and
absence of P. malariae (Red), P. ovale (Blue) or both (Purple) by country based on a literature review. Barplots show pro-
portion of P. falciparum infections with co-infections of P. malariae (Red), P. ovale (Blue), P. vivax (Green), or two species
(Purple) based on the Pf3K dataset. Stars indicate origin of sample used for reference genome assembly and points show
additional samples used. b)Maximum likelihood phylogenetic tree of the Plasmodium genus, showing the P. malariae
clade (Red) and the P. ovale clade (Blue) together with the divergence times of the species as calibrated to the P. falci-
parum/P. reichenowi split (x). Silhouettes show infectivity of the different species. Values within branching points indicate
bootstrap values as calculated using RAxML 331.
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Table 1.2: Comparison of genome features of all human-infective Plasmodium species and P. malariae-like
Feature P. falci-
parum




P. malariae P. malariae-
like
Assembly
-Size 23.3 24.4 29.1 33.5 33.5 33.6 23.7
-Scaffoldsa 14(0) 14(297) 14(226) 14(638) 14(771) 14(47) 14(36)
-Gaps 0 98 560 894 1,264 0 3,697
-GC content 0.19 0.39 0.40 0.29 0.29 0.24 0.30
-Isochore No No Yes Yes Yes Yes N/A
Genes
-Number 5,355 5,284 6,671 7,198 7,052∗ 6,591 4,764∗
-Pseudogene 153 7 147 494 N/A 628 N/A
-Density 1/4.3kb 1/4.6kb 1/4.5kb 1/5.0kb 1/5.2kb 1/5.6kb 1/5.3kb
-Intron Size
(mean)
167bp 275bp 173bp 178bp N/A 229bp N/A
Subtelomeric
Genes
-pir 227 67 1,217 1,949 1,375 255 4
-var 103 0 0 0 0 0 0
-SICAvar 0 241 0 0 0 0 0
-STP1 0 0 9 70 94 166 2
-pv-fam-a 3 13 37 41 33 42 7
-pv-fam-e 0 0 30 8 6 3 3
-ETRAMP 13 9 9 7 11 7 4
-PHIST 77 2 27 24 21 10 3
-fam-l 0 0 0 0 0 396 0
-fam-m 0 0 0 0 0 283 1
a Unassigned contigs indicated in parentheses
∗ Non-curated gene-models
was produced using Illumina sequencing from parasites isolated from a chimpanzee co-infected with
P. reichenowi. The P. malariae-like genome was more fragmented than the other assemblies and its
23.7Mb sequence misses most subtelomeric regions. This lack of subtelomeres is likely due to the
whole genome amplification step that was performed prior to sequencing,which preferentially am-
plifies core regions of the genome where the PCR primers are most likely to bind due to the more
moderate GC content.
Most of the P. malariae genome is collinear with P. vivax, however I did see two instances of large
reciprocal translocation breakpoints. The chromosomes syntenic to the P. vivax chromosomes 6 and
10 have recombined (figure 1.2 a) and a large pericentric inversion has occurred on chromosome 5
(figure 1.2 b). This was confirmed by mapping sequence data from additional P. malariae samples
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back to the reference assembly and then looking for sequencing reads that span the recombination
breakpoints . Across the four genomes, between 4,764 and 7,198 genes were identified using a com-
bination of ab initio gene prediction and projection of genes from existing Plasmodium genome se-
quences. Manual curation performed by Ulrike Boehme was used to correct 2,516 and 2,424 genes
for both the P. malariae and P. o. curtisi reference genomes respectively.
1.5 Comparison to Alternatives
Concurrently to the analysis in this chapter having been performed, draft genomes for both P. ovale
and P. malariae were published by another research group10. In comparison to the draft genomes
produced by Ansari et al. 10 , three of the genomes assembled here (PmUG01, PocGH01, PowCR01)
are similar in size but significantlymore contiguous (table 1.3). The genomeof a chimpanzee-infecting
species known as P. malariae-like (PmlGA01) is unique to the present study but lacks good coverage
of the subtelomeric regions due to biased template representation introduced by the whole genome
amplification process. The assembly of P. malariae PmUG01 is based on long reads and comprises
just 63 pieces. It has no gaps and surpasses the other assemblies according to all metrics reported.
The assemblies of the present study aremore contiguous, especially in the subtelomeric regions of the
genomes.
The manual curation of gene models in the present study made a clear difference to the annota-
tion. In addition to the annotation of pseudogenes, it enabled the identification of approximately
10%more genes as clear 1:1 orthologues of genes in both P. falciparum and P. vivax. Indeed, in terms
of this metric, other available assemblies10 are similar to the draft assembly of P. malariae-like. The
highly conserved genes are especially important for cross-species comparisons and analyses. Using 1:1
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Figure 1.2: Reciprocal translocation breakpoints in P. malariae compared to P. vivax. a) ACT 55 view showing recombi-
nation of chromosomes 6 and 10 in P. malariae. The red lines indicate blast similarities, chromosome 6 in orange and
chromosome 10 in brown. b) ACT 55 view showing a pericentric inversion in chromosome 5 of P. malariae. Red lines indi-

















































































































































































































































































































































































































































































































































































































































































































orthologues as indicators of genes within the conserved core regions of chromosomes, I see that my
assemblies have about 20% more short genes (less than 100 codons) annotated (averages: 100 versus
82), being thereby more similar in number to those seen in P. falciparum (101). Multi-exon genes are
notoriously difficult to annotate; looking at the number of 1:1 orthologues in the different assemblies
to P. vivax and P. falciparum genes with over 7 exons (300), the genomes presented here (excluding
PmlGA01) have both 10%more 1:1 orthologues annotated and less variable median lengths between
assemblies (range: 462-478 versus 368-50010). The large number of partial genes observed in some of
the genomes assembled by Ansari et al. 10 is due to the higher amount of genes truncated by contig
boundaries.
The subtelomeres in P. malariae and P. ovale required significant manual curation due to the high
number of pseudogenes present and the ease in which exons can mistakenly be missed during anno-
tation. Excluding PmlGA01 that lacks most subtelomeric regions, all assemblies presented here have
significantly more genes annotated as pseudogenes than those by Ansari et al. 10 (averages: 869 ver-
sus 7). The latter study also reports more short genes than my assemblies (averages: 640 versus 81),
suggesting potential problems with gene models. Finally, the high gene numbers reported for the as-
semblies in Ansari et al. 10 can largely be attributed to putative subtelomeric genes, most of which are
short with no assigned function and therefore have an increased likelihood of being spurious.
1.6 Phylogenetics
Amaximum likelihood tree was constructed using 1,000 conserved core genes that are present as sin-
gle copies in 12 selected Plasmodium species (figure 1.1 b). The four newly assembled genomes did
not cluster with any other Plasmodium species, but formed two distinct and novel clades. Similar to
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a recent study using apicoplast data14, the two P. ovale species formed a sister clade with the rodent
malaria species, the latter being an ingroup to the ‘superfamily’ of primate-infective species in this
tree. A further exploration of the phylogenetic tree I report here is detailed in Appendix B. I also saw
that P. malariae-like has a longer branch length than P. malariae, which may be a reflection of the
higher levels of diversity in P. malariae-like (figure 1.3 a). This lack of diversity in P. malariae com-
pared to the chimpanzee species mirrors the situation of P. falciparumwith P. reichenowi 338, another
chimpanzee-infective species.
I estimated the time of divergence for the four species using a Bayesian inference tool, G-PhoCS125.
G-PhoCS uses a large number of unlinked neutrally evolving loci and a given phylogeny to estimate
demographic parameters based on the coalescent theory125. Absolute divergence time estimates are
inherently uncertain due to mutation rate and generation time assumptions, and I therefore scaled
these parameters to date the P. falciparum and P. reichenowi split using G-PhoCS to approximately
4 million years ago (MYA), as previously published (3.0 - 5.5MYA)322. Assuming that the mutation
rates and generation times are similar for P. ovale and P. falciparum, I find that the relative split of the
twoP. ovale species is about 5-times earlier than the split ofP. falciparum andP. reichenowi. Using the
same mutation rate and generation time as I used to calibrate the P. falciparum/P. reichenowi split to
≈4MYA, I thereby date the divergence of the twoP. ovale subspecies to approximately 22.8MYA.Due
to being based on non-coding elements, this divergence time is not proportional to the branch lengths
of the phylogenomic tree in figure 1.1 b, where coding regions were used. The large divergence time
strongly supports the classification of P. o. curtisi and P. o. wallikeri as separate species rather than
subspecies of P. ovale.
Using the samemutation rate and a longer generation time to account for the longer intra-erythrocytic
54
Figure 1.3: P. malariae-like has signi cantly longer branch lengths than P. malariae, and P. brasilianum is identical to P.
malariae. a) A phylogenetic tree of all P. malariae and P. malariae-like samples generated using PhyML 128 based on all P.
malariae genes. P. malariae samples are indicated by a green bar and P. malariae-like samples are indicated by a purple
bar. Silhouettes represent infectivity. b) A PhyML 128 phylogenetic tree of all P. brasilianum 18S rRNA sequences 177,
indicated by a red bar and red tree tips, and the corresponding 18S rRNA sequences from the P. malariae and P. malariae-
like assemblies, labeled as such. Silhouettes represent the host origin for each sample.
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cycle, I dated the split of P. malariae from P. malariae-like to≈3.9MYA. This is similar to the esti-
mated divergence of P. falciparum and P. reichenowi, suggesting a significant evolutionary event that
promoted speciation in Plasmodium at that time. It has been suggested that a New World primate-
infective species termed P. brasilianum is the same species as P. malariae177. To investigate this fur-
ther using the new genome assemblies, I aligned theP. brasilianum ribosomal rRNA177 genes to both
the P. malariae and P. malariae-like orthologous genes, showing that the P. brasilianum genes are
identical to those of P. malariae, but that P. malariae-like is indeed very different (figure 1.3 b). Sub-
sequent to this analysis, using the recently published P. brasilianum genome sequence344, I found
that over 16Mb of the P. brasilianum genome sequence matches that of P. malariae with over 99%
nucleotide similarity, further indicating that they are likely to be the same species.
1.7 Gene Changes
The greater number of genes in both P. malariae and P. ovale compared to existing Plasmodium
genomes is mostly due to gene family expansions in the subtelomeres, such as Plasmodium inter-
spersed repeat (pir) and STP1 genes (table 1.2). In addition, on chromosome 14, a large expansion
was identified in P. malariae that comprised 22 tandemly duplicated genes (including two pseudo-
genes), orthologous to a single P. falciparum gene encoding gamete antigen 25/27 (pfg27) (figure 1.4
a). P. vivax and P. falciparum only have one and two copies respectively. pfg27 is expressed highly
during early gametocytogenesis201, and is essential for correct gametocyte development252. This ga-
metocyte gene expansion may be an adaption by P. malariae to ensure sexual reproduction in low
parasitaemia infections.
In the P. ovale species, certain genes are also tandemly duplicated. Nine homologs (including two
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Figure 1.4: Large gene duplications in P. malariae and P. ovale. a) Expansion of pfg27 in P. malariae (top) compared to
P. falciparum (bottom) with red lines indicating blast similarities. b) Expansion of PVP01_1270800 (PF3D7_1475900
in P. falciparum), a genewith no known function, in P. o. curtisi and P. o. wallikeri, with different copy numbers in each,
compared to the one copy in P. vivax. Functional genes are shown in red and orange (depending on presence/absence of
functional annotation) and pseudogenes are shown in grey.
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pseudogenes) of PVP01_1270800 are present in P. o. curtisi and 7 homologs are present in P. o. wal-
likeri (figure 1.4 b). The P. vivax homolog is most highly expressed in sporozoites but has no known
function203. Using I-TASSER380, the predicted 3D structure of this gene appears to be similar to
a nuclear pore complex (TM-Score > 0.4), suggesting a role in transport. This potential sporozoite
change may be indicative of differences in liver-stage invasion or possibly hypnozoite formation.
Multiple genes have become pseudogenes in the two reference genomes compared to other human-
infective Plasmodium species (table 1.4), ie. no canonical structure could be predicted for the genes
due to in-frame stop codons, frame shifts or a truncated coding sequence. These pseudogenized genes
include homologs of a multidrug efflux pump gene (PF3D7_0212800) which suggests that these
species might have a higher innate susceptibility to some drugs. A phosphofructokinase, central to
glycolysis, appears to be a pseudogene in both P. ovale species, suggesting an alternate route (e.g. the
pentose phosphate pathway) for glucose turnover in these species. I also saw orthologous genes that
are pseudogenes in P. o. wallikeri but not in P. o. curtisi, such as a serine-threonine protein kinase
and a reticulocyte binding protein 1b (RBP1b), that is also pseudogenized in P.malariae as discussed
below. One gene of specific interest that is pseudogenized in P. o. wallikeri but not in P. o. curtisi is a
homolog of a cyclin in P. falciparum (PF3D7_1227500), an observation that may explain the differ-
ent relapse times of the two P. ovale species244. The highest number of pseudogenes is seen in the P.
malariae subtelomeres, where 40% of the genes are pseudogenized in this species, indicating reduced
selection pressure to cleanse the genome of these remnant genes, or the pseudogenes potentially being
a reservoir for recombination and diversification.
P.malariaehas a significantly longer intra-erythrocytic lifecycle compared toother human-infective
Plasmodium species. All threePlasmodium cyclins295 are highly conserved inP.malariae, suggesting
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Table 1.4: Pseudogenized and deleted core genes in the two reference genomes
P. vivax ID Annotation P. malariae P. ovale curtisi
PVP01_0412100 Multidrug efflux pump Pseudo Pseudo
PVP01_0309300 Erythrocyte vesicle protein 1 Pseudo
PVP01_1032500 Conserved Plasmodium protein, unknown function Pseudo
PVP01_1344900 Serine/Threonine protein phosphatase CPPED1 Pseudo
PVP01_1407400 MORN repeat protein Pseudo
PVP01_1107900 6-cysteine protein (P92) Deleted
PVP01_1117100 Conserved Plasmodium protein, unknown function Pseudo
PVP01_0906000 WD repeat-containing proteinWRAP73 Deleted
PVP01_0929100 6-phosphofructokinase Pseudo
PVP01_0940700 Carbonic anhydrase Deleted Pseudo
PVP01_1445600 Conserved Plasmodium protein, unknown function Pseudo
PVP01_1237400 Nucleoside Transporter 3 Pseudo
PVP01_1123700 Conserved Plasmodium protein, unknown function Pseudo Pseudo
PVP01_1246900 Biotin protein ligase Pseudo
The first column shows the gene identifier of the P. vivax P01 homolog of the gene pseudogenized/deleted in one or more of the two
reference genome assemblies. The second column is the P. vivax P01 annotation of that gene. The following two columns show whether
the gene is functional (blank), pseudogenized (Pseudo) or deleted (Deleted).
that the genetic cause may be elsewhere. AWD repeat-containing protein (WRAP73) is deleted in P.
malariae but conserved across all other Plasmodium species. It is part of a large gene family known
to be involved in a number of cellular processes, including cell cycle progression64.
Both P. ovale species are able to form hypnozoites, similar to P. vivax 51 and the simian-infective
P. cynomolgi 341. Of 64 genes exclusive to these hypnozoite-forming species, two genes (table 1.5) do
not belong to subtelomeric gene families, encode proteins with transmembrane domains and have
orthologs expressed in P. vivax sporozoites366. The product of one of the two genes has weak sim-
ilarity to the P. falciparum ring-exported protein 4. Looking at genes previously suggested to be in-
volved in hypnozoite formation341, I did not find P. ovale orthologs of the three genes shared exclu-
sively by P. vivax and P. cynomolgi that contain sporozoite-specific ApiAP2 motifs. However, I did
find such motifs in six out of nine dormancy related genes identified341 (table 1.6), including Ran
(PocGH01_09023900) previously identified in a P. vivax screen for potential hypnozoite genes51.
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Table 1.5: Potential hypnozoite genes in P. ovale curtisi
PVP01 Annotation P. vivax P. cynomolgi P. ovale curtisi
Ring-exported protein 4* PVP01_0623900 Pcyb_063280 PocGH01_00129400
Conserved Plasmodium protein PVP01_1402600 Pcyb_141110 PocGH01_00080600
*not in the same orthologous group as P. falciparumREX4.
These are the two orthoMCL gene clusters that contain exclusively all hypnozoite-forming Plasmodium species and are not
part of subtelomeric gene families.
Table 1.6: Additional hypnozoite gene candidates
P. vivax PVP01 P. o. curtisi Annotation
PVP01_0726200 PocGH01_07035100 Serine/threonine protein phosphatase 4
PVP01_0825700 PocGH01_08034100 Serine/threonine protein phosphatase 6
PVP01_0918300 PocGH01_09023900 GTP-binding nuclear protein Ran/TC4
PVP01_1115000 PocGH01_00015700 Protein kinase 5
PVP01_1205500 PocGH01_12013900 Tyrosine kinase-like protein
PVP01_1257700 PocGH01_12063800 Transcription factor IIIb subunit
Dormancy-related genes identified as containing a sporozoite-specificApiAP2motif their 1kb5’ upstreamregion
in P. vivax, P. cynomolgi, and P. o. curtisi.
1.8 Subtelomeric Gene Families
The Plasmodium genus is characterized by species-specific subtelomeric gene family expansions, such
as var genes in P. falciparum336 and pir genes in P. yoelii 256. In P. malariae and P. ovale, where
approximately 40% of the total genome size is subtelomeric, large expansions of gene families that are
species-specific are also seen (figure 1.5 a) (table 1.2). The three largest gene clusters that I identified
were in P. malariae. Of these, one cluster is composed of STP1 genes. Some of these are remarkably
similar to surface interspersed genes (surfins) in P. falciparum371, further supporting the proposed
close relationship of these two gene families108.
The other two large P. malariae clusters consist of two novel gene families, here termed fam-l and
fam-m, consisting of 346 and 283 two-exon ≈250 amino acid long genes respectively. Despite the
assembly lacking the majority of the subtelomeres, I also found a fam-m gene in the genome of P.
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Figure 1.5: Subtelomeric gene family expansions in P. malariae and P. ovale. a) Gene network based on sequence similar-
ity of all genes in P. malariae (Red), P. ovale (Blue), and P. vivax (Green). Cluster 1 contains fam-l genes, Cluster 2 contains
fam-m genes, and Cluster 3 contains sur n and STP1 genes. b) Chromosome 5 subtelomeric localization of fam-l and
fam-m genes in doublets (Blue brackets) on the telomere-facing strand. Also showing pseudogenes (Grey) and hypothet-
ical gene (Blue). c) Predicted 3D-structure of fam-l (above) and fam-m (below) overlaid with the RH5 crystal structure
(Purple). Left images show front of protein, right images show protein tilted to the right.
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malariae-like, suggesting that this species also contains at least one member of these novel families.
The first exon of each fam-l and fam-m gene contains a signal peptide and a PEXELmotif –the signa-
ture in P. falciparum for export from the parasite into host erythrocytes139. In addition, the second
exon contains two transmembrane domains flanking a hypervariable region. The remainder of the
gene sequence is conserved between members of the same family and differentiates the two families
from each other. These characteristics support the notion that the proteins encoded by these genes
are exported from the parasite andmay be targeted to the infected red blood cell surface and play a role
in host-parasite interactions.
Ninety-three percent of fam-l and fam-m genes are on the same strand facing the telomeres (figure
1.5 b). This pattern, similar to pir genes in P. yoelii 256, may be an adaptation to facilitate recombina-
tion between these genes. Uniquely, 60% of these new genes are found as fam-l and fam-m doublets
(figure 1.5 b). Mirror tree analysis suggests that the pairs may be co-evolving over short periods of
time (figure 1.6 a), likely through being duplicated together, but that pairing may be disrupted by
recombination over longer periods. I did not see any evidence of co-evolution between pir genes in
close proximity of fam-m genes (figure 1.6 b), supporting the fact that this is not an artifact from their
subtelomeric location. This suggests that proteins encoded by fam-l and fam-m genes may form het-
erodimers when they are exported, a feature not previously seen among subtelomeric gene families in
Plasmodium.
Finally, I used I-TASSER380 to predict the 3D structure from both a fam-l and a fam-m encoded
protein. High-confidence (TM score > 0.5) structures were predicted in both cases. These structures
overlap the crystal structure of theP. falciparumRH5proteinwell (TMscore > 0.8), with 100%of the
RH5 structure covered even though they only have 10% sequence similarity (figure 1.5 c). RH5 is a
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Figure 1.6: Co-evolution of fam-m and fam-l genes, but not with pir genes. a) Mirror tree 248 for 79 fam-m and fam-l
doublets, where the two phylogenetic trees correspond to either of the families with lines connecting branch tips of the
same doublet. 35 branches (Red) weremanually selected due to exhibiting recent branching. Inset shows the correlation
between the two trees for all branches (above, r2=0.19, p < 0.001) and red branches (below, r2=0.53, p < 0.001). This
shows that the two families are co-evolving, especially when doublets that recently branched are selected. b)Mirror
tree 248 for 79 pir and fam-m pseudo-doublets (Appendix A), where the two phylogenetic trees correspond to either of
the families with lines connecting branch tips of the same doublet. 35 branches (Red) weremanually selected due to
exhibiting recent branching. Inset shows the correlation between the two trees for all branches (above, r2=0.09, p > 0.05)
and red branches (below, r2=0.10, p > 0.05). This shows that the two families are not co-evolving, and that subtelomeric
location does not produce sporadic signals of co-evolution.
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prime vaccine target in P. falciparum due to its essential binding to human basigin during invasion74.
The RH5 kite-shaped fold is known to be present in RBP2a in P. vivax 127, and may be a conserved
structure necessary for the binding capabilities of all RH andRBP genes. This suggests that fam-l and
fam-m encoded proteins also have an adhesion role, possibly binding host receptors.
While neither P. ovale species has fam-l or fam-m genes, they both have large expansions of the
pir gene family with 1,949 and 1,375 pir genes in P. o. curtisi and P. o. wallikeri respectively, while P.
malariae only has 255 pir genes. This is the largest number of pir genes in any sequencedPlasmodium
genome to date, explaining the large subtelomeres of this species. These pir genes form large species-
specific clusters suggesting recent expansions (figure 1.5 a), butmost closely resemble those inP. vivax.
An analysis performed togetherwithAdamReid fromtheWellcomeSanger Institute found thatmany
subfamilies of pir genes in P. malariae and P. ovale are shared with P. vivax, while almost none are
shared with the rodent-infecting species (figure 1.7 a). This suggests that pir genes are relatively well
conserved between non-falciparum species infecting humans. Interestingly, all hypnozoite-forming
species (bothP. ovale, P. vivax, andP. cynomolgi) contain over 1,000 pirs each, significantlymore than
non-hypnozoite-forming Plasmodium species. Using additional draft genome assemblies for both P.
o. curtisi and P. o. wallikeri, I show that the two species of P. ovale share significantly fewer pir genes
inter-specifically than they do intra-specifically or intra-genomically (99% identity over 150 amino
acids), further suggesting that the two species are not recombining with each other (figure 1.7 b).
1.9 Reticulocyte andDuffy Binding Proteins
RBPgenes encode amerozoite surfaceprotein familypresent across allPlasmodium species andknown
to be involved in red blood cell invasion and host specificity155. Compared to P. vivax, P. malariae
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Figure 1.7: pir genes in P. malariae and P. ovale resemble those in P. vivax, and pir genes are less similar between the two
P. ovale thanwithin. a) Heatmap showing the sharing of pir subfamilies between different species based on tribeMCL 96.
Columns show pir subfamilies and rows show species. Colours indicate the number of genes classi ed into each subfamily
for each species. Subfamilies were ordered by size, species were ordered for clarity. pir genes in rodent-infecting species
fall into a small number of well-de ned families. Those in P. vivax, P. malariae and P. ovale are howevermuchmore diverse.
There is little overlap between rodent subfamilies and human-infecting subfamilies, despite P. ovale being a sister taxa
to the rodent-infecting species. P. knowlesi has some sharing with other species, but its largest families are species-
speci c, suggesting it has undergone specialization of its pir repertoire. b) Gene network of pir genes for both high-quality
assemblies of P. o. curtisi (Dark red) and P. o. wallikeri (Dark blue) and draft assemblies of each (Light red and light blue
respectively). pir genes with BLASTP 5 identity hits of 99%+ over 150 amino acids become connected in the graph. Genes
without connections were removed. There is one connection between the two species (circled in black andwith a zoomed
in version), 801 between the P. o. curtisi assemblies, 524 between the P. o. wallikeri assemblies, 527 on average within
each P. o. curtisi assembly, and 423 on average within each P. o. wallikeri assembly.
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has lost multiple RBPs including nearly all RBP2 genes and RBP1b, though it does have a functional
RBP3. On the other hand, the two P. ovale species each have multiple full-length RBP2 genes (seven
in P. o. curtisi and four in P. o. wallikeri) compared to three copies in P. vivax (figure 1.8 a). The
two P. ovale species have very similar RBP2s, such as PocGH01_00019400 and its ortholog, a num-
ber of RBP2 pseudogenes in the two genomes match with a functional copy in the other genome
(figure 1.9 a). The RBP1b pseudogene in P. o. wallikeri is less degenerate than in P. malariae and
in P. malariae-like where only a short fragment of the gene was found (figure 1.8 b). The specific
mutation introducing a stop codon is conserved across the two P. o. wallikeri samples (figure 1.9 b),
indicating that RBP1b has become pseudogenized recently in this species, or that the shortened form
may be functional and has therefore been maintained under selection. It is interesting to note that
the positioning of RBP1b and RBP1a is conserved across all these species, but not with the rodent
malaria species.
RBP genes are thought to be involved specifically in reticulocyte invasion, which explains the gene
loss in P. malariae, a species that preferentially invades normocytes68 (figure 1.8 c). Both P. ovale
species exclusively invade reticulocytes67 and may have developed novel invasion pathways through
theRBP2 expansion, similar toP. vivax. This supports a role for RBP2 gene expansions specifically in
reticulocyte invasion. RBP3 genes seem to be pseudogenized in all reticulocyte-infective species, while
they are fully functional in normocyte-infective species, suggesting a role in normocyte-invasion for
RBP3.
Duffybinding proteins (DBPs) are also important for erythrocyte invasion155. P.malariae has one
functional and one recently pseudogenized DBP, while both P. ovale have two functional copies. It
is believed that P. vivax struggles to infect duffy-negative humans due to relying on its DBP binding
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Figure 1.8: Reticulocyte binding protein changes in P. malariae and P. ovale. a) Phylogenetic tree of all full-length func-
tional RBPs in P. malariae (Red branches), P. o. curtisi (Blue branches without stars), P. o. wallikeri (Blue branches with
stars), and P. vivax (Green branches). Brackets indicate the different subclasses of RBPs: RBP1a, RBP1b, RBP2, and RBP3.
b) ACT 55 view of functional (Orange) and pseudogenized (Grey) RBP1a and RBP1b in ve species (P. vivax, P. o. curtisi,
P. o. wallikeri, P. malariae, P. malariae-like). Blue indicates assembly gaps. Red bars between species indicate level of se-
quence similarity, with darker colour indicating higher similarity. c) Number of RBP genes in each of the three RBP classes
(RBP1, RBP2, RBP3) by species (P. vivax, P. o. curtisi, P. o. wallikeri, P. cynomolgi, P. malariae, P. knowlesi) grouped by
erythrocyte invasion preference (reticulocyte versus normocyte).
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Figure 1.9:Multiple RBP-encoding genes are pseudogenized between the two P. ovale species. a) PhyML 128 generated
phylogenetic tree of all RBP-encoding genes over 1kb long in P. o. curtisi (light blue) and P. o. wallikeri (light red). Pseu-
dogenes are denotedwith P. Multiple functional RBP2 genesmatch upwith pseudogenized copies in the other genome.
The gene IDs in the gure are not meant to be legible. b) ACT 55 view of RBP1b in red for P. o. curtisi (bottom) and the
corresponding disrupted open reading frame in P. o. wallikeri (top), with black ticks indicating stop codons. Reads (in blue)
from an additional P. o. wallikeri sample (PowCR02) con rm the bases introducing the frameshift (green square) and
premature stop codon (yellow square) in RBP1b.
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the Duffy antigen, with recent studies showing an association between duffy-negative infectivity and
P. vivax strains containing a DBP duplication218. The fact that P. malariae and P. ovale are found
throughout Africa (figure 1.1 a) suggests that they are capable of infecting duffy-negative individuals.
This implies that one DBP copy appears to be sufficient for P. malariae to infect humans who are
duffy-negative.
1.10 Differential Selection Pressures
Using four additional P. malariae samples, two additional P. o. curtisi samples and two P. malar-
iae-like and P. o. wallikeri samples each (appendix table A.1), I investigated differences in selection
pressures between two species that diverged based on host differences (P. malariae and P. malariae-
like), and two species that supposedly diverged within the same host (P. o. curtisi and P. o. wallikeri).
GATK’s UnifiedGenotyper215 was used to call SNPs and, following standard filtering (Appendix A),
I retained 230,881 SNPs in P. malariae and 1,462,486 SNPs in P. ovale (tables 1.7 & 1.8). Excluding
subtelomeric regions, the pairwise nucleotide diversity between the different P. malariae samples is
3.2 x 10−4 and for the P. o. curtisi samples it is 1.9 x 10−4, which are lower than the estimates we
obtained for P. vivax (9.9 x 10−4) and P. falciparum (5.7 x 10−4) using the same methodology. The
nucleotide diversity for P. malariae-like is 6.5 x 10−3. Interestingly, the nucleotide diversity of P. o.
wallikeri (3.7 x 10−4) appears to be much higher than that of P. o. curtisi, though this is difficult to
confirm due to low sample numbers.
Every core gene withmore than 5 nucleotide substitutions and which had identifiable orthologs in
P. falciparum andP. vivax (2,343 genes inP.malariae, 4,023 genes inP. o. curtisi) was analysed for ev-
idence of selection, using the following approaches: theHudson-Kreitman-Aguade ratio (HKAr)152,
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Table 1.7: P. malariae & P. malariae-like SNPCalling Results
Sample ID PmMY01 PmID01 PmMA01 PmGN01 PmlGA01a PmlGA02a
Raw SNPs 218,334 164,541 173,028 239,655 458,790 211,686
- Private 48,094 19,475 25,901 66,377 260,540 68,793
- Ref 712,758 696,634 706,817 737,236 386,915 261,042
- Missing* 50,394 86,900 74,936 28,776 165,813 415,250
Filtered SNPs 8,970 8,589 7,742 7,878 161,551 140,113
- Private 2,149 2,066 1,908 2,066 77,781 56,571
- Ref 221,923 222,247 223,058 223,003 69,466 90,571
- Missing* 0 0 0 0 0 0
a P. malariae-like sample
*sites at which the sample has no coverage
SNP calling results as per mapping all P. malariae and P. malariae-like samples against the PmUG01 PacBio reference genome assembly. The
raw SNPs are the total number of SNPs that I called using GATK 215 default parameters in the different samples. Of these raw SNPs, some are
exclusive to a certain sample (Private), are identical to the reference genome (Ref), or there is no coverage and therefore no SNP call could be
made (Missing). The same information is also shown for the filtered SNPs, which were filtered according to a number of different parameters
(Appendix A).
Table 1.8: P. ovale curtisi & P. ovale wallikeri SNPCalling Results
Sample ID PocGH02 PocCR01 PowCR01 PowCR02
Raw SNPs 171465 277978 2139946 1881088
- Private 36487 99083 333727 83609
- Ref 2287008 2249682 693405 674071
- Missing* 84743 72495 104013 149166
Filtered SNPs 29099 46695 1415164 1410434
- Private 6162 16026 21081 16699
- Ref 1433387 1416042 45978 50845
- Missing* 0 0 0 0
a P. ovale wallikeri sample
*sites at which the sample has no coverage
SNP calling results as per mapping all P. o. curtisi and P. o. wallikeri samples against the PocGH01
Illumina reference genome assembly. The raw SNPs are the total number of SNPs that I called using
GATK 215 default parameters in the different samples. Of these raw SNPs, some are exclusive to a certain
sample (Private), are identical to the reference genome (Ref), or there is no coverage and therefore no
SNP call could bemade (Missing). The same information is also shown for the filtered SNPs, whichwere
filtered according to a number of different parameters (Appendix A).
70
which is the ratio of interspecific nucleotide divergence to intraspecific polymorphisms (ie. diversify-
ing selection), Ka/Ks241, to look for an enriched number of nonsynonymous differences compared to
synonymous differences (ie. positive selection), and the McDonald Kreitman (MK) Skew174, a mea-
sure of maintained polymorphisms (ie. balancing selection). Appendix A contains further details on
how these selection measures are calculated. Due to differences in denominators for HKAr measures
making comparisons between the species pairs invalid, for each species pair I therefore calculated the
mean HKAr and used a threshold of two standard deviations above that mean to signify an elevated
HKAr. For P. malariae/P. malariae-like, a threshold of HKA > 0.27 was determined while a thresh-
old of HKA > 0.075 was found for P. o. curtisi/P. o. wallikeri. Using those thresholds, I found 3.5%
of genes (81/2,343) to have an elevated level of HKAr in P. malariae but significantly fewer (1.4%;
55/4,023) in P. o. curtisi (2-sample test for equality of proportions, p < 0.001) (table 1.9). More genes
under significant balancing selection were seen in P. malariae (17/2,343, 0.7%) than in P. o. curtisi
(4/4,023, 0.1%) (p < 0.001). Additionally, more genes are under strong positive selection (Ka/Ks > 2)
in P. malariae (131/2,343, 5.6%) than in P. ovale (58/4,023, 1.4%) (p < 0.001), with most P. malar-
iae genes having a higher ratio of nonsynonymous to synonymous fixed mutations compared to P.
o. curtisi (figure 1.10 a). This genome-wide increase in nonsynonymous fixations is indicative of a
population bottleneck, which may underlie the high proportion of genes with signatures of positive
or balancing selection in P. malariae.
Looking at specific genes under selection, similar geneswere identified in theP.malariae/P.malar-
iae-like test as in an earlier P. falciparum/P. reichenowi study259, hinting at conserved selection pres-
sures in speciation between human and chimpanzee hosts (table 1.10). A number of genes have
high HKAr values in both comparisons (figure1.10 b), including MSP1 and a number of gameto-
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Figure 1.10: Population genetics measures differ between P. malariae and P. o. curtisi. a) Nonsynonymous versus syn-
onymous xedmutations per gene for both the P. o. curtisi/P. o. wallikeri (blue) and the P. malariae/P. malariae-like (red)
comparisons. While the former hasmost genes centred around the x=y line, the latter hasmost genes below this line with
more nonsynonymous than synonymousmutations, indicative of an ancestral bottleneck. b) Gene-wide HKAr values for
the P. falciparum/P. reichenowi comparison, described earlier 259, versus HKAr for the P. o. curtisi/P. o. wallikeri (blue)
and the P. malariae/P. malariae-like (red) comparisons (respective thresholds shown in corresponding colours). Three
genes show elevated HKAr values for both comparisons: 1) ADP/ATP carrier protein (PF3D7_1004800) 2) merozoite
surface protein 1 (PF3D7_0930300) 3) conserved Plasmodium protein (PF3D7_0311000). c) Log2 of p-values of gene-
wideMK tests for the P. falciparum/P. reichenowi comparison 259 by P. o. curtisi/P. o. wallikeri (blue) and P. malariae/P.
malariae-like (red) comparisons. Three genes have signi cantMK skews (log2(p) < -3) for both comparisons: 1) con-
served Plasmodium protein (PF3D7_1361800) 2) apical membrane antigen 1 (PF3D7_1133400) 3) NAD(P)H-dependent
glutamate synthase (PF3D7_1435300). d) Barplots of proportion of P. malariae (above) and P. o. curtisi (below) genes
expressed at different stages (No peak expression (grey), ookinete (blue), gametocyte (green), intraerythrocytic (red), and
other stage(yellow)) binned by Ka/Ks, with the number of genes in each bin displayed (n =). P. o. curtisi genes with very
high Ka/Ks values (> 2.5) are enriched for gametocyte genes.
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Table 1.9: Genes with signi cant scores in two ormore population genetics measures
Species Gene ID Gene Product
P. malariae PmUG01_05040800 hypothetical protein
P. malariae PmUG01_07023900 alkaline phosphatase
P. malariae PmUG01_13030900 transcription factor with AP2 domain
P. malariae PmUG01_14040200 conserved Plasmodium protein
P. malariae PmUG01_14019500 conserved Plasmodium protein
P. malariae PmUG01_12012900 conserved Plasmodium protein
P. malariae PmUG01_07042000 merozoite surface protein 1
P. malariae PmUG01_10013600 formin 1
P. malariae PmUG01_13030700 rRNA (adenosine-2’-O-)-methyltransferase
P. malariae PmUG01_14062900 merozoite surface protein 9
For the three population geneticsmeasures (HKAr, Ka/Ks, andMKSkew), the table shows the genes that have significant values
in two or more of these measures. These genes therefore represent genes under significant selection pressures.
cyte/ookinete genes such as EGF-like membrane protein, ferrodoxin reductase-like protein and an
ADP/ATP carrier protein. Two blood stage genes have significant MK skews for both comparisons
(figure 1.10 c), including a conserved protein of unknown function and apical membrane antigen 1.
Amongst genes with significant selection coefficients in both comparisons Gene Ontology (GO) an-
notations of ‘pathogenesis’ and ‘entry into/exit from host cell’ are significantly enriched. Similarly, a
number of blood stage genes are found to have both high HKAr and significant MK skews, includ-
ingMSP1,MSP9, and formin-1, all of which are known to be important in invasion and also have the
sameGOterms enriched. Oneof the geneswith the highestKa/Ks in theP.malariae/P.malariae-like
comparison is RBP1a, which has 37 nonsynonymous fixed differences between the two species and
only 6 synonymous fixed differences. The other two intact RBPs are much more highly conserved.
These data overall suggest that the selection pressures acting on P. malariae and P. falciparum lin-
eages have been similar since the split from their chimpanzee-infecting relatives, and that this selection
is acting primarily on blood stage genes and certain sexual stage genes.
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Table 1.10: Genes with signi cant scores in same test for both P. falciparum/P. reichenowi and either P. o. cur-
tisi/P. o. wallikeri or P. malariae/P. malariae-like
Species Gene ID Gene Product
P. malariae PmUG01_09042600 apical membrane antigen 1
P. malariae PmUG01_11024300 conserved Plasmodium protein
P. malariae PmUG01_03026800 ferrodoxin reductase-like protein
P. malariae PmUG01_07042000 merozoite surface protein 1
P. malariae PmUG01_08020600 ADP/ATP carrier protein
P. malariae PmUG01_08045200 conserved Plasmodium protein
P. malariae PmUG01_11040300 EGF-like membrane protein
P. o. curtisi PocGH01_13025000 NAD(P)H-dependent glutamate synthase
For the three population genetics measures (HKAr, Ka/Ks, and MK Skew), the table shows the genes that have significant
values in both the P. falciparum/P. reichenowi comparison and either the P. o. curtisi/P. o. wallikeri or the P. malariae/P.
malariae-like comparison.
As expected, I do not see any significant sharing of selection pressures for the two P. ovale species
with P. falciparum/P. reichenowi (table 1.10), besides an NAD(P)H-dependent glutamate synthase
which has a significant MK skew in both comparisons (figure 1.10 c). P. ovale genes with significant
HKAr values include a number of transporters, including a homolog of anABC transporter (MRP2),
with GO terms enriched for ‘drug transmembrane transport’ and ‘intracellular transport’. However,
the five genes with the highestHKAr are all gametocyte and ookinete genes, including among others a
transcription initiation factor TFIID and a mago nashi homolog protein, the latter potentially being
involved in sex determination195. We also find that genes with lowKa/Ks (<0.5) and very high Ks/Ks
(>2.5) are enriched for gametocyte genes (hypergeometric test, p < 0.0001 and p < 0.001 respectively)
(figure 1.10 d). Genes with high Ka/Ks values that are gametocyte-associated are enriched for genes
of unknown function (hypergeometric test, p < 0.001), suggesting important novel Plasmodium bi-
ology. Of the four genes with significant MK skews in P. o. curtisi, one is a kelch protein while the
others are involved in ‘DNA replication’ and ‘Telomeremaintenance’. These results hint at a number
of possible divergences between the two P. ovale species, including possible differences in drug sus-
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ceptibility, changes in gametocyte genes that may have enabled speciation, while differences in DNA
replication may possibly be linked to the different relapse times.
1.11 Conclusion
The high-quality genome sequences of P. malariae and P. ovale and their annotation presented here
provide a rich new resource for comparative Plasmodium genomics. They provide a foundation for
further studies into the biology of these two neglected malaria species, as well as new tools to explore
genus level similarities and differences in infection. The genome sequences have revealed a number of
genomic adaptations andpossible consequences related to the success of these species in sustaining low
parasitaemia infections, including gametocyte gene expansions and an increase in genome size. The
genome sequences suggest that the rodent-infective malaria species may be the result of an ancestral
host switch from a primate-infective species and also conclusively show that P. ovale is a species com-
plex, consisting of two highly diverged species, P. o. curtisi and P. o. wallikeri. The genome sequences
reveal a novel type of subtelomeric gene family in P. malariae occurring in doublets and potentially
having anRH5-like fold. Having access to a larger number of genome sequences also allows us to iden-
tify features such as the RBP2 gene expansion in reticulocyte invading Plasmodium species. Multi-
sample analysis of the two species highlights differences in selection pressures between host-switching
and within-host speciation, as well as the omnipresent selective pressure during red blood cell inva-
sion. These genome sequences will now enable more comprehensive studies of human-infectivity in
Plasmodium species.
In addition to their important uses in understanding the evolutionary history of the Plasmodium
genus, these new genome sequences will now also enable us to better understand and characterize the
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P. malariae, P. o. curtisi and P. o. wallikeri infections that are detected in clinical settings. Upon
completing the analysis presented in this chapter, I was made aware of the fact that the patient who
provided the P. malariae sample used for the reference genome assembly had subsequently returned
to the hospital with a recrudescent infection of P. malariae. Analysing and understanding from a ge-




The belief is growing on me that the disease is communi-
cated by the bite of the mosquito. … She always injects a
small quantity of fluid with her bite - what if the parasites
get into the system in this manner?
Ronald Ross, Letter to Patrick Manson, 1896 CE
2
A case of clinical treatment failure in a P.
malariae infection
2.1 Abstract
Plasmodium malariae is the only human malaria parasite species with a 72-hour intraerythrocytic
cycle and the ability to persist in the host for life. Here I present a case of a P. malariae infection with
clinical recrudescence after directly observed administration of artemether/lumefantrine. By using
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whole-genome sequencing, I show that the initial infectionwas polyclonal and the recrudescent isolate
was a single clone present at lowdensity in the initial infection. Haplotypic analysis of the clones in the
initial infection revealed that they were all closely related and were presumably recombinant progeny
originating from the same infective mosquito bite. I review possible explanations for the P. malariae
treatment failure and conclude that a 3-day artemether/lumefantrine regimen is suboptimal for this
species because of its long asexual lifecycle.
2.2 Introduction
During the past decade, intensification of malaria control efforts has substantially reduced the global
burden ofmalaria from Plasmodium falciparum. This trend has often been associated with increased
recognition of the burden of malarial disease caused by the other Plasmodium species1. P. malariae,
one of the six Plasmodium species that commonly infect humans, is endemic throughout parts of
Africa222,39, South America311, Asia, and the Western Pacific163. P. malariae is unique among the
human-infective Plasmodium species in having a 72-hour intraerythrocytic lifecycle with variable but
often prolonged pre-erythrocytic intrahepatic development68. P. malariae can persist in the human
host for years and possibly an entire lifetime. Although it is often asymptomatic, chronic parasitemia
in endemic areas is associated with substantial rates of illness, including anemia and nephrotic syn-
drome119,87,178.
A key strategy for malaria elimination is the strengthening of health systems to deliver early diag-
nosis and highly effective therapy. Artemisinin-based combination therapy (ACT) has been central
to this approach, with proven efficacy against multidrug-resistant P. falciparum, multidrug-resistant
P. vivax, and against P. knowlesi 246,290,86,124. In recent years, there have been increasing calls for a uni-
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versal policy of ACT for all species of malaria246,290,86,124. However, the efficacy of ACT against P.
malariae is poorly documented.
Although chronic infection with P. malariae is well-recognized19, little is known regarding how
the parasites manage to evade host immunity and the intrahost dynamics of the underlying parasite
population. In Chapter 1, I described the production and analysis of a new reference genome for P.
malariae. The P. malariae reference genome is 33.6 Mb in size, has 6,540 genes, and has an average
GC content of 24%301.
Here I report a case of a P. malariae infection in a patient residing in a non–malaria-endemic envi-
ronment that resulted in recrudescence months after treatment with artemether/lumefantrine (AL).
By using whole-genome sequencing of isolates from the initial and the recrudescent infection, I show
that the two major P. malariae haplotypes, constituting 90% of the parasite load in the initial infec-
tion, were cleared successfully by AL, whereas a third haplotype, constituting a minority subpopula-
tion in the initial infection, survived and recrudesced.
All methods used for this chapter are detailed in Appendix C. The clinical work performed in the
‘patient presentation’ section was performed by Dr. Ian Marr from the Royal Darwin Hospital in
Australia, while the genetic data analyses were all performed by me.
2.3 Patient Presentation
A 31-year-old Uganda-born man, weighing 77 kg (170 lbs), who had been a resident in Australia for
5 years sought care at Royal Darwin Hospital (Darwin, Northern Territory, Australia) on March 1,
2015, with a 4-day history of fevers and headaches. He had returned to Australia 56 days previously
after a 2-week trip toUganda visiting friends and relatives (figure 2.1 a& e). He had spent 14 days in a
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ruralmalaria-endemic area in easternUganda. Althoughhe hadnot taken regularmalaria prophylaxis,
he had self-medicatedwith a locally acquired oral course of AL on the second and third day of his trip,
despite being clinically well (figure 2.1 b & d). He returned to Australia (now a malaria-free country)
in January 2015 until seeking care after a short febrile illness in late February. On examination, he
had a tympanic temperature of 37.5°C and a heart rate of 110 beats/min but no manifestations of
severe malaria. Rapid diagnostic testing with BinaxNOW (Binax, Inc, InvernessMedical Professional
Diagnostics, Scarborough, ME, USA) for malaria was positive for aldolase but negative for histidine-
rich protein 2. Species-specific PCR was positive for P. malariae and negative for all other Plasmod-
ium species. Thick and thin blood film examination confirmed P.malariae parasitemia (12,140 para-
sites/µL) with all stages of asexual development visible on the blood film (figure 2.2 a& b). The blood
filmwas otherwise unremarkable; in particular, no evidence for hyposplenismwas found. The patient
was not immunosuppressed, and an HIV serologic test was negative. A hepatitis C serologic test was
positive but with a viral load that was below the limit of quantification (<12 IU/mL).
The patient was administered a single 20/120mg tablet of AL on the first day because of a prescrib-
ing error but subsequently continuedwith a supervised standard regimenof 80/480mgevery 12hours
taken with fatty food to complete a full course of 6 doses over 3 days, equivalent to a total dose of 6.2
mg/kg of artemether and 37.4 mg/kg of lumefantrine. Glucose 6-phosphate dehydrogenase function
was normal, and a single 30-mg dose of primaquine was administered on day 2. His hemoglobin was
126 g/dL and he received no blood transfusion. After treatment, his parasitemia declined to 1,269/µL
at 32 hours, 488/µL at 41 hours, and 55/µL at 56 hours. He was afebrile and symptom-free within
36 hours of admission. However, before discharge on day 6, thick blood film examination was still
positive (192/µL), but by day 11, his repeat blood film examination and his aldolase rapid diagnostic
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Figure 2.1: Timeline of the clinical case of a patient with Plasmodiummalariae infection diagnosed and treated at Royal
Darwin Hospital, Darwin, Northern Territory, Australia, March–April 2015, showing the timing (A), treatment (B), para-
site’s genotype as inferred fromwhole-genome sequencing (C), clinical presentation (D), and location (E). The rounded ar-
row indicates the recrudescence of theminor haplotype 2 in the initial infection to dominatemonoclonally in the second
infection. AL, artemether/lumefantrine; H1, haplotype 1; H2; haplotype 2;MPAg, pan-malarial antigen; R1, reference
haplotype.
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Figure 2.2: Positive Plasmodiummalariae thin blood lms. Thin smear scans of the initial infection (A, B) and of the re-
crudescence (C, D), both indicating a P. malariae infection.
test results were negative.
The patient remained in urban Darwin but returned to the hospital 52 days later, on April 22,
2015, with a 2-week history of fevers, fatigue, and headache. Microscopy again identified P. malariae
with a parasite count of 3,332/µL (figure 2.2 c & d). Chloroquine was unavailable, so the patient
was retreated with oral hydroxychloroquine with an 800-mg loading dose, followed by 400 mg at 6
hours, 400 mg at 24 hours, 400 mg at 48 hours, and a single 45-mg dose of oral primaquine. The
parasite count declined rapidly to 37/µL at 28 hours, 191/µL at 49 hours, and 76/µL at 88 hours of
treatment. His symptoms resolved rapidly. Thick and thin blood films were negative on day 4 and
remained negative on retesting at days 8, 35, 41, and 84, and the patient remained free of symptoms
throughout. A PCR on blood collected at 12 weeks was also negative.
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Figure 2.3: Similar SNP spectra for PmUG01 and PmUG02. Multidimensional scaling plot based on differences in SNP
spectra between the different P. malariae samples 301, showing that the initial (PmUG01) and the recrudescent (PmUG02)
infections are signi cantly more similar to each other than to the other P. malariae samples. This suggests that the two
infections have a similar origin.
2.4 Whole-Genome Sequencing
Extensive sequencing was performed from blood samples obtained from the initial (PmUG01) and
recrudescent (PmUG02) infection (appendix table C.1), covering >99% of the genome at >20x for
both infections. By using additional P. malariae samples published previously301, I identified single-
nucleotide polymorphisms (SNPs) using GATK’s UnifiedGenotyper (Broad Institute, Cambridge,
MA, USA)215 and filtered them based on several parameters (appendix table C.2). A multidimen-
sional scaling plot of the samples based on their SNP allele frequency-spectra revealed that PmUG01
and PmUG02 were more closely related to each other than to any of the other samples (figure 2.3), as
expected if they were related recombinants derived from the same original infection.
Searching solely for SNPs that distinguish PmUG01 and PmUG02, I identified 2,631 variants af-
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Table 2.1: Changes in genotype calls between the two infections








HR=Homozygous reference, HA =Homozygous alternate, h = heterozygous
* in repetitive region of rhoptry-associated membrane antigen
ter filtering (appendix table C.3). PmUG01 was the sample from which the reference genome (R1)
was constructed301, and only one SNP in PmUG01 suggested a nucleotide base different from the
reference strain, probably because it was in a repetitive region (table 2.1). PmUG01 appeared to be a
polyclonal infection with a bimodal distribution of alternate (ie., nonreference) alleles at frequencies
of 0.15 and 0.35 (figure 2.4 a). Conversely, PmUG02 appeared to be amonoclonal infectionwith 85%
of sites being either fixed for the reference allele or for an alternative allele (figure 2.4 b). Comparison
of the initial and recrudescent infections revealed that heterozygous sites in the initial infection had
become either homozygous alternate (40%) or homozygous reference (45%) (table 2.1). Analysis of
the genotype calls across the genome (figure 2.5) revealed that, whereas the heterozygous sites from
the initial infection were spread evenly across the 14 chromosomes, the homozygous alternate sites
in the recrudescent infection were present in distinct clusters, implying that the initial infection was
polyclonal and that the recrudescence was attributable to a single clone that was closely related to the
reference clone.
Comparison of the distribution of the alternate allele frequencies throughout the genome of the
initial and recrudescent strain (figure 2.6) revealed bands of alleles at frequencies of 0.15 and 0.35 in
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Figure 2.4: Differences in SNP frequencies between PmUG01 and PmUG02. SNP frequency bar plots for both the initial
infection (A) and the recrudescence (B), showing that there was a signi cant shift in the SNP frequency spectra between
the two infections, with the initial infection being a polyclonal infection, while the recrudescence seems to bemonoclonal.
Interestingly, the initial infection seems to have a bimodal distribution of heterozygous SNPs.
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Figure 2.5: Clustered SNP distribution in PmUG02 across chromosomes. Distribution of heterozygous sites (yellow) in
the initial infection (PmUG01) and homozygous alternate sites (other colors) in the recrudescence (PmUG02) across
the 14 chromosomes of P. malariae. The different colors for the homozygous alternate SNPs are arbitrary. Chromosome
regions withmore heterozygous sites in the initial infection becoming homozygous reference than becoming homozygous
alternate in the recrudescence aremarked in green. Genotypes were plotted using Artemis 300.
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the initial infection spatially clustered throughout the genome (figure 2.7). The alleles that increased
in relative frequency in PmUG02weremostly at frequencies of 0.15, whereas the alleles at frequencies
of 0.35 decreased in frequency and the positions became homozygous reference in PmUG02 (figure
2.7 & 2.6). These data strongly suggested that, in addition to R1, two minor clones (minor haplo-
types) were also present. Of these two, the clone with the haplotype comprising alternate alleles at
frequencies of 0.35 (H1) appeared to have been eliminated during the drug treatment because no al-
leles specific to H1 were present in the recrudescent infection. The other minor clone comprised a
haplotype with alternate alleles at frequencies of 0.15 (H2) in the initial infection; this clone appeared
to have caused the recrudescence (figure 2.1 c). Based on the relative alternate allele frequencies of
the 3 haplotypes in the initial infection, 60% of the parasites were of the R1 haplotype, 30% of H1,
and 10% of H2. These estimates were broadly consistent with the ratio of alleles in tri-allelic sites
(0.69:0.22:0.09) (appendix table C.4). The ratio of alleles in these tri-allelic sites changes markedly
in PmUG02 (0.13:0.06:0.81), with over half of sites becoming homozygous for H2 but with some
heterogeneity in the other sites (appendix table C.5), probably because of the low coverage depth and
because they were in repetitive regions.
Unexpectedly, several SNPs at high allele frequencies (>0.4) also increased in frequency in the re-
crudescent strain. Testing by using additional P.malariae samples301 showed that 80% of these SNPs
were homozygous for the alternate allele in >1 other P.malariae samples, whereas 30%were homozy-
gous in all other P. malariae samples (figure 2.8). This observation indicated that of these unusual
SNPs, 50%were highly polymorphic, whereas 30%were probably low frequency SNPs with rare vari-
ants present in the reference strain. This would explain the observation of SNPs with high reference
allele frequency in the initial infection that became homozygous alternate in the recrudescence, given
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Figure 2.6: Changes in the SNP frequencies from the initial infection (left) to the recrudescence (right), coloured by
whether the SNP increases in frequency (green) or decreases (red).
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Figure 2.7: Analysis of theminor haplotype (H2) that caused recrudescence of Plasmodiummalariae infection in a pa-
tient at Royal Darwin Hospital, Darwin, Northern Territory, Australia, March–April 2015, showing distribution of SNP
alternative (nonreference) allele frequencies across the 14 chromosomes (boxes in themiddle and dotted vertical lines)
in the initial infection (bottom plot) and the recrudescence (top plot). The SNP colors (green, increasing in frequency; red,
decreasing in frequency) form two clear bands, corresponding to H1 (yellow box) andH2 (pink box). H2 probably caused
the recrudescence given that all of its alleles increase considerably in frequency. Colored boxes in center of chart indicate
chromosome sharing. H1, haplotype 1; H2, haplotype 2; R1, reference genome; SNP, single nucleotide polymorphism.
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Figure 2.8: Unusual SNPs in other P. malariae samples. Presence/absence in other P. malariae samples of SNPswith SNP
frequencies of over 0.4 in the initial infection that increased in frequency in the recrudescence. The black bar indicates
SNPs that are present in all other P. malariae, suggesting that the reference strain is rather the variant compared to the
general population. The gray bar indicates SNPs that are present in multiple other P. malariae samples, suggesting that
they are highly polymorphic sites. In sum, this suggests that most of these SNPs are likely SNPs shared by both H1 and
H2, explaining why they have high frequencies in the initial infection and in the recrudescence.
that they were probably SNPs with alternate alleles shared by H1 and H2.
To clarify the relationships of the different haplotypes with each other, I classified every genome
region by whether any of the 3 haplotypes were identical to each other (figure 2.7). Approximately
25% of the genome is shared between H1 and R1 and between H2 and R1. No regions were shared
between H1 and H2, which suggested that both H1 and H2 were half-siblings of R1, although they
did not share any parent between themselves (figure 2.9). The finding that all haplotypes were related
to each other through R1 further suggested that all strains were transmitted from the same mosquito
bite and that the mosquito ingested at least 4 different parental haplotypes (figure 2.9).
Analysis of SNPs in orthologs of known drug-resistance genes identified three nonsynonymous
SNPs in the multidrug resistance protein 2 (pfmdr2) gene, one of which was in the ABC transporter
domain, and two in the ABC transporter domain of ABC transporter C family member 2, present
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Figure 2.9: Inferred number of parental haplotypes. The relatedness of the three haplotypes in the initial infection (off-
spring haplotypes) as inferred by the sharing of genomic regions. This sharing suggests that there were four parental
haplotypes present in themosquito that interbred to form the three haplotypes we see in the initial infection. Of these, it
seems that R1 is a half-sibling with both H1 andH2, but via a different parental haplotype.
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in the recrudescent strain (H2) but not the other strains (table 2.2). No evidence was found for copy
number variation in any gene compared with the reference strain, and the reference strain did not
appear to have an amplification of the multidrug resistance protein 1 gene compared with any of the
other P. malariae samples.
2.5 Discussion
This report of a case of recurrent P. malariae malaria is unusual in that it describes the molecular
characterization and confirmation of a treatment failure after directly observed, appropriately admin-
istered, quality-assured AL dosing in a nonendemic environment where reinfection was not possible.
Whole genome sequencing demonstrated that the recrudescence was attributable to a minor clone
present in the initial polyclonal infection. The case raises two important questions: first, what was
the cause of treatment failure; and second, why did recrudescence arise from the minor clone rather
than a dominant reference clone?
Although the efficacy of AL for P. malariae infection is assumed in many national guidelines176,
P. malariaemonoinfections are relatively unusual and often of low density. To my knowledge, there
have been no published efficacy series of ALwith the long follow-up necessary to assess efficacy against
a parasite with a 72-hour life cycle. In a non-randomized efficacy study of 4 PCR-confirmedP.malar-
iae infections treated with AL in Gabon (one P. malariaemonoinfection and three mixed P. malar-
iae/P. falciparum infections), all 4 weremicroscopy negative at day 28, with no follow-up beyond this
time223. Among 80 PCR-confirmed P. malariae/P. falciparummixed species infections in Uganda,
12% were still PCR-positive for P. malariae at day 7 and 6% were still PCR-positive on day 1731.





































































































































































































































































































































































































































































































and four months after AL treatment of an initial microscopy-diagnosed P. falciparum infection in
returned travelers with no further possible malaria exposure327,107,46.
Several plausible explanationsmight account for a recurrence ofP.malariae parasitemia after treat-
mentwithAL (figure 2.10). The last indigenous case ofmalaria in theNorthernTerritorywas in 1962,
with no subsequent cases of introduced malaria or autochthonous transmission170; hence, the possi-
bility of reinfection can be excluded (figure 2.10 a). Additionally, the presence of the H2 haplotype
in the initial infection and recrudescent infection confirms treatment failure.
Inadequate drug absorption resulting in suboptimal serum drug concentrations can cause treat-
ment failure (figure 2.10 b). Artemether is rapidly absorbed and eliminated (half-life of a few hours),
whereas lumefantrine is variably absorbed and more slowly eliminated (half-life approximately 3.2
days)99. Lumefantrine is a lipophilic compound with erratic bioavailability unless administered with
a small fatty meal17, and for this reason, guidelines recommend administration of AL with a fatty
meal such as milk or a small biscuit. In the case of this patient, adequate serum concentrations of
lumefantrine could not be confirmed; however, the patient took a complete course of treatment, and
all doses were supervised in the hospital and administered with a milk biscuit to ensure good absorp-
tion. None of the treatment doses were vomited. In this scenario, one would expect >98% efficacy
against P. falciparum376. In addition, the clones associated with the R1 andH1 haplotypes, account-
ing for 90% of the parasite load, were cleared, suggesting that the plasma drug concentrations were
sufficient to eliminate both infections. Nevertheless, considerable inter-individual variation exists in
lumefantrine exposure, and this patient may have had relatively low concentrations.
Cure of malaria in a nonimmune patient requires that antimalarial blood concentrations are sus-
tained above theparasites’miniumuminhibitory concentration (MIC)until the entire parasite biomass
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Figure 2.10: The different scenarios under which a second Plasmodiummalariae infection could have occurred from the
initial infection diagnosed in a patient at Royal Darwin Hospital, Darwin, Northern Territory, Australia, March–April 2015.
Initial infection is shown in the inner circle. A) A completely new infectionmight have caused the secondmalaria onset. B)
The drugmight not have been absorbed at suf cient levels to kill all the parasites in the blood (pharmacokinetic cause).
C) The longer intraerythrocytic lifecycle of P. malariae (72 hours) might have enabled some parasites to survive the drug
action until lumefantrine concentrations became subtherapeutic (pharmacokinetic cause). D) H2 parasites might have
differentially sequestered with a biomass out of proportion with the peripheral parasitemia. E) Some parasites might have
formed dormant stages in the liver, blood, or elsewhere (pharmacodynamic cause). F) An immune responsemight have
been differentially primed against haplotypes at higher biomass. G) A haplotype within the initial infectionmight have
been relatively drug resistant ( tness advantage). H1, haplotype 1; H2; haplotype 2; R1, reference genome.
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has been eliminated. In the presence of antimalarial drugs, the parasite biomass generally decreases
over time in an exponential manner, with drug concentrations needing to be sustained above the
MIC for >4 lifecycles367. In the case of this patient, the baseline parasitemia at initial presentation
was 12,000/µL, which is relatively high compared with most P. malariae clinical infections68. Thus,
the combination of the long parasite lifecycle resulting in one rather than two asexual cycles being
exposed to artemether, and the short period (16 days) for which lumefantrine was at concentrations
sufficient to kill the parasite may have resulted in parasites surviving the initial treatment and reestab-
lishing a chronic parasitemia that was then sustained for 50 days before recrudescing (figure 2.10 c).
Another possibility is that someparasites couldhave sequestered (figure 2.10d) or becomedormant
(figure 2.10 e). Whereas dormancy would allow a proportion of the parasites to evade blood stage
schizontocidal activity, plausible sites for sequestration of P. malariae–infected erythrocytes would
still be exposed to therapeutic concentrations of blood stage antimalarials, making this possibility an
unlikely explanation for this patient’s recrudescent infection. P.malariae is well-recognized as having
a prolonged preerythrocytic phase and a prepatent period of 16–59 days68. The initial treatment
course of AL was administered 56 days after the patient left Uganda, so any preerythrocytic stages
were probably not present at the time of initial AL treatment.
Although the ability to form hypnozoites (dormant exoerythrocytic stages) occurs in three human
malaria parasite species (P. vivax, P. ovale curtisi, and P. o. wallikeri), the evidence that latent exoery-
throcytic stages do not occur in P. malariae is limited68. Case reports have documented P. malariae
producing symptomatic disease many years after exposure to infection, as noted in the case of a 74-
year-oldwoman inGreecewithP.malariae reactivation after >40 years357. Such latency suggests that
low-level parasitemia could persist for many years after infection, and indeed may be lifelong. In the
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case of this patient, parasite recrudescence occurred >100 days after he had left amalaria-endemic area.
Although inadequate drug absorption (figure 2.10 b), duration of treatment (figure 2.10 c), or
dormancy (figure 2.10 e) all may have contributed to parasite recrudescence, these indiscriminate ex-
planations would be expected to occur primarily in the dominant strain during the initial infection367
(figure 2.11 a). One could speculate that theH2minor parasite populationmight have emerged from
a hepatic schizont that ruptured days after those giving rise to the majority haplotypes and, despite
genetic similarity, had substantial differences in surface antigenicity. The antibody response to the
primary infection, which would have reached a maximum 3 weeks after the illness began, would have
been directed against the majority haplotypes and might not have recognized the minor population
(figure 2.10 f). Alternatively, more of the minor population might have been in the dormant state
compared with the dominant circulating clones with R1 or H1 haplotypes, or more might have been
at a higher biomass in erythrocytes sequestered elsewhere, enabling a proportion to evade antimalarial
drug action and recrudesce.
Finally, the minority clone with the H2 haplotype might have recrudesced because of a fitness ad-
vantage over the other clones/haplotypes (figure 2.11 b & c), possibly including relative resistance
to either artemether or lumefantrine (figure 2.10 g). In P. falciparum, resistance to artemether is ac-
quired through mutations in the propeller domain of K13334, whereas P. falciparum resistance to
lumefantrine is associated with mutations and copy number variation in the pfmdr1 gene283,356. Al-
though neither of these genes had nonsynonymous mutations in H2, one nonsynonymous muta-
tion was noted in the ABC transporter domain of pfmdr2, potentially involved in artemisinin re-
sistance221,208, and two nonsynonymous mutations were noted in the pfmrp2 gene, which has been
implicated in reduced ex vivo susceptibility to lumefantrine in P. falciparum251. I also identified two
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nonsynonymous SNPs in the dihydrofolate reductase homologue. Low serumconcentrations, amod-
est reduction in lumefantrine efficacy, the prolonged life cycle of P. malariae, and rapid elimination
of lumefantrine all might have contributed to the observed treatment failure in this patient.
2.6 Conclusion
I have described a case of P. malariae recrudescence occurring in a non–malaria-endemic country
after adequately administered AL. Whole-genome sequencing data revealed that the monoclonal re-
crudescence consisted of a minor haplotype that accounted for≈10% of the initial infection and that
all the haplotypes in the initial infection were related to each other and therefore probably originated
from the same infective mosquito bite. Although the haplotypes were closely related, the genomic
data suggests that 4 parental haplotypes were ingested by themosquito, indicating considerable diver-
sity and transmission of P. malariae. This case raises concerns about the adequacy of ACTs with a
short half-life partner drug, such as AL, in treating P. malariae infections and suggests that optimal
ACTs to treat P. malariae should include a slowly eliminated partner drug. This reinforces the im-
portance of a longer duration of follow-up monitoring of patients infected with P. malariae for late
recrudescence.
Thenewly assembledP.malariae reference genome sequenceopenedup thepossibility of analysing
and better characterising this particular case of recrudescentmalaria. While it was possible to gain new
insight into the potential sequence of events that led to the present case of P. malariae recrudescence,
little is known about drug resistance mechanisms in P. malariae and consequently only inferences
based on sequence homology could be made. Even for P. falciparum, understanding the genetic basis
of drug resistance is not straightforward. In Chapter 3, I will present an analysis I performed to better
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Figure 2.11: Indiscriminate versus targeted interventions. Differences in probabilities for (A) indiscriminate interventions
(i.e., explanations for a recrudescence) that affect all haplotypes in the infection equally, such as insuf cient drug dosage
or drug avoidance through a longer lifecycle, versus (B) targeted interventions that potentially affect one haplotype
different to another, for example haplotype-speci c drug resistance or an increased propensity for greater sequestered
biomass in one haplotype. The two scenarios show that the difference is in how an intervention ‘selects’ for n number
of parasites in the recrudescence. In an indiscriminate intervention, all haplotypes have the same probability of being
selected, while H2 is x timesmore likely to be selected in a targeted intervention. An indiscriminate intervention has a low
probability (<0.05) at all values of n > 1 (C), while the probability of a targeted intervention increases across all values of n
the higher x. If an indiscriminate intervention were to be the sole explanation for a recrudescence, then it would suggest
that only a singly parasite survived from the entire initial infection, an unlikely scenario. On the other hand, a targeted
intervention presents amore parsimonious explanation for the lower level haplotype recrudescing.
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understand the genetic basis of mefloquine response in P. falciparum malaria parasites, specifically
those that have acquired multidrug resistance in the Southeast Asian setting.
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Science, especially natural and medical science, is always
undergoing evolution, and one can never hope to have said
the last word upon any branch of it.
Alphonse Laveran, Arch. Méd. Expérim., 1892 CE
3
Genetic architecture of mefloquine
sensitivity in KEL1/PLA1 P. falciparum
3.1 Abstract
The current frontline antimalarial combination therapy, dihydroartemisinin-piperaquine, is rapidly
losing efficacy in Southeast Asia as the multidrug resistant KEL1/PLA1 P. falciparum co-lineage
spreads through the region. In the field, the spread of KEL1/PLA1 parasites has been accompanied
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by the disappearance of themdr1 copy number amplification, associated with mefloquine resistance.
This suggests that artesunate-mefloquine is an effective replacement first-line treatment. However, the
speed at whichmdr1 copy number has changed raises questions about the sustainability of a switch to
a mefloquine-based treatment. In this chapter I present an analysis of 430 Cambodian P. falciparum
field isolates that were whole-genome sequenced and assayed in vitro for mefloquine response (IC50).
I show that KEL1/PLA1 parasites are hypersensitive to mefloquine as a result of having merged with
the PLA1 lineage. Furthermore, a genome-wide association analysis identified a novel SNP associated
withmefloquine sensitivity, which has rapidly increased in frequency from2010 to 2013. Themutant
allele at this SNP is only observed to occur on the hypersensitive KEL1/PLA1 background, further
increasing the sensitivity tomefloquine of these parasites. The combined effect of the deamplification
ofmdr1, the acquisition of the PLA1 lineage, and the emergence of this novel SNP have resulted in
a complex genetic architecture of mefloquine sensitivity, which suggests that artesunate-mefloquine
could be effective and sustainable in the field.
3.2 Introduction
Artemisinin combination therapies, consisting of a potent but short-acting artemisinin derivative and
a longer-acting partner drug, are the frontline treatment for severe and uncomplicated malaria368.
Dihydroartemisinin-piperaquine treatment, used inCambodia,Vietnam,Thailand,Myanmar,China,
and Indonesia, is now increasingly becoming ineffective as resistance to treatment has emerged187,185.
Resistance to artemisinin, characterized by a reduction in the speed of parasite clearance, was first re-
ported in 2008 inWesternCambodia243, fromwhich it quickly spread throughout the region84,15,351.
While these slow-clearing artemisinin-resistant parasites were initially still cleared by the partner drug,
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piperaquine, they eventually acquired resistance to it9, leading to cases of complete treatment fail-
ure185,187,6.
Both artemisinin and piperaquine resistance have a genetic basis, with artemisinin resistance hav-
ing been linked to mutations in the propeller domain of the kelch 13 gene219,221,13, and piperaquine
resistance being associated with a copy number amplification of the plasmepsin 2 and plasmepsin 3
genes8,372. While artemisinin resistance has been shown to have emerged multiple times in Southeast
Asia342, one particular lineage, KEL1, outperformed others and eventually combined with the PLA1
lineage, associated with piperaquine resistance9. This multidrug resistant KEL1/PLA1 lineage is the
main agent of the current outbreak ofmultidrug resistance in Southeast Asia9,150, having spread from
Western Cambodia to other countries149, including Thailand, Laos, and Vietnam6,149,307,346.
In response to the loss of efficacy of dihydroartemisinin-piperaquine, alternative antimalarial drugs
are increasingly being looked at, including artesunate-mefloquine186. Anecdotal reports from the
field indicate that artesunate-mefloquine remains an effective treatment in regionswhereKEL1/PLA1
is widespread186. Mefloquine had been used as a monotherapy in the region during the late 1980s
and early 1990s, which eventually led to the rise of mefloquine resistance245. The genetic basis of
mefloquine resistance was mapped to a copy number amplification of themdr1 gene370,70,282, which
was widespread in Southeast Asia by the turn of the millennium282,246. As KEL1, and eventually
KEL1/PLA1, increased in frequency, the frequencyof themdr1 copynumber amplificationdecreased
in the region9,149, potentially leading to the current situation ofmefloquine being effective in the field.
As a result, deploying artesunate-mefloquine throughout the region is now an attractive option,
however the rapid spreadofKEL1/PLA1and the correspondingdeamplificationobserved formdr19,149
put into question the sustainability of deployingmefloquine in the long term. This concern is further
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exemplified by the recent observation of a rise in frequency of triple mutants in the region297. As a
consequence, a number of questions remain before this course of action can feasibly be considered.
While artesunate-mefloquine appears to be successful in regions where KEL1/PLA1 is widespread,
the individual response KEL1/PLA1 tomefloquine is not fully understood. If KEL1/PLA1 is meflo-
quine sensitive, then is this due to the loss of the mdr1 amplification or does KEL1/PLA1 exhibit
genetic changes that actively contribute to the sensitivity? Are there any other genomic changes in the
parasite population that associate with this observed mefloquine sensitization? And finally, is there
any evidence to believe that this sensitization is sustainable and that triple resistance won’t arise?
In this chapter, I present an analysis of 430Cambodian P. falciparum field isolates that were whole
genome sequenced and assayed in-vitro for mefloquine (MQ) 50% inhibitory concentration (IC50).
I show that KEL1/PLA1 parasites appeared to be hypersensitive to mefloquine as a result of having
mergedwith thePLA1 lineage, specifically through the acquisitionof the plasmepsin 2/3 copynumber
amplification. Furthermore, a genome-wide association study (GWAS) of all the samples identified a
novel SNP (F1068L) in themdr1 gene that appears to associate with mefloquine sensitivity and has
rapidly increased in frequency from 2010 to 2013. This SNP is only observed on the hypersensitive
KEL1/PLA1 background, leading these parasites to become ultrasensitive to mefloquine. The deam-
plificationofmdr1, amplificationof plasmepsin 2/3, and the acquisitionof this novelmdr1 SNP result
in a complex genetic architecture of mefloquine sensitivity that suggests that artesunate-mefloquine
may be more effective and sustainable in the field than initially thought.
All methods used for this chapter are detailed in Appendix D. All sample collection, sequencing,
and in vitro drug resistance assays were performed by collaborators. All data analysis presented in this
chapter was performed by me. A similar analysis that I performed using chloroquine IC50 values is
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described in Appendix E.
3.3 KEL1/PLA1 is hypersensitive to mefloquine
Originating from three provinces in Cambodia (Pursat, Preah Vihear, and Ratanakiri), 430 clinical
P. falciparum isolates were collected between 2010 and 2013 in clinical studies15,6,8,7 (table 3.1). At
the time of collection, artemisinin and piperaquine resistance were entrenched in Pursat, emerging in
Preah Vihear and rare in Ratanakiri6,8,7,15, as mediated by the outbreak of the KEL1/PLA1 P. fal-
ciparum co-lineage from Pursat to Preah Vihear9 and beyond150. To better understand the individ-
ual response of KEL1/PLA1 co-lineage parasites to mefloquine treatment, the collected samples were
subjected towhole genome sequencing (WGS) and phenotyped formefloquine (MQ) 50% inhibitory
concentration (IC50).
Table 3.1: Sample origin and collection year information
Year Pursat Preah Vihear Ratanakiri Total
2010 53 0 42 95
2011 76 58 54 188
2012 26 31 22 79
2013 37 19 12 68
Total 192 108 130 430
Number of samples whole genome sequenced and phenotyped from each of the provinces each year.
Of the430P. falciparum samples, 77 (17.9%)wereKEL1/PLA1parasites, 48 (11.2%)wereKEL1/non-
PLA1, 27 (6.3%) were non-KEL1/PLA1, and 268 (62.3%) did not belong to either lineage, with
10 (2.3%) samples being unclassifiable due to missing data. Additionally, mdr1 amplifications were
present across these groups (figure 3.1). I investigated the average response toMQ treatment of these
different parasite populations stratified bymdr1 amplification, as samples with the amplificationwere
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Figure 3.1: Showing the distribution of genotypes across the dataset, including KEL1, PLA1, andmdr1 ampli cation
genotype. Samples for which any of these three genotypes cannot be ascertained are considered unclassi able.
Figure 3.2:Me oquine IC50 by KEL1/PLA1 lineagemembership and strati ed bymdr1 CNV. The horizontal lines indicate
themedian (bold) and interquartile range (thin) of the respective distributions.
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significantly more resistant to MQ than those without (mean IC50 ± SD: 35.4 nM ±15.0 vs. 19.5
nM±11.1, Wilcoxon rank sum test with continuity correction: p < 5 x10−15 ) (figure 3.2). I found
that KEL1/PLA1 parasites appeared to be significantly more sensitive to mefloquine than wild type
(WT) parasites (12.7 nM ±10.2 vs. 23.5 nM ±12.3, p < 5 x10−15). This very significant difference
remains true when I stratify both by samples withoutmdr1 amplification (11.8 nM±9.8 vs. 21.7 nM
±10.4, p < 5 x10−14) and by those with the amplification (22.6 nM ±12.3 vs. 37.2 nM ±16.5, p <
0.05). While I find a significant difference between KEL1/non-PLA1 samples compared toWT para-
sites (30.6 nM±13.1 vs. 23.5 nM±12.3, p < 5 x10−4), this difference is due to the overrepresentation
of themdr1 amplification in the KEL1/non-PLA1 group compared toWTparasites (47% [21/45] vs.
12% [31/254]) and disappears when we control formdr1 amplification (mdr1 amplification present:
38.7 nM±11.7 vs. 37.2 nM±16.5, p = 0.52;mdr1 amplification absent: 23.6 nM±10.4 vs. 21.7 nM
±10.4, p = 0.30). I do however find a significant difference between KEL1/non-PLA1 parasites and
those of the KEL1/PLA1 co-lineage overall (30.6 nM±13.1 vs. 12.7 nM±10.2, p < 5 x10−12), and
when controlling formdr1 status (mdr1 amplification present: 38.7 nM±11.7 vs. 22.6 nM±12.3,
p < 0.05 ;mdr1 amplification absent: 23.6 nM±10.4 vs. 11.8 nM±9.8, p < 1 x10−6). These results
strongly suggest that KEL1/PLA1 is hypersensitive to mefloquine, likely through the acquisition of
the PLA1 component of the co-lineage.
3.4 Themdr1 and plasmepsin 2/3CNVs may be antagonistic
The PLA1 lineage is principally characterized by the presence of an amplification of the plasmepsin
2 and plasmepsin 3 genes9, presence of which is linked to piperaquine resistance8,372. It has previ-
ously been shown thatmdr1 amplification has the opposite effect to the plasmepsin 2/3 amplification,
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namely increasing the piperaquine sensitivity of parasiteswith themdr1 amplification8. Additionally,
using the Pf6 dataset (www.malariagen.net), a collection of over 5,000 P. falciparumWGS sampled
globally, I observe that the two amplifications co-occurred less frequently in Cambodia than expected
by chance (Fisher’s exact test for count data: p < 5 x10−6) (table 3.2). As a result of these appar-
ent links betweenmdr1 amplifications and plasmepsin 2/3 amplifications, I investigated the interplay
of the two types of amplification on MQ IC50 by looking at samples for which both amplification
genotypes could be ascertained (figure 3.3). I found a very strong effect of the two copy number am-
plifications impacting theMQIC50 in an opposingmanner, withmdr1 amplifications increasingMQ
IC50 compared to WT parasites (37.8 nM±14.6 vs. 21.9 nM±10.4, p < 5 x10−13) and plasmepsin
2/3 amplifications decreasing MQ IC50 compared to WT (12.3 nM±10.1 vs. 21.9 nM±10.4, p < 5
x10−16). There is consequently a very significant difference between parasites with anmdr1 amplifica-
tion and thosewith a plasmepsin 2/3 amplification (37.8 nM±14.6 vs. 12.3 nM±10.1, p < 1 x10−16).
Interestingly, parasites containing both types of amplification appear to have anMQ IC50 phenotype
comparable to that of WT parasites (23.0 nM ±10.7 vs. 21.9 nM ±10.4, p = 0.52), suggesting that
the opposing effects of the two amplifications phenotypically cancel each other out. The observation
that the two copy number amplifications appear to impact both mefloquine and piperaquine resis-
tance in opposing manners appears to suggest that they may operate in an antagonistic manner. The
fact that parasites with both amplifications are as susceptible tomefloquine asWT parasites, indicates
that triple mutants297 may not necessarily exhibit triple resistance.
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Table 3.2: Copy number ampli cation co-occurrence
plasmepsin 2/3CNV Total
Absent Present
mdr1CNV Absent 438 198 636
Present 112 14 126
Total 550 212 762
Pf6 samples from Cambodia with both genotypes ascertained and filtered for QC Pass.
Fisher’s exact test for count data, p < 5 x10−6
Figure 3.3:Me oquine IC50 by presence and absence of the two copy number ampli cations. Samples of the KEL1 lineage
are highlighted in orange. The horizontal lines indicate themedian (bold) and interquartile range (thin) of the respective
distributions.
3.5 Anovelmdr1 SNPassociateswith increasedmefloquine susceptibility
In order to identify additional markers of mefloquine resistance other than themdr1 amplification, I
conducted a genome-wide association study (GWAS) analysis using MQ log(IC50) as the dependent
variable. I called SNPs across all 430 samples withMQ IC50 values and, following filtering (appendix
D), retained 12,445 SNPs. Controlling for sample origin and for population structure (Appendix
D), I identified 15 SNPs that passed the suggestive threshold (p < 4 x10−4), one of which exceeded
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the threshold for genome-wide significance (p < 4 x10−6) (table 3.3 & figure 3.4). Unexpectedly, this
particular SNP is located within themdr1 gene and codes for an F1068L amino acid alteration. Sam-
ples with the F1068L mutation appear to have a significantly lower MQ IC50 compared to wild type
samples (6.5 nM±5.2 vs. 22.4 nM±12.9, p < 5 x10−9), ie. samples with this mutation are more sus-
ceptible to mefloquine. Looking further into the 19 samples with this SNP, I noticed that all of them
contain a plasmepsin 2/3 amplification and no mdr1 amplification (one sample had a missing geno-
type call for themdr1CNV).Rerunning theGWASanalysiswhile controlling for bothCNVs, yielded
the same F1068Lmdr1 SNP as the most significant SNP genome-wide (figure 3.5 & table 3.5), sug-
gesting that the SNP has an effect independent of the two copy number amplifications. Comparing
the MQ IC50 of samples with the SNP with those without, while excluding samples withmdr1 am-
plifications and stratifying by plasmepsin 2/3 amplification, I found that the F1068L SNP associates
with increased MQ sensitivity above and beyond the hypersensitivity induced by the plasmepsin 2/3
amplification alone (6.5 nM±5.2 vs. 13.9 nM±10.6, p < 5 x10−4) (figure 3.6), making these samples
ultrasensitive to mefloquine.
3.6 The genetic architecture of mefloquine hypersensitivity
The F1068L SNP inmdr1 is a novel SNP and has not previously been described in the literature. The
SNP occurs in the 9th putative transmembrane domain of the MDR1 protein (www.uniprot.org),
polymorphisms in which have previously been implicated with chloroquine resistance254, suggesting
that an amino acid alterationheremayplay a functional role. In thePf6dataset (www.malariagen.net),
the SNP is limited to Cambodia and has not been previously observed in any other region. The
SNP first appeared in 2010 with an allele frequency of 2% and then rapidly increased in frequency
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Figure 3.4: GWAS analysis usingme oquine log(IC50) as the dependent variable. Each point corresponds to a SNP,
coloured by the chromosome it is located on and they are ordered by their position on the chromosome. The line indicates
the genome-wide threshold for signi cance (p < 4 x10−6). The SNPs exceeding the signi cance threshold are labeled by
the gene they are found in and the amino acid alteration they code for.
Table 3.3: SNPsmost strongly associated with linearMQ IC50
Chromosome Position Gene ID Gene Description N or S Alteration p-value
5 961,093 PF3D7_0523000 Multidrug resistance protein 1 N F1068L 5.5 x10−8
6 909,326 PF3D7_0622300 Vacuolar transporter chaperone N S330F 8.4 x10−6
1 532,536 PF3D7_0113800 DBL containing protein S 1.1 x10−5
6 831,420 PF3D7_0619800 Conserved Plasmodium protein N D2487N 1.2 x10−5
6 1,068,475 PF3D7_0626400 Sec14 domain containing protein N K1110R 1.2 x10−5
1 535,099 PF3D7_0113800 DBL containing protein N E2484G 1.3 x10−5
2 438,323 PF3D7_0210800 Conserved Plasmodium protein N K227R 1.3 x10−5
6 806,029 PF3D7_0619300 Conserved Plasmodium protein N S2842C 1.4 x10−5
6 703,002 PF3D7_0616900 Conserved Plasmodium protein N F1251I 1.9 x10−5
6 878,937 PF3D7_0621400 Pf77 protein N I50V 2.0 x10−5
2 463,586 PF3D7_0211500 GAF domain-related protein N S142G 2.2 x10−5
14 420,625 PF3D7_1410400 Rhoptry-associated protein 1 N D62N 3.4 x10−5
7 304,718 PF3D7_0706200 Conserved Plasmodium protein N N66S 4.2 x10−5
6 664,920 PF3D7_0615900 Protein phosphatase N R979P 7.5 x10−5
1 531,949 PF3D7_0113800 DBL containing protein N E1526K 9.3 x10−5
Table 3.4: SNPs that pass either the Bonferroni-adjusted p-value threshold (p < 4 x10−6) or themore lenient suggestive
threshold (p < 1 x10−4) are listed in order of increasing p-value. The table shows chromosome and nucleotide position of
the SNP, the ID and description of the gene in which the SNP occurs, whether it is a synonymous (S) or nonsynonymous
(N) mutation, what amino acid alteration it encodes if it is nonsynonymous, and the p-value associated with the SNP.
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Figure 3.5: GWAS analysis usingMQ log(IC50) as the dependent variable and using themdr1 and plasmepsin 2/3 CNV
genotypes as covariates, while controlled for population structure and sample origin. Each point corresponds to a SNP,
coloured by the chromosome it is located on and they are ordered by their position on the chromosome. The dotted
line indicates the genome-wide threshold for signi cance (4 x10−6). The SNPs exceeding the signi cance threshold are
labeled by the gene they are found in and the amino acid alteration they code for.
Table 3.5: SNPsmost strongly associated withMQ log(IC50) when correcting for mdr1 and plasmepsin 2/3 ampli cations
Chromosome Position Gene ID Gene Description N or S Alteration p-value
5 961,093 PF3D7_0523000 Multidrug resistance protein 1 N F1068L 1.9 x10−6
2 438,323 PF3D7_0210800 Conserved Plasmodium protein N K227R 1.4 x10−5
2 463,586 PF3D7_0211500 GAF domain-related protein N S142G 1.4 x10−5
6 1,068,475 PF3D7_0626400 Sec14 domain containing protein N K1110R 4.1 x10−5
14 420,625 PF3D7_1410400 Rhoptry-associated protein 1 N D62N 7.4 x10−5
10 598,412 PF3D7_1014800 Conserved Plasmodium protein N E411A 9.2 x10−5
Table 3.6: SNPs that pass either the Bonferroni-adjusted p-value threshold (p < 4 x10−6) or themore lenient suggestive
threshold (p < 1 x10−4) are listed in order of increasing p-value. The table shows chromosome and nucleotide position of
the SNP, the ID and description of the gene in which the SNP occurs, whether it is a synonymous (S) or nonsynonymous
(N) mutation, what amino acid alteration it encodes if it is nonsynonymous, and the p-value associated with the SNP.
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Figure 3.6: Difference inMQ IC50 betweenwild type parasites (grey), those with a plasmepsin 2/3 ampli cation (blue)
and those with both the ampli cation and the F1068L SNP in themdr1 gene (red). Samples with anmdr1 ampli cation
have been removed from this analysis. The horizontal lines indicate themedian (bold) and interquartile range (thin) of the
respective distributions.
to 19% country-wide (figure 3.7). Within Cambodia, the SNP initially appeared in Western Cambo-
dia (WKH) and appears to have spread toNorthernCambodia (NKH)by 2012 (figure 3.7), following
the same purported route as the KEL1/PLA1 co-lineage9,150. Within NKH, the SNP seems to have
increased very rapidly in frequency up to 66% in 2015 (figure 3.7), though the sample number is very
low for that year (n = 3). From the available data, the SNP has not yet reached Northeastern Cambo-
dia (NEKH) though no samples were collected in 2015 in this region. Looking at the genomic regions
flanking the SNP, I see that they are largely identical (figure 3.8 b) and therefore suggests a single origin
of this SNP. I also observe that samples with the SNP are not identical across the genome (figure 3.8
a), indicating that it is not a single clone with this SNP and that the SNP appears to have recombined
with a number of different genetic backgrounds. The rapid rise in frequency of the SNP from a single
origin suggests that the SNP provides some form of fitness advantage to the parasites harbouring it.
Finally, once I corrected for the F1068L SNP in a final GWAS (figure 3.9 a), I noticed that only
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Figure 3.7: Annual allele frequency of themdr1 F1068L SNP in Cambodia shown in black and by Cambodian region:
Western Cambodia (WKH) in red, Northern Cambodia (NKH) in orange, and Northeastern Cambodia (NEKH) in green.
The inverted barplot shows the number of samples collected in each region by year.
two SNPs pass the suggestive threshold (table 3.7). These SNPs are located in the same region on
chromosome 2, in two genes coding for a conserved protein (K227R SNP in PF3D7_0210800) and
a GAF-domain related protein (S142G SNP in PF3D7_0211500). They are in very strong linkage
with each other, only 17 samples having differing genotype calls for the two SNPs out of a total of
411 samples with MQ IC50 values and both genotypes ascertained. While we see the K227R SNP
globally, the S142GSNP is exclusive to Southeast Asiawith 80%of sampleswith the SNPbeing found
inCambodia (210/264). The SNP is first seen in 2007 at 3% frequency, fromwhere it rapidly increases
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Figure 3.8: a) Amultidimensional scaling plot for all 430 samples withMQ IC50 values, based on all SNPs called genome-
wide. Green dots represent samples with the F1068Lmutation. b) Flanking regions around themdr1 gene, showing the
genotype of the 430 samples (rows) for all SNPs within 100kb of either side of mdr1. The genotypes are either reference
(blue), alternate (red), or missing (white). The position of themdr1 gene is indicated with a yellow box. The bar to the left
showswhich samples have the F1068Lmutation inmdr1 (green) andwhich don’t (black).
to roughly 55% in 2015 (figure 3.10). Due to being exclusive to Southeast Asia and the rapid change
in frequency, the S142G SNP appears to be the more likely candidate for the observed significant
associationwithMQIC50 in theGWASand the following analyseswere therefore based on the S142G
SNP.
The S142G SNP is non-randomly distributed, frequently co-occurring with the mdr1 F1068L
SNP (p < 5 x10−5), though not necessarily with the plasmepsin 2/3 amplification (p > 0.05) (table
Table 3.7: SNPsmost strongly associated withMQ log(IC50) when correcting for mdr1 and plasmepsin 2/3 ampli cations
as wewell as the F1068Lmdr1 SNP
Chromosome Position Gene ID Gene Description N or S Alteration p-value
2 438,323 PF3D7_0210800 Conserved Plasmodium protein N K227R 1.8 x10−5
2 463,586 PF3D7_0211500 GAF domain-related protein N S142G 2.9 x10−5
Table 3.8: SNPs that pass either the Bonferroni-adjusted p-value threshold (p < 4 x10−6) or themore lenient suggestive
threshold (p < 1 x10−4) are listed in order of increasing p-value. The table shows chromosome and nucleotide position of
the SNP, the ID and description of the gene in which the SNP occurs, whether it is a synonymous (S) or nonsynonymous
(N) mutation, what amino acid alteration it encodes if it is nonsynonymous, and the p-value associated with the SNP.
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Figure 3.9: a) GWAS analysis usingme oquine log(IC50) as the dependent variable, with population structure, sample ori-
gin, mdr1 and plasmepsin 2/3 copy number ampli cations, and the F1068L SNP inmdr1 as covariates. Each point corre-
sponds to a SNP, coloured by the chromosome it is located on and they are ordered by their position on the chromosome.
The dotted red line indicates the genome-wide threshold for signi cance (4 x10−6) and the dotted green line is a more
lenient suggestive threshold (1 x10−4). b) Me oquine IC50 values by different combinations of three genetic markers
for me oquine susceptibility: plasmepsin 2/3 ampli cation (pink), the F1068L SNP inmdr1 (green), and the S142G SNP
in PF3D7_0211500 (turquoise). Each point represents a clinical isolate and samples withmdr1 ampli cations have been
removed. The horizontal lines indicate themedian (bold) and interquartile range (thin) of the respective distributions.
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Figure 3.10: Annual allele frequency of the S142G SNP in gene PF3D7_0211500 in Cambodia.
3.9). Additionally, the SNP is very rarely found together with anmdr1 amplification (p < 5 x10−5)
(table 3.9). In spite of this, the S142G appears to associate with an increase in mefloquine sensitiv-
ity in an independent manner to that conferred by the plasmepsin 2/3 amplification and the F1068L
mdr1 SNP (figure 3.9 b). Looking only at samples without anmdr1 amplification, I see a significant
increase in sensitivity in samples with the S142G SNP compared to those without, in absence of both
plasmepsin 2/3 amplification and the F1068L SNP (16.9 nM±8.8 vs. 22.3 nM±10.4, p < 0.05), in
presence of plasmepsin 2/3 but absence of F1068L (11.8 nM ±11.9 vs. 16.4 nM ±10.0, p < 0.05),
and a near significant effect despite the low sample numbers for samples with both the plasmepsin 2/3
amplification and the F1068L SNP (6.0 nM±6.4 vs. 7.5 nM±3.0, p = 0.056). This is therefore yet
another example of a SNP associating with a particular set of mutations that all appear to result in
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sensitizing the parasite to mefloquine treatment.
Table 3.9: Co-occurrence of different markers with the S142G SNP
S142G SNP
Absent Present
plasmepsin 2/3 Absent 443 134
CNV Present 174 74
F1068L Absent 585 177
mdr1 SNP Present 24 27
mdr1 Absent 442 167
amplification Present 112 15
Pf6 samples from Cambodia with both genotypes for each comparison ascertained and filtered for
QC Pass.
plasmepsin 2/3CNV: fisher’s exact test for count data, p > 0.05
mdr1 SNP: fisher’s exact test for count data, p < 5 x10−5
mdr1 amplification: fisher’s exact test for count data, p < 5 x10−5
3.7 Discussion
The current crisis of multidrug resistance in Southeast Asia necessitates an informed, effective, and
sustainable response in order to avoid increasing levels of complete treatment failure and, worse, a
spreadofmultidrug resistance toothermalaria endemic regions. Complete treatment failure of dihydroartemisinin-
piperaquine inCambodia andotherneighbouring countries, causedby the emergenceofKEL1/PLA1
parasites, therefore now requires an immediate response. A switch to either artesunate-mefloquine or
triple combination therapy, combining artemisinin with both piperaquine and mefloquine, are two
options that are currently being explored due to the initial reports of mefloquine efficacy in the field.
A number of questions however remained concerning the source of this mefloquine efficacy and the
potential sustainability of deploying this drug in a region rampant with multidrug resistance.
In this chapter I have shown that KEL1/PLA1 parasites are not only sensitive to mefloquine, but
appear to exhibit a heightened level of susceptibility above and beyond that of wild type parasites,
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which we term mefloquine hypersensitivity. I have linked this hypersensitivity to the acquisition of
the PLA1 component of the KEL1/PLA1 co-lineage, implying that KEL1/PLA1 are necessarily and
inherently hypersensitive to mefloquine. Furthermore, the PLA1 lineage being characterized by the
presence of the plasmepsin 2/3 amplification, I have suggested that the mdr1 amplification and the
plasmepsin 2/3 amplification may be antagonistic in affecting both mefloquine and piperaquine re-
sponses in opposite ways, implying that triple mutants may not necessarily exhibit triple resistance.
I have also identified a novel F1068L SNP in themdr1 gene that has recently arisen on a plasmepsin
2/3 background and that has spread through the population, thereby displaying classical hallmarks of
positive selection. I have shown that this SNP is associatedwith an evengreater level ofmefloquine sen-
sitization than that conferred by PLA1 acquisition, resulting inmefloquine ultrasensitivity. A further
novel SNP in a GAF domain-related gene also associates with mefloquine sensitization, complicating
the situation evenmore. The results reported here shed light on the observed efficacy ofmefloquine in
field, but raise a number of new questions relating to the molecular mechanism of mefloquine sensi-
tization and the evolutionary mechanisms that drive this complex genetic architecture of mefloquine
ultrasensitivity.
Mefloquine is thought to act in the cytoplasm by binding to 80S ribosomes and thereby inhibit-
ing protein synthesis373, with clinical resistance to the drug being mediated by an amplification of
themdr1 gene370,70,282, which codes for a transporter protein on the food vacuole membrane. The
MDR1 protein purportedly transports mefloquine into the food vacuole and thereby away from its
active site, meaning that the higher abundance ofMDR1 inmdr1 amplified parasites would result in
more mefloquine being pumped into the food vacuole. This thereby results in reduced mefloquine
efficacy and, consequently, clinical resistance to the drug. Similarly, the effect of mdr1 gene copy
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number amplification on increasing piperaquine sensitivity can be explained with piperaquine acting
in the food vacuole and the MDR1 protein pumping the drug to where it needs to be. The novel
F1068L SNP inmdr1 that I have identified can similarly be explained by potentially reducing the ca-
pability of theMDR1 protein to pumpmefloquine into the food vacuole, increasing the effectiveness
of the drug. Looking at available data on piperaquine IC50 8, presence of the F1068L SNP does not
appear to confer significantly higher levels of piperaquine resistance compared to those without (65.3
nM ±30.6 vs. 58.3 nM ±32.5, p > 0.05) (figure 3.11). This suggests that the two drugs are trans-
ported in different ways through the MDR1 protein, and that the SNP may therefore be potentially
involved in somehow compensating for the plasmepsin 2/3 amplificationwithwhich it co-occurs. The
plasmepsin 2/3 genes code for enzymes present in the food vacuole that are involved in hemoglobin
catabolism, specifically conversion of heme to hemozoin61. Piperaquine is thought to block this con-
version and resistance to the drug is thereby mediated by increasing the availability of the Plasmepsin
2/3 enzymes to overcome the inhibition by piperaquine372,8. It is possible that the increased level of
Plasmepsin 2/3 enzymes in the food vacuole may require an increased abundance/depletion of other
substrates that are imported/exported by the MDR1 protein, a requirement that may be satisfied by
a compensatory mutation at the F1068L position. The missing piece in this puzzle of an explanation
is the observed effect of plasmepsin 2/3 amplification on mefloquine sensitivity, as the enzymes are in
the food vacuole and the drug acts in the cytoplasm. It is possible that, comparable to the F1068L
SNP, the increased abundance of Plasmepsin 2/3 in the food vacuole indirectly affects the type of
substrates that the MDR1 protein pumps into the food vacuole. If this change in metabolic activity
of theMDR1 protein would result in a reduced level of mefloquine being pumped into the food vac-
uole, thenwewould observe a heightened level ofmefloquine sensitivity in parasites with a plasmepsin
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Figure 3.11: Difference in piperaquine IC50 betweenwild type parasites (grey), those with a plasmepsin 2/3 ampli cation
(blue) and those with both the ampli cation and the F1068L SNP in themdr1 gene (red). Samples with anmdr1 ampli ca-
tion have been removed from this analysis. The horizontal lines indicate themedian (bold) and interquartile range (thin) of
the respective distributions.
2/3 amplification.
Thinking about the hyper-sensitization of the parasite population from an evolutionary perspec-
tive raises questions about the dynamics of population replacement by hard selective sweeps. The
population structure of Southeast Asian P. falciparum parasites differs substantially from that of its
African counterparts, namely by being significantly more structured. Hard selective sweeps, as driven
by selection for chloroquine resistance for instance, have swept through the region in the past. The
current outbreak of KEL1/PLA1 is yet another such sweep. The speed at which this spread has oc-
curred is also of significant importance, due to the lag in being able to respond from a policy/logistics
perspective. It is especially worrying to see the speed at which KEL1/PLA1was able to shed themdr1
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amplifications that were present in the field at the time8,9. It brings up the possibility of the PLA1
component being similarly lost rapidly and replaced with mdr1 amplification in the case of a pol-
icy switch to mefloquine treatment. While the presence of the F1068Lmdr1 SNP may suggest that
additional genetic components would have to be dismantled to acquire mefloquine resistance, it is
unclear, firstly, how rapidly this could occur and, secondly, whether we wouldn’t simply see a new
mefloquine resistant lineage combining with the KEL1/non-PLA1 parasites that still circulate in the
field. It is also bizarre to see that the KEL1/PLA1 co-lineage arose in West Cambodia, close to the
border with Thailand where artesunate/mefloquine was the front line treatment for many years. One
would hypothesize that this would have an attenuating effect on parasites that acquire hypersensitiv-
ity to mefloquine. It however explains why KEL1/PLA1 parasites did not spread to Thailand in the
initial stages of the outbreak. Worryingly, Thailand has now switched the recommended treatment
regime to dihydroartemisinin/piperaquine, which would open up the doors to the KEL1/PLA1 co-
lineage spreading into the country. Anecdotal reports suggest that the new treatment is less effective
in the eastern parts of Thailand than the original treatment (Thanat Chookajorn ofMahidol Univer-
sity Thailand, personal communication). Harnessing the findings of this study should now open up
the possibility of better understanding the dynamics that are seen in the field and to better respond
by exploiting the underlying interactions between the different drugs that we have at our disposal.
Making thebest use of our arsenal of antimalarial drugs is essential for long-term sustainablemalaria
control and elimination. In order to determine how to most effectively deploy our drugs requires a
deep understanding of the interactions between the drugs. In this chapter I have shown that being
aware of the antagonistic effect of mefloquine and piperaquine selection pressures on the emergence
of the respective drug resistance mutations opens up the door to developing either ‘resistance-proof’
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drug treatments or to rolling out policy changes that explicitly use this new information to rotate
between the drugs for maximum effect and sustainability. In the following chapter I wish to further
explore the potential interactions between different antimalarial drugs by analysing available data on
four different antimalarial drugs, including chloroquine, mefloquine, piperaquine, and artemisinin.
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The Second World War and the conflict in Vietnam
brought us most of the drugs available today. The list is
small, and the parasite has not been idle: Plasmodium fal-
ciparumhasnowdeveloped resistance to all of our available
drugs.
Nicholas White, J. Antimicrob. Chemother., 1992 CE
4
The role of a super-chloroquine resistant
pfcrt haplogroup in multidrug resistance
4.1 Abstract
Emergenceofmultidrug resistance inPlasmodiumfalciparum is leading to treatment failure of artemisinin
combination therapies in Southeast Asia and is threatening the recent progress made in combating
malaria. To unveil novel phenotype-genotype associations and to better understand the parasite pop-
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ulation substructuring as a function of multidrug resistance, I harness a large-scale dataset of chloro-
quine, mefloquine, piperaquine, and artemisinin phenotype data for over 1,000 P. falciparum field
isolates in conjunction with over 5,000 whole genome sequences from the Pf6 MalariaGEN release
(www.malariagen.net). Employing a haplogroup analysis of two well-characterized drug resistance
genes, pfcrt and mdr1, I identify a pair of pfcrt haplogroups that exhibit super-resistance to chloro-
quine. These pfcrt haplogroups, characterized by the combination of a CVIET haplotype with the
N326S and I356T mutations, also display artemisinin resistance and act as genetic backbones for
copy number variations leading tomefloquine and piperaquine resistance. These super-resistant hap-
logroups are present at high frequency throughout Southeast Asia andmay have had a single origin in
the western parts of the region. The study highlights the potential for haplogroup analyses to enable
us to uncover new biological findings. The findings reported here shed new light on pfcrt, one of the
most well-studied genes in the P. falciparum genome, and potentially suggest that it plays a role in the
acquisition of artemisinin resistance.
4.2 Introduction
Antimalarial drug resistance is inevitable. Plasmodium falciparum, the apicomplexan parasite that
causes the majority of malaria cases worldwide, has developed resistance to every antimalarial drug
that it has been confronted with. The parasite mutates on average every base of its genome across
the span of a single blood infection63, an incredible basis for genetic adaptability that has only re-
cently been described. However, the propensity for the parasite to adapt to the challenges imposed
by anti-malarial drugs has long been recognized. Beginning with chloroquine in the 1950s93, P. falci-
parum has subsequently developed resistance to proguanil, sulfadoxine-pyramethamine, mefloquine,
127
and halofantrine370. Each drug lost effectiveness within years of being rolled out, resulting in resis-
tance that still persists to this day as each new generation of drug resistant parasites evolves from the
previous one. This is aptly demonstrated by the global pervasiveness of chloroquine resistance cur-
rently, even though the drug is officially no longer used to treat P. falciparum infections.
With the rollout of artemisinin, the World Health Organization (WHO) recommended switch-
ing from mono-therapies to combination therapies. The highly effective but short-lived artemisinin
compound was only to be administered in combination with long-lived partner drugs, such as piper-
aquine. The longer-lived partner drug would clear parasites surviving the artemisinin therapy, pre-
venting resistance from emerging. While logical in theory, P. falciparum has again proven its ability
to adapt, developing resistance to both artemisinin and to piperaquine187,330. In this case, instead of
the sequential selection for resistance that occurred with mono-therapies, P. falciparum developed
resistance concurrently to both drugs. The combination therapy essentially selected for multidrug
resistance.
This rise and spread of multidrug resistant malaria parasites has resulted in a paradigm shift in
malaria epidemiology. It is no longer sufficient to look at a single drug and a single drug resistance
phenotype. Combination therapies are likely here to stay, evidenced by the currently on-going clinical
trials of triple-compound therapies211. However, the specific combinations of compounds to be used
will need to be carefully decided upon in the light of the drug resistance landscape. Traditionally,
policy makers have in part relied on epidemiological models to inform them on the best course of
action. The resolution and accuracy, and consequently usefulness, of these models depend in large
part on our understanding of drug resistance.
Wecurrently have abasic understanding for a variety of key resistancemutations, such as the chloro-
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quine resistance transporter (pfcrt) K76T mutation for chloroquine resistance103,82,321, a number of
mutations in the kelch 13 (K13) gene13,221 for artemisinin resistance, and copy number amplifications
of the plasmepsin 2/38,372 andmultidrug resistance protein 1 (mdr1) genes370,280,282 for piperaquine
andmefloquine resistance respectively. While thesemutations enable us to differentiate between likely
resistant and likely susceptible samples, there is still a significant amount of unexplained variance in
the resistance phenotypes. Additionally, how these resistance mutations associate with each other
within the complicated multidrug resistance landscape is also little understood. This will be vital in
order to uncover antagonistic interactions, such as the mdr1 amplification (involved in mefloquine
resistance) increasing a parasite’s susceptibility to piperaquine8,268 and plasmepsin 2/3 amplification
increasing mefloquine sensitivity as described in Chapter 3.
Increased understanding of factors underlying the variance in drug resistance phenotypes and the
interactions between them will be key to making the most informed policy decisions and to design-
ing the most effective combination therapies. By harnessing this fine-grained knowledge, we will be
able to turn the parasite’s adaptability against itself. Using selective pressures exerted by antimalarial
drugs to our advantage will enable us to optimize the use of our existing drugs, and thereby make the
treatments ‘resistance-proof’36. This will be critical, as the antimalarial drug-development pipeline is
thin and mostly includes derivatives of existing drugs, to which resistance has often already spread. It
is therefore vital that we better understand the drugs currently at our disposal.
In this chapter I describe an analysis of 5,835 whole genome sequences of P. falciparum field iso-
lates sampled worldwide in conjunction with previously published phenotype information for four
antimalarial drugs: chloroquine, mefloquine, piperaquine, and artemisinin6,7,15,209. I apply a hap-
logroup analysis to classify two known drug resistance genes, pfcrt andmdr1, and place these within
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the larger context of the global drug resistance landscape. I show that two specific pfcrt haplogroups
exhibit super-resistance to chloroquine and that they share a key N326S mutation in pfcrt likely lead-
ing to the super-resistance phenotype. Both haplogroups are very common in Southeast Asia, but
absent elsewhere in the world, with a gradient of being more common in the western parts of the
region than on the eastern side. These super-resistant haplogroups act as genetic backbones for the
other types of drug resistance observed in the region: artemisinin, mefloquine and piperaquine resis-
tance. I discuss the implications of these findings and suggest a possible role for pfcrt in the process of
developing artemisinin resistance in the Southeast Asian setting.
All methods used for this chapter are detailed in Appendix F. All sample collection, sequencing,
and in vitro drug resistance assays were performed by collaborators. All data analyses presented in this
chapter are my own work unless specifically noted otherwise.
4.3 Data Overview
To better understand the genetic basis ofmultidrug resistance in Southeast Asia, as well as to place the
findingswithin a global context, I performed a comprehensive haplogroup analysis of twowell-studied
drug resistance genes, pfcrt andmdr1, using the globally sampled Pf6 dataset (www.malariagen.net).
These two genes are attractive targets to use for this study for a number of reasons. Firstly, their
functional roles in resistance to chloroquine103,82,321 andmefloquine370,280,282, respectively, are well-
studied and thereby give us a solid basis to place any results into context with previous findings. Sec-
ondly, both genes have previously been implicated in studies of other antimalarial drugs, such as
artemisinin for pfcrt 221 andpiperaquine formdr18. Finally, both pfcrt andmdr1 genes code for trans-
membrane proteins located on the membrane of the digestive vacuole, mediating intake and efflux of
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Figure 4.1: Distribution of phenotype data among the 1110 clinical P. falciparum isolates with at least one antimalarial
resistance phenotype assayed. Numbers below antimalarial compound indicate number of samples assayed for that
compound. Of the 1110 samples, 207 have been assayed for all four compounds.
compounds, and are thought therefore potentially to interact on a mechanistic level through shared
biological pathways. A better understanding of the impact of different haplotypes of pfcrt andmdr1,
as well as the specific pairing of these, on different drug resistance phenotypes is therefore needed.
The ongoing sequencing projects led by theMalariaGEN consortium have led to the assembly of a
dataset consisting of 5,835 P. falciparum whole genome sequences (WGS) (www.malariagen.net). A
number of these samples were collected as part of different drug resistance surveillance studies6,7,15,209
and as a result have drug resistance phenotype information associated with them in the form of 50%
inhibitory concentration (IC50) values for chloroquine (CQ) (n = 391), mefloquine (MQ) (n = 420),
and piperaquine (PPQ) (n = 305), and in the form of parasite clearance half-life (PCt1/2) values for
artemisinin (ART) (n = 1,016) (figure 4.1). In total, 1,110 P. falciparum isolates have at least one an-
timalarial drug resistance phenotype assayed and 207 have phenotypes assayed for all four antimalarial
compounds (figure 4.1).
To perform the haplogroup analysis, Jacob Almagro Garcia from the Big Data Institute in Oxford
classified samples by all their nonsynonymous mutations, as well as insertions/deletions, for pfcrt and
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mdr1 independently (Appendix F). In terms of terminology, I employ the term ‘haplogroup’ here
instead of the more conventional ‘haplotype’ because the ultimate aim of this particular study is to
group similar haplotypes into ‘haplogroups’ that in themselves likely represent a single evolutionary
origin. While at the point of writing up this chapter the grouping of haplotypes has not yet been un-
dertaken, I havenonetheless chosen toproceedwith thefinal terminologyof ‘haplogroup’. To increase
the robustness and reliability of the classification, only WGS with no missing genotype calls within
the target genes were included (4,424 and 4,573 samples formdr1 and pfcrt respectively). Heterozy-
gous calls in the respective genes (indicative ofmixed genotype infections)were set tomissing and thus
removed from being classified. It is important to note that it is possible that in cases of a mixed geno-
type infection with a dominant strain, either or both of the genes could be classified if it happens that
none of the SNP calls in the genes are called as heterozygous. Each sample was thereby assigned to a
haplogroup for that particular gene, within which every sample has an identical amino acid sequence,
coded for by an identical set of mutations. Using this method, 113 uniquemdr1 haplogroups (figure
4.2) and 49 unique pfcrt haplogroups (figure 4.3) were identified.
4.4 Description of themdr1Haplogroups
Themdr1 haplogroups have on average two genetic differences to themdr1 3D7 reference sequence
(figure 4.2). Only a single genetic change was present in over half of mdr1 haplogroups (65/113),
namely the Y184F mutation. Other mutations common to a number of different haplogroups in-
clude N86Y (15/113), N1042D (8/113), and D1249Y (8/113). However, the majority of the ge-
netic changes differentiating the different mdr1 haplogroups were exclusive to specific haplogroups
(42/70). The two most frequentmdr1 haplogroups (mdr1.h1 andmdr1.h2) are present in over half
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Figure 4.2: All 113mdr1 haplogroups with the genetic changes that characterize them. Columns indicate genetic
changes, labeled with the nucleotide position of the change and the primary amino acid change (multi-allelic positions
may result in an alternate change). Colours represent the genetic changes, with white representing no change, light green
representing a SNP and dark green representing an alternate SNP in amulti-allelic position. The number of samples in
each haplogroup is indicated on the right side of the diagram.
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Figure 4.3: All 49 pfcrt haplogroups with the genetic changes that characterize them. Columns indicate genetic changes,
labeled with the nucleotide position of the change and the primary amino acid change (multi-allelic positions may result in
an alternate change). Colours represent the genetic changes, with white representing no change, light green representing
a SNP and dark green representing an alternate SNP in amulti-allelic position. The purple and pink represent different
insertions/deletions, while blue indicates positions coded for as missing due to an insertion/deletion. The number of
samples in each haplogroup is indicated on the right side of the diagram.
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of the samples (2,538/4,424) (figure 4.4 a), with the latter being identical to the 3D7 referencemdr1
sequence andmdr1.h1 differing from the reference only by theY184Fmutation. They are both found
throughout Africa and Southeast Asia and of the 113mdr1 haplogroups, only 29 are found in more
than one P. falciparum population, the others being region specific (figure 4.4 b). A large propor-
tion of these region-specificmdr1 haplogroups are found inWest Africa (35/84), however these tend
to be haplogroups with very few samples. I noticed that a number of larger haplogroups are specific
to Eastern Southeast Asia, includingmdr1.h10 (36 samples),mdr1.h16 (10 samples),mdr1.h19 (15
samples),mdr1.h20 (14 samples), andmdr1.h21 (9 samples) among others (figure 4.4 a & b).
Focusingon the ten largestmdr1haplogroups,which account for over 85%of samples (3865/4424),
I see that they are generally closely related to each other (figure 4.5 a) and that only nine mutations
differentiate all of them (figure 4.5 c). Looking at the MQ IC50 by haplogroup, I don’t see any sig-
nificant difference between the two largest mdr1 haplogroups (t-test: p > 0.05), but I observe that
mdr1.h10 has a significantly lower mean MQ IC50 compared to them (p < 0.0005) (figure 4.5 b).
This particular haplogroup is exclusive to Eastern Southeast Asia (figure 4.5 d) and has a mutation
that is specific to this haplogroup (F1068L) and was described in the previous chapter in a genome
wide association analysis of mefloquine resistance using the same dataset. As described there, the
F1068L mutation seems to have recently emerged and is rising in frequency. The first samples with
the mutation are from 2010, where they accounted for about 1% of the total samples from Eastern
Southeast Asia (3/276), by 2012 it was 5% (10/189), and by 2015 almost 20% of samples carried this
mutation (4/21).
Looking at the distribution of the phenotype data for the three other antimalarial drugs, I see large
differences in the average level of artemisinin resistance between the differentmdr1 haplogroups (fig-
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Figure 4.4: Showing the number of samples for eachmdr1 haplogroup (a) and the proportion of samples from the differ-
ent P. falciparum populations for eachmdr1 haplogroup (b).
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Figure 4.5: Features of themajor mdr1 haplogroups. a) Tree showing the genetic similarity of the different mdr1 hap-
logroups to each other, with branch height indicating themean number of genetic differences between nodes. b)Me o-
quine IC50 bymdr1 haplogroup. The horizontal lines indicate themedian (bold) and interquartile range (thin) of the
respective distributions. Blue bars indicateWelch two-sample t-tests performed between two distributions, with stars
indicating the level of signi cance of that comparison (see inset legend). c) The genetic differences between the differ-
ent mdr1 haplogroups, with rows indicating different amino acid positions within themdr1 protein. The rst column
(mdr1.h2) shows the reference amino acid sequence. Empty cells correspond to the reference amino acid as well, while
grey boxes show the new amino acid when there was a change. d) Bars indicate the proportion of samples originating
from the different P. falciparum populations (see legend) for eachmdr1 haplogroup. The numbers below the bars indicate
the number of samples in each of the haplogroups.
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ure 4.6 a). Specifically, mdr1.h4, mdr1.h5, and mdr1.h8 are all significantly more susceptible to
artemisinin than mdr1.h1 (all t-test: p < 0.005) (figure 4.6 a). These three haplogroups are related
to each other by sharing the N86Y mutation (figure 4.5 c), and indeed there is a very significant dif-
ference in the level of artemisinin resistance between samples with the wildtype N and the mutant Y
genotype (3.9hr vs. 2.2hr, p < 5 x 10−16). While this is confounded by the fact that the haplogroups
containing themutant genotype are not found in Southeast Asia (figure 4.5 d) and therefore appear to
lack the kelch 13mutations, I still find a significant difference between the two groups when I exclude
samples with kelch 13 mutations (3.0hr vs. 2.2hr, p < 1 x10−5) (figure 4.6 b). However, we observe
that this difference is driven by samples from Eastern Southeast Asia and that when I remove all sam-
ples from the Southeast Asian region, that the difference in artemisinin resistance disappears (2.3hr
vs. 2.2hr, p > 0.05). This suggests that there are additional factors that drive artemisinin resistance
within Southeast Asia other than the kelch 13 mutations, but that these are apparently unrelated to
themdr1 haplotype.
Finally, I also observe significant differences between mdr1 haplogroups in their average level of
piperaquine IC50 (figure 4.6 c) and chloroquine IC50 (figure 4.7 a). For the former, mdr1.h1 has
a significantly higher level of piperaquine IC50 than mdr1.h2 (41nmol/L vs. 31nmol/L, p <0.01)
and mdr1.h3 (41nmol/L vs. 22nmol/L, p < 0.005) (figure 4.6 c). This is likely due to the overrep-
resentation of the plasmepsin 2/3 amplification in this haplogroup ( 10%, 131 out of 1,279) com-
pared to the other two (both <1%, 8 out of 1,230 and 1 out of 424 formdr1.h2 andmdr1.h3 respec-
tively). For chloroquine IC50, I observe a significant difference betweenmdr1.h2 withmdr1.h1 and
mdr1.h10 (figure 4.7 a), which differ from each other by the Y184F mutation (figure 4.5 c). While
I do see a significant difference between samples with the Y184F mutation compared to those that
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Figure 4.6: Artemisinin PCt1/2 bymdr1 haplogroup (a) and bymdr1N86Y genotype for samples without kelch 13muta-
tion (b) and piperaquine IC50 bymdr1 haplogroup (c). The horizontal lines indicate themedian (bold) and interquartile
range (thin) of the respective distributions. Blue bars indicateWelch two-sample t-tests performed between two distribu-
tions, with stars indicating the level of signi cance of that comparison (n.s. = p > 0.05, * = p < 0.05, ** = p < 0.005, *** = p <
0.0005). In (b), the colors of the samples correspond to the P. falciparum population they originate from (see inset legend).
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don’t (441nmol/L vs. 277nmol/L, p < 5 x10−13) (figure 4.7 b), this difference is confounded by the
differential distribution of pfcrt haplogroups (see below) (figure 4.7 b). When I stratify by pfcrt hap-
logroup I do not observe a difference in chloroquine IC50 betweenmdr1 haplogroups (figure 4.7 c).
These results suggest that mdr1 haplogroup may have little effect on the level of resistance to anti-
malarial drugs other than mefloquine and shows to which extent the population structure can act as
a confounder.
4.5 Description of the pfcrtHaplogroups
With an average of six genetic differences, the 49 identified pfcrt haplogroups are overall significantly
more diverged from the pfcrt reference sequence than the mdr1 haplogroups were from the mdr1
reference sequence (t-test: p < 0.01) (figure 4.3). The largest haplogroup (pfcrt.h1) consists of 1,584
samples and is identical to the 3D7 reference strain, while 13 of the 49 haplogroups contain only a sin-
gle sample (figure 4.8 a). The eight largest haplogroups each contain over 30 samples and collectively
account for over 95% of all samples (4,355/4,573) (figure 4.8 a). Of the 49 haplogroups, 37 contain
the K76T mutation and of these, 27 have a CVIET haplotype. Interestingly, the CVIDT haplotype
is found in only one haplogroup (pfcrt.h5) and contains a number of ancillary mutations (A144S,
A144V, L148I, I194T, T333S) that distinguish it clearly from all other haplogroups (figure 4.9 a),
suggesting that the CVIDT haplotype may have had a single origin. The only exception to this obser-
vation is pfcrt.h50 (containing only one sample), which has a CVIET haplotype but does contain a
number of these ancillary mutations and may be a recombinant of CVIDT and CVIET parents. Of
the 27 CVIET haplogroups, 25 contain the A220S, Q271E, and R371I mutations, with the remain-
ing two haplogroups either lacking R371I (pfcrt.h25) or Q271E (pfcrt.h30). There is therefore strong
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Figure 4.7: Chloroquine IC50 bymdr1 haplogroup (a), bymdr1 Y184F genotype (b) and bymdr1 haplogroup only within
samples with a pfcrt.h2 haplogroup (c). The horizontal lines indicate themedian (bold) and interquartile range (thin) of the
respective distributions. Blue bars indicateWelch two-sample t-tests performed between two distributions, with stars
indicating the level of signi cance of that comparison (n.s. = p > 0.05, * = p < 0.05, ** = p < 0.005, *** = p < 0.0005).
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Figure 4.8: Showing the number of samples for each pfcrt haplogroup (a) and the proportion of samples from the different
P. falciparum populations for each pfcrt haplogroup (b).
linkage of the CVIET haplotype with these accessory mutations and it will be difficult to disentangle
the respective contributions of these mutations to the resistance phenotype.
Two additional mutations are common to a number of CVIET haplogroups (N326S and I356T),
with 18CVIEThaplogroups carryingN326S and 20CVIEThaplogroups carrying I356T, and 17/27
carrying both. Over half of all genetic changes differentiating the different haplogroups (26/45) are
single mutations unique to specific haplogroups. Additionally, looking at the structure of the pfcrt
protein, a large number of the genetic changes are located in transmembrane domains (34/45) (figure
4.9 b), which is a significant enrichment compared to the overall fraction of the protein that is trans-
membrane (227/424) (chi-squared test: p < 0.01). This was even more evident when looking only
at the genetic changes that are found in multiple haplogroups (17/19) (chi-squared test: p < 0.005).
The genetic changes mainly occur in the first three and in the eighth and the ninth transmembrane
142
domains (out of a total of ten transmembrane domains) (figure 4.9 b).
Looking at the geographical distribution of the pfcrt haplogroups using information on the sample
origin revealed a number of interesting patterns. Firstly, the wild type pfcrt.h1 is common in Africa,
being the most common haplogroup in a number of African countries, but is underrepresented in
most other parts of the world (figure 4.10). The most widespread haplogroup besides pfcrt.h1 seems
to be pfcrt.h3, which has a high frequency in both Africa and parts of Asia, and is the quintessential
CVIET haplogroup, containing the CVIET haplotype and the three ancillary mutations. No hap-
logroup with a CVIET haplotype is observed in South America or in Oceania. I also observe that
regions outside Africa tend to be dominated by haplogroups specific to those regions, such as pfcrt.h2
in Southeast Asia, pfcrt.h6 inOceania, and pfcrt.h13 and pfcrt.h17 in Colombia and Peru respectively
(figure 4.10). Within Africa, Ethiopia differs from the other African countries in having the pfcrt.h8
haplogroup as the most common pfcrt haplogroup, despite being virtually absent elsewhere. It is in-
teresting to note that while I saw striking differences in the pfcrt haplogroups between the different re-
gions and even between different countries, little diversity in haplogroupswas foundwithin countries,
most places only harbouring a handful of haplogroups. The exception to this was Eastern Southeast
Asia, which exhibited a large number of different haplogroups, including the CVIDT haplogroup,
which is exclusive to that region (figures 4.8 b & 4.10).
4.6 Overlap ofmdr1 and pfcrtHaplogroups
Looking at the overlap of the mdr1 haplogroups with the pfcrt haplogroups, I notice a number of
interesting features. Focusing on haplogroups that have at least ten samples with bothmdr1 and pfcrt
haplogroups confidently called, it appears that the two sets of haplogroups do not pair up randomly
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Figure 4.9: Features of themajor pfcrt haplogroups. a) Left: Tree showing the genetic similarity of the different pfcrt
haplogroups to each other, with branch height indicating themean number of genetic differences between nodes. Center:
The genetic differences between the different pfcrt haplogroups, with columns indicating different amino acid positions
within the pfcrt protein. The rst row (pfcrt.h1) shows the reference amino acid sequence. Empty cells correspond to the
reference amino acid as well, while grey boxes show the new amino acid when there was a change. Right: Bars indicate
the proportion of samples originating from the different P. falciparum populations (see legend below) for each pfcrt
haplogroup. The numbers on the right indicate the number of samples in each of the haplogroups. b) Showing amodel
structure of the PfCRT protein, with its ten transmembrane domains (pink) sitting within themembrane of the digestive
vacuole (blue). Each circle corresponds to an amino acid within the protein, with shaded circles referring to amino acids
that vary between the eight major pfcrt haplogroups, with a line linking these back to the previous panel.
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Figure 4.10:Worldmap showing the distribution of the different pfcrt haplogroups. Countries are coloured by themost
prevalent pfcrt haplogroup in the country. Dashed circles indicate different P. falciparum populations, with pie charts
showing the proportions of the different pfcrt haplogroups within those populations. The number of samples in each of
those populations is indicted next to the pie chart.
(chi-squared test: p<10−16). I find that specific combinations of haplogroups are either strongly over-
represented or strongly underrepresented (hypergeometric test: p < 10−15) (figure 4.11). For pfcrt.h1,
which is the reference sequence pfcrt, it pairs up more often than expected withmdr1.h1, but almost
never pairs upwithmdr1.h3,mdr1.h6,mdr1.h7, andmdr1.h9. This is as expected from their respec-
tive distributions, as pfcrt.h1 is rare outsideAfrica and the latter fourmdr1 haplogroups are not found
in Africa. The opposite pattern is found for pfcrt.h2, which is very prevalent in Southeast Asia and
pairs very often withmdr1.h3,mdr1.h6 andmdr1.h7. Indeed, many of the signals of association for
the pairs of haplogroups are driven by the differential geographical distribution of the haplogroups.
Some of themore unexpected combinations are exhibited by the smaller haplogroups. I found that
mdr1.h19only occurs in conjunctionwith pfcrt.h2,whichmaybe a result of a clonal expansion related
to the plasmepsin 2/3 copy number amplification present in all these samples (figure 4.11). The same
may have occurred for pfcrt.h10, which was only found together with mdr1.h1, and with pfcrt.h12
only co-occurring withmdr1.h10, all of which have the plasmepsin 2/3 amplification. It is therefore
interesting to note that it was possible to use haplogroup information to dissect the samples to get at
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Figure 4.11: Number of samples containing certain combinations of pfcrt andmdr1 haplogroups. Empty cells indicate that
no sample had that speci c combination of haplogroups. Cells that have over 20% of samples withmdr1 copy number
ampli cations are indicated with blue squares, while those with over 20% of samples exhibiting plasmepsin 2/3 copy
number ampli cations are indicated with pink squares. Haplogroup combinations that are signi cantly overrepresented
or underrepresented are indicated with green and red backgrounds respectively (hypergeometric test: p < 10−15).
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observations relating to their geographical origins and their potential drug resistance phenotypes.
4.7 A Super Chloroquine ResistantHaplogroup
Using the available phenotype data, I investigated whether the eight major pfcrt haplogroups differ
in their susceptibility to chloroquine (figure 4.12 a). Of the five major pfcrt haplogroups for which
I had CQ IC50 values, I found that the samples with the pfcrt.h1 haplogroup were as expected very
susceptible to chloroquine due to carrying the wild type pfcrt haplotype (42nmol/L vs 373nmol/L,
p < 4 x10−11). I also found significant differences in CQ IC50 values between the haplogroups carry-
ing the CVIET haplotype (figure 4.12 a). All three haplogroups are chloroquine resistant, however
they differ in their levels of resistance. The archetypical CVIET haplogroup, pfcrt.h3, had a signifi-
cantly lower average level ofCQ IC50 than both pfcrt.h2 (275nmol/L vs 443nmol/L, p < 6 x10−8) and
pfcrt.h7 (275nmol/L vs 672nmol/L, p < 0.005). The pfcrt.h7 haplogroup also had a slightly higher
level of chloroquine resistance than pfcrt.h2 (672nmol/L vs 443nmol/L, p < 0.05), though the num-
ber of samples with the pfcrt.h7 haplogroup is low. What distinguishes the super-resistant pfcrt.h2
and pfcrt.h7 haplogroups from the pfcrt.h3 haplogroup is the presence of the I356T and N326S mu-
tations (figure 4.9 a). These mutations fall into neighbouring transmembrane domains in the PfCRT
protein (figure 4.9 b) and may potentially interact through their physical proximity to produce the
perceived increased level of chloroquine resistance.
Differences in the level of chloroquine resistance in field isolates have previously been described for
parasites carrying the CVIET and CVIDT haplotypes90,36, where it was shown that CVIDT para-
sites exhibit a lower level of CQ IC50 than CVIET parasites90. The data from the present study show
that this observed difference is due to the heterogeneity in CQ IC50 levels within the CVIET carry-
147
ing parasites. Indeed, significant differences in the levels of CQ IC50 between CVIDT parasites and
archetypical CVIET parasites of haplogroup pfcrt.h3 were not seen (259nmol/L vs 275nmol/L, p >
0.05) (figure 4.12 a). This is an important observation, because it suggests that the previously ob-
served phenotypic differences between CVIDT and CVIET parasites were not due to differences in
their respective haplotypes (ie. amino acid positions 72-76), nor due to differences in accessory mu-
tations that accompany these haplotypes (figure 4.3). Rather, the perceived difference was due to the
confounding effect of the super-resistant pfcrt.h2 and pfcrt.h7 haplogroups, which were significantly
more chloroquine resistant than CVIDT parasites (443nmol/L & 672nmol/L vs 259nmol/L, p < 7
x10−12 & p < 0.005 respectively).
The pfcrt.h2 and pfcrt.h7 haplogroups do not only exhibit high-level resistance to chloroquine;
the average parasite clearance half-life (PCt1/2) for artemisinin is also significantly higher for both of
these haplogroups compared to the other pfcrt haplogroups (PCt1/2 of 4.5hr & 5.1hr vs 2.9hr, p < 5
x10−16 & p < 3 x10−5 respectively) (figure 4.12 a). This is not surprising due to the fact that the ma-
jority of the kelch 13mutations, implicated in artemisinin resistance13,334,221, have occurred on these
two haplogroup backgrounds (figure 4.12 b). Indeed, one of the pfcrt mutations defining these hap-
logroups (I356T) came up as a strong candidate in a genome-wide association study for artemisinin
resistance221. Furthermore, it is known that mefloquine resistance and piperaquine resistance, me-
diated by copy number amplifications in themdr1370,280,282 and plasmepsin 2/38,372 genes, have oc-
curred largely on kelch 13mutant backgrounds268,9. Markers for mefloquine and piperaquine resis-
tance were indeed enriched in the samples carrying the super-resistant pfcrt haplogroups (figure 4.12
b). However, I did not observe a significantly higher level of mefloquine or piperaquine resistance in
these haplogroups (all t-tests: p > 0.05) (figure 4.13), likely as a result of the observation that the two
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Figure 4.12: Phenotype associations withmajor pfcrt haplogroups a) Chloroquine IC50 by pfcrt haplogroup (above) and
artemisinin PCt1/2 by pfcrt haplogroup (below). The horizontal lines indicate themedian (bold) and interquartile range
(thin) of the respective distributions. Blue bars indicateWelch two-sample t-tests performed between two distributions,
with stars indicating the level of signi cance of that comparison (n.s. = p > 0.05, * = p < 0.05, *** = p < 0.0005). b) Addi-
tional genetic features of the pfcrt haplogroups, rst row showing pfcrt haplotype (positions: 72-76), second row showing
proportion of samples with a kelch 13mutation (grey) and those without (black), third row showing proportion of sam-
ples with anmdr1 ampli cation (grey) and those without (black), and fourth row showing proportion of samples with a
plasmepsin 2/3 ampli cation (grey) and those without (black).
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Figure 4.13: a)Me oquine IC50 by pfcrt haplogroup and b) piperaquine IC50 by pfcrt haplogroup. The horizontal lines
indicate themedian (bold) and interquartile range (thin) of the respective distributions.
types of copy number amplifications act in an antagonistic manner8,9. I have therefore described the
presence of two related pfcrt haplogroups that exhibit high-level resistance to chloroquine and that
act as a genetic backbone for multidrug resistance.
4.8 Distribution and Prevalence of the Super-ResistantHaplogroups
Both of the super-resistant haplogroups, pfcrt.h2 and pfcrt.h7, are unique to Southeast Asia and are
at a very high prevalence in that region (figure 4.10). It is intriguing that, despite its increased chloro-
quine resistance, pfcrt.h2, which is the most common haplogroup in Southeast Asia, isn’t known to
be found elsewhere in theworld. Furthermore, pfcrt.h2 has been essentially fixed inwestern Southeast
Asia since at least 2001 (figure 4.14). This suggests that, either, these haplogroups have reduced fit-
ness but ongoing chloroquine pressure in Southeast Asia that sustains them, or that selection for the
other drug resistance markers (ie. kelch 13, plasmepsin 2/3,mdr1) maintains these pfcrt haplogroups
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through hitch-hiking or through some epistatic effects.
Within Southeast Asia, I observed a gradient in the prevalence of the two super-resistant hap-
logroups (figure 4.14). They are most prevalent in western Southeast Asia, such as Myanmar (96%,
192/200) and Thailand (98%, 722/735), and become less common as you head east within the region
across Cambodia (58%, 405/695) to Laos (12%, 12/101) and Vietnam (38%, 66/173). This gradi-
ent is particularly evident within Cambodia, where the two haplogroups account for 88% of samples
in the western region of Pailin (n = 120), 38% in the central region of Preah Vihear (n = 105), and
only 7% in the eastern region of Ratanakiri (n = 144) (figure 4.14). Interestingly, while the pattern
within Cambodia is the same, the overall regional pattern is the opposite to that observed for kelch 13
mutations, which are most common in eastern Southeast Asia and less so in the western parts of the
region219. The super-resistant pfcrt haplogroups therefore likely spread independently of the kelch 13
mutations, and suggests that they may have originated from the western part of Southeast Asia.
I alsoobserved interesting temporal patternswithinSoutheastAsia for theprevalenceof the pfcrt.h2
and pfcrt.h7 haplogroups (figure 4.14). In the western parts of the region, their prevalence has re-
mained close to fixation since 2001. However, in Laos and Vietnam I observed an increase in their
prevalence from 3% (1/32) to 25% (6/25) (2010-2012) and from 25% (2/8) to 50% (11/22) (2009-
2012) across the years of collection, while they appear to have become less common inCambodia, 67%
(4/6) to 38% (18/48) (2008-2014), though there appears to have been a recent spike to 61% (11/18) in
2015 (figure 4.14). The apparent decline in Cambodia is unexpected, especially with the knowledge
that the other drug resistancemarkers have increased in prevalence in Cambodia across the same years
of collection8. One possible explanationmay be the large heterogeneity in prevalence between the dif-
ferent regions inCambodia, which could cause spurious patterns through uneven sampling across the
151
Figure 4.14: Southeast Asianmapwith pie charts for the different sampling regions showing the proportion of samples
that have a super resistant pfcrt haplogroup (pfcrt.h2 and pfcrt.h7), shown in green, compared to other haplogroups,
shown in grey. The size of the pie chart is proportional to the number of samples from that region. The bar charts show
the proportion of samples that have a super resistant haplogroup by year for the different countries (background colour
corresponds to country). The numbers above the bar charts indicate the number of samples collected during that particu-
lar year.
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Figure 4.15:Map of Cambodia with bar charts showing the proportion of samples that have a super chloroquine resistant
haplogroup (pfcrt.h2 and pfcrt.h7) by year for the different sampling regions. The numbers above the bar charts indicate
the number of samples collected during that particular year.
years. Stratifying Cambodia by sampling region, I see that there has not been any change in the preva-
lence of the super-resistant haplogroups, and that the apparent decreasewas due to increased sampling
in Pailin and Tasanh in the early years of collection (figure 4.15). On the other hand, the increase in
prevalence in Laos and Vietnam is worrying, not only due to the threat of increased chloroquine re-
sistance, but also due to the fact that we know that these haplogroups act as genetic backbones for
the other types of drug resistance. The spread of these haplogroups is therefore synonymous with a
spread in multidrug resistance and could be an urgent public health issue.
4.9 Strong Linkage Disequilibrium around pfcrt
Todeterminewhether these super-resistanthaplogroups arosemultiple times independently orwhether
they only have one or a handful of origins, I looked at the coding regions flanking the pfcrt gene (102
SNPs, 100kb upstream and 50kb downstream) (figure 4.16). I found that samples with the pfcrt.h1
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haplogroup,which is identical to the 3D7wild type reference strain, have comparatively little structure
in their flanking regions, with an average of 18.7 SNPs differing between the samples (n = 765). On
the other hand, the super-resistant pfcrt.h2 haplogroup-containing samples only differ by 1.8 SNPs
on average across the same region (n = 1,040), and a striking amount of structure is clearly visible (fig-
ure 4.16). The level of structure that is apparent strongly suggests that the pfcrt.h2 haplogroup likely
only had a small number of origins, possibly only one.
Figure 4.16: Flanking regions around pfcrt by haplogroup, showing variant calls (blue: reference, red: alternate) in coding
regions 50kb upstream and 100kb downstream of pfcrt (yellow). Each row corresponding to one sample and each column
corresponding to a variant position. The chromosome region is shown below, with variants mapped to the respective
genes (black) they are found in. The anking regions are shown by four pfcrt haplogroups, with the gradual increase of
mutations from one haplogroup to the other being shown on the left. Hierarchical clustering trees for each haplogroup
show the genetic relationships of the samples to each other based on the anking regions, with themean branch height
(ie. average number of differences) for each haplogroup shown below. Between the hierarchical trees and the anking
region plot, ve columns indicate additional sample-speci c information, including: haplogroupmembership, P. falciparum
population, kelch 13mutation genotype, plasmepsin 2/3 copy number ampli cation presence, andmdr1 copy number
ampli cation presence (see legend below for each of these).
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An interesting picture emerges when looking at pfcrt.h3 and pfcrt.h4which represent potential evolu-
tionary stepping stones from pfcrt.h1 to pfcrt.h2, as they have all the pfcrt.h2mutations except pfcrt.h3
lackingN326S and I356T and pfcrt.h4 lacking only N326S. Both pfcrt.h3 and pfcrt.h4 contain an in-
termediate amount of SNPdifferences between the different samples, 9.1 SNPs on average for pfcrt.h3
(n = 400) and 7.1 SNPs on average for pfcrt.h4 (n = 266), coinciding with their placements between
pfcrt.h1 and pfcrt.h2 (figure 4.16). Surprisingly, the structure that is visible for pfcrt.h3 and pfcrt.h4
resembles the SNP pattern seen for the pfcrt.h2 haplogroup, potentially suggesting that that the three
haplogroups have non-independent origins.
As an additional method of investigating the flanking regions, I calculated the extended haplotype
homozygosity303 on either side of the pfcrt gene (figure 4.17). This further shows the extent of di-
versity within the pfcrt.h1 samples, as the EHH breaks down extremely fast for this cluster, especially
downstream of the gene, where EHH reaches zero almost instantaneously (figure 4.17). This rapid
breakdown of EHH potentially suggests the presence of a recombination hotspot downstream of
pfcrt, which in turn draws attention to the absence of a rapid EHH dropoff in the other three hap-
logroups. The EHH breakdown for these three haplogroups corresponds to the results obtained by
looking at the overall similarity in the flanking regions, pfcrt.h3 drops off fastest and pfcrt.h2 the slow-
est (figure 4.17). Calculating the average relative EHH (rEHH)303 across the 100kb upstream and
downstream of pfcrt for each of the four tested pfcrt haplogroups compared to the other three, I find
that pfcrt.h1 has the lowest rEHH of 0.04± 0.02 (two standard errors of the mean), then pfcrt.h3 of
0.82± 0.05, pfcrt.h4 has a mean rEHH of 2.42± 0.12 and pfcrt.h2 has the highest rEHH of 15.47±
1.23. This further demonstrates the high amount of haplotype conservation around the pfcrt locus
in the super-resistant haplogroup.
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Figure 4.17: Extended haplotype homozygosity (EHH) for 100kb on either side of pfcrt (set at zero) shown for four pfcrt
haplogroups (see inset legend). The EHH is the probability that two random samples within a haplogroup are homozygous
at all SNPs in the interval from the core region (pfcrt) to the speci ed distance away from it 303.
4.10 Discussion
The identification of a pair of pfcrt haplogroups (pfcrt.h2 and pfcrt.h7) that act as genetic backbones
for multidrug resistance fit within the overall narrative of population substructuring that is emerg-
ing within the Southeast Asian setting. It is well-documented that the P. falciparum population in
Southeast Asia is highly structured221,8,9, likely a result of the many selective sweeps that have driven
through the population as a result of drug pressure. This genetic architecture poses difficulties for tra-
ditional genome-wide association studies but also offers a unique opportunity to better understand
the evolutionary history of drug resistance. The I356T mutation in pfcrt, a marker of pfcrt.h2 and
pfcrt.h7, came up as a confounding candidate SNP in a genome-wide association study of artemisinin
resistance221, which we now know is because it forms part of the pfcrt haplogroups that act as ge-
netic backbones for the kelch 13mutations. The fact that these haplogroups exhibit super-resistance
to chloroquine and that the locus around the pfcrt gene is incredibly conserved raise a number of
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questions.
The most immediate question is why the mutations involved in artemisinin resistance and other sub-
sequent partner drug resistances occurred on these particular pfcrt haplogroups. While the super-
resistant haplogroups are essentially fixed inWestern Southeast Asia, they are less common in Eastern
Southeast Asia where the other drug resistance mutations are thought to have originated from219,9.
Additionally, we know that kelch 13 mutations have arisen multiple times independently in the re-
gion342, but seemingly almost exclusively on the super-resistant pfcrt haplogroups (figure 4.12 b) (fig-
ure 4.16). This situation is further complicated by the observation that parasites with pfcrtmutations
leading to chloroquine resistance tend to be less fit thanwild-type parasites184. Therefore, whywould
we observe kelch 13mutations arise multiple times independently only on a specific pfcrt haplogroup
that is of intermediate prevalence and that likely has reduced fitness compared to other parasites in the
region?
One possibility that may explain this seemingly unexpected observation is that there may be some
epistatic effects of pfcrt on the acquisition of kelch 13mutations. This means that the super-resistant
pfcrt haplogroup is a pre-requisite for the kelch 13mutations to bemaintained and spread. It is known
that mutations in pfcrt can affect the expression of a large number of other genes in the genome326
and it has also been reported that the level of artemisinin resistance conferred by kelch 13mutations
is dependent on the genetic background of the parasite334. The fact that artemisinin is thought to
act by inducing oxidative stress that is dependent on hemoglobin digestion by the parasite168 and
the observation that the mutations in pfcrt leading to chloroquine resistance result in reduced fitness
due to interferingwith hemoglobin digestion190, potentially through reduced heme transport22, sug-
gest that there may be a mechanistic basis for pfcrt mutations providing the optimal background for
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artemisinin resistance mutations to continually emerge on. This in turn may also provide an expla-
nation for the lack of artemisinin resistance in Africa, as the super-resistant haplogroups are absent
in that region and therefore the kelch 13 mutations that would arise there would not have the same
fitness advantage as those that appear in the Southeast Asian context. Further studies are required to
test this hypothesis.
Another question that arises from the results in this study relates to the strong conservation of hap-
lotype structure around the pfcrt gene and how this is maintained in the population. The striking
similarities in the structure of the flanking regions between the major CVIET containing pfcrt hap-
logroups (pfcrt.h2, pfcrt.h3, pfcrt.h4) suggests that they have had a non-independent origin and that
pfcrt.h2, which has the highest rEHH, may potentially have arisen from a pfcrt.h4 background. Tak-
ing into account that pfcrt.h3 and pfcrt.h4 also exhibit high amounts of structure conservation (figure
4.16) and assuming that they are the result of the spread in chloroquine resistance from Southeast
Asia to Africa in the 1970’s12, then it suggests that pfcrt.h2 may have a relatively old origin. This is
supported by the fact that many of the samples collected in 2001 inMae Sot contain the pfcrt.h2 hap-
logroup (figure 4.14). One would expect the structure to have broken down across such a long period
of time. This is especially true considering the rapid breakdown in EHH I observe in the pfcrt.h1 hap-
logroup containing samples (figure 4.17). It is possible that SNPs in other genes in the vicinity of pfcrt
may act as compensatory mutations for the pfcrt mutations and are therefore maintained, resulting
in the observed level of structure. The suggestion that this entire region of the genome is essentially
prevented from evolving in order to maintain the pfcrt haplogroup implies that there is very strong
selection for the pfcrt haplogroup.
The origin for this level of selection could be twofold. Firstly, continuing use of chloroquine may se-
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lect for high-level chloroquine resistance conferred by the super-resistant haplogroups. Chloroquine
is currently still used in the region to treat Plasmodium vivax inducedmalaria cases, potentially creat-
ing selective pressure on the P. falciparum population in cases of mixed-infections and when people
treat themselves using chloroquine obtained illicitly. The observed gradient of pfcrt.h2 being most
prevalent in Myanmar and the western parts of Thailand (figure 4.14), suggest that the level of selec-
tion is stronger in that part of the region and/or that the haplogroup originated there. The implemen-
tation of malaria policy is difficult in Myanmar due to widespread poverty and political uncertainty,
with counterfeit malaria drugs not being uncommon129. It is possible that this may be the source
of the super-resistant haplogroups. In addition to this, the appearance of drug resistance mutations
to other antimalarial drugs on these super-resistant pfcrt backgrounds would have provided a second
source of strong selective pressure to maintain these pfcrt haplogroups. This is especially true if we
assume that there is an actual mechanistic way in which the pfcrt haplogroups enable the acquisition
of artemisinin resistance as I outlined above.
4.11 Conclusion
Having employed a haplogroup analysis of two well-characterized drug resistance genes, pfcrt and
mdr1, I have identified a pair of pfcrt haplogroups that exhibit super-resistance to chloroquine. These
pfcrt haplogroups, characterized by the combination of a CVIET haplotype with the N326S and
I356T mutations, act as genetic backbones for artemisinin resistance and as a consequence also for
copy number variations leading to mefloquine and piperaquine resistance. The observation that the
kelch 13mutations seemingly only persist on these super-resistant pfcrt backgrounds suggests a mech-
anistic inter-relationship, with pfcrt acting as a form of prerequisite for artemisinin resistance. These
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super-resistant haplogroups are present at high frequency throughout Southeast Asia and may have
had a single origin in the western parts of the region as evidenced by the flanking regions surrounding
the pfcrt gene and the distribution of the haplogroups. The high level of conservation in these flanking
regions suggests ongoing selection for these super-resistant haplogroups, potentially through contin-
uing use of chloroquine or as a consequence of selection for resistance to the other antimalarial drugs.
The apparent rise in frequency of these haplogroups in Laos and Vietnam is reason for increased vig-




I believe it’s not only possible to eradicate malaria; I believe
it’s necessary. Ultimately, the cost of controlling it endlessly
is not sustainable. The only way to stop this disease is to end
it forever.
Bill Gates, www.gatesnotes.com, 2014 CE
5
Conclusion
5.1 Summary of Results
I set out writing this thesis and performing the associated research with the underlying question of
‘What can genomics tell us about human malaria parasites?’. The simple, yet resounding, answer to
that question is ‘a lot’. Throughout this thesis, I have tackled our current understanding of human
malaria and attempted to expand on it from a number of different perspectives. These analyses varied
both in the species studied, evolutionary timescale examined, and type and wealth of data that went
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into informing the different studies.
In Chapter 1, I took advantage of recent progress in sequencing technology and sample preparation
to assemble reference genome sequences for P. malariae and for both species of P. ovale, thereby fill-
ing a crucial gap in our genomic understanding of human malaria. I was able to use those genome
sequences to conclusively show that P. ovale wallikeri and P. ovale curtisi are indeed highly differen-
tiated species. The genome sequences also enabled me to infer the phylogenetic relationship of the
different Plasmodium species to each other using the largest and most complete amino acid align-
ment to date, showing that the rodent malaria parasites appear to form a sister clade with the P. ovale
species and therefore fall within the clade of human-infective malaria parasites, suggestive of an ances-
tral host switch. I also discovered two large novel gene families in P. malariae, fam-l and fam-m, that
occur in doublets throughout the subtelomeres of that species and that appear to be transported to
the red blood cell surface where theymay adopt anRH5-like fold. Having also assembled the genome
sequence of a chimpanzee-infective species closely related to P. malariae, P. malariae-like, I was able
to show symmetry in signals of selection of human-infective species (P. malariae and P. falciparum)
diverging from chimpanzee-infective species (P. malariae-like and P. reichenowi).
In Chapter 2, harnessing the newly assembled reference genome sequence of P. malariae, I character-
ized a clinical recrudescence case ofP.malariae. Iwas able to show that the initial infection (whichwas
the one used for the reference genome assembly), consisted of three haplotypes at different frequencies
and that it was the least prevalent haplotype that resulted in the recrudescent infection. Additionally,
I discovered that the three haplotypes in the initial infectionwere very closely related to each other and
that they likely resulted from sexual recombination of four parental haplotypes. Comparing SNPs, I
identified a number of SNPs in drug resistance genes thatmay explain how the rare haplotype survived
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the drug treatment, while the more prevalent ones were completely cleared. Different scenarios were
considered that could explain the recrudescence, with drug resistance providing a potential explana-
tion.
In Chapter 3, I wished to better understand the genetic basis of antimalarial drug resistance and thus
focused on the current outbreak of multidrug resistance in Southeast Asia by looking at the response
of KEL1/PLA1 P. falciparum parasites to mefloquine treatment. I have shown that KEL/PLA1 par-
asites appear to be hypersensitive to mefloquine treatment compared to wild type parasites due to
their acquisition of the PLA1 co-lineage. I have suggested that, as the PLA1 lineage is characterized
by the presence of the plasmepsin 2/3 copy number amplification, that this amplification mediates
mefloquine response in an antagonistic way to mdr1 amplification, mirroring their antagonism on
piperaquine response, and suggesting that triple mutants may not necessarily display triple resistance.
Additionally, I identified a novel mutation in the mdr1 gene that appears to have arisen on a plas-
mepsin 2/3 amplified background, leading to an even higher level of mefloquine sensitivity. This par-
ticular SNP is shown to have had a single origin and has rapidly increased in frequency and spread
through the region, all hallmarks of positive selection. Finally, I discussed the potential mechanistic
and evolutionary implications of this finding together with the apparent antagonism of the types of
copy number amplifications.
In Chapter 4, I used a haplogroup approach to analyse how haplotypes of two well-studied genes,
pfcrt andmdr1, associate with multidrug resistance, doing so by harnessing phenotype data on mul-
tiple drugs. I showed that, while I find few associations of drug response with individualmdr1 hap-
logroups, except for the one haplogroup containing the novel SNP identified in Chapter 3, that a
specific pair of pfcrt haplogroups appear to exhibit super-resistance to chloroquine, over and above
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the level of resistance conferred by the quintessential chloroquine resistance mutation K76T. These
two haplogroups share two important mutations at amino acid positions 326 and 356 that may be
functionally mediating this super-resistance. I showed that these super-resistant pfcrt haplogroups
appear to act as the genetic backbone on which artemisinin and consequently multidrug resistance
emerged. These super-resistant haplogroups are restricted to Southeast Asia and display high levels
of extended haplotype homozygosity around the pfcrt gene. I proposed that the pfcrt gene may play
a functional role in enabling the acquisition of artemisinin resistance and that the high frequency of
these super-resistant pfcrt haplogroups in Southeast Asia may be the reason for artemisinin resistance
having arisen in that region and not having spread elsewhere.
5.2 AnOverarchingNarrative
While the overarching question of the thesis was in certain ways a rhetorical one, I attempted to struc-
ture and sequence the different analyses in such away as to add value by exploring the interactions and
transferable knowledge that one study can have on another. The most direct example of that is the
inability of performing the analysis of clinical recrudescence of P.malariae in Chapter 2 without pre-
viously having assembled the reference genome sequence for that species in Chapter 1. The analysis
of Chapter 1, which in many ways was one of past evolutionary events, now opens up the possibility
of improving our understanding of current evolutionary events, such as surveying changes in the ne-
glected human malaria parasite species populations or potentially identifying the emergence of drug
resistance early on, as I may have done in Chapter 2. The findings of Chapter 2 are evidently impor-
tant at the present time in the clinic, but they also bring up questions aboutmore distant evolutionary
events, such as whether drug resistance is already present in the field, but simply not recognised, and
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whether past clinical recrudescence cases could be explained in a similar way. The identification of
KEL1/PLA1 as being hypersensitive to mefloquine sheds light on the evolutionary events that have
given rise to the co-lineage, such as the disappearance ofmdr1 amplifications from the field. Finally,
while the presence of a super-chloroquine resistant haplogroup acting as a backbone to artemisinin re-
sistance may inform us about the potential sequence of evolutionary events that led to the emergence
of artemisinin resistance, it is also an important finding for the present, as it suggests that parasites are
very unlikely to revert to becoming chloroquine sensitive in the region.
Another leitfaden throughout this thesis has been that of layering increasingly complex sets of data: I
began by comparing genome sequences to each other inChapter 1, I then layered on clinical metadata
in Chapter 2, while in Chapter 3 I added in phenotype data for one drug, and finally, in Chapter 4, I
harnessed phenotype data formultiple drugs. At each level, I identified newbiology that both expands
our understanding of human malaria in general and sheds light on the specifics of antimalarial drug
resistance. In Chapter 1, the assembly of the genome sequences led to immediate new findings, such
as the identification of new gene families or pseudogenization of RBPs, though many of the results
of that chapter were also the consequence of comparing the new assemblies to existing ones of other
species, such as improving our understanding of thePlasmodium phylogeny, showing the value of ad-
ditional data in the form of more genome sequences. In Chapter 2, it was only because of the clinical
metadata that it became apparent that it was the same patient from whom the two P. malariae sam-
ples originated from, allowing me to identify the recrudescence of the minor haplotype. The clinical
metadata was also crucial in ruling out specific explanations for the recrudescence, givingmore weight
to the potential explanation of drug resistance. While it was known that there were changes in the fre-
quencies of themdr1 and plasmepsin 2/3 amplifications in the field and that mefloquine appeared to
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be effective, it was only with access to the mefloquine IC50 values that it was possible to show that
the two amplifications appear to be antagonistic and that KEL1/PLA1 parasites are hypersensitive to
mefloquine. Finally it was known that certain pfcrt mutations were associated with artemisinin resis-
tance, but it was only with phenotype data onmultiple drugs that it became apparent that artemisinin
and chloroquine resistance were highly correlated in the field because the former appears to have only
arisen on a particular pfcrt haplogroup mediating chloroquine super-resistance. It has been exciting
analysing these datasets and seeing what new questions can be answered with the addition of new
types of data.
5.3 Future Directions
There still remains a lot to be learned and the best studies simply raise new questions: how have the
two P. ovale species speciated? What genes enable P. malariae to remain in the host for decades un-
noticed? What is the mechanistic explanation for mefloquine hypersensitivity induced by plasmepsin
2/3 acquisition? Why has multidrug resistance in Southeast Asia exclusively arisen on a single pfcrt
haplotype? The questions that arise are broad and involve numerous different fields and branches
of malaria research; describing or even just listing all the immediate questions is beyond the scope of
this conclusion chapter. To focus the discussion, and to keep in line with the two themes guiding the
narrative of this thesis, namely the overlaying of increasing levels of data and the interplay between
current and past evolutionary events, I wish to outline how I see the next research steps pertaining to
each of these.
Data is becoming ever more abundant and complex, as evidenced throughout this thesis. Even a sin-
gle whole genome sequence contains a mind-baffling amount of information, nevermind analysing
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hundreds of them together. In this thesis I have shown how integrating different sets of data can re-
veal new biological insights. One particular ‘combination’ of data that I foresee as being incredibly
exciting, and that may happen in the coming years, is a pan-Plasmodium population genetics study.
The jump in my thesis from P. malariae and P. ovale in Chapters 1 and 2 to P. falciparum in Chap-
ters 3 and 4 may appear abrupt and almost non sequitur, and in many ways it is because so far these
fields of study have not been linked up. As more and more sequencing data becomes available for all
human malaria parasite species, as is now happening for P. vivax for instance, it will become natural
to combine these divergent datasets. Combining these will enable novel analyses to be developed to
look for instance at symmetries in selection signals across multiple species, to analyse correlations in
changes in transmission intensity (which can be inferred genetically) of different species, or to study
the frequency of co-infections and potential genetic adaptations linked to those. At the outset of this
thesis, I explained the need for genome sequences for all humanmalaria parasites in order to enable ef-
fective surveillance and a better understanding of those neglected species that will likely pose themost
difficulty in the endgame of malaria elimination. Analyses that incorporate timely and well-sampled
genetic data from across all human malaria parasites will open up new research avenues that will pro-
vide a more holistic picture of malaria elimination, and will ensure that no blind spots remain as we
make a concerted push towards the endgoal.
The second exciting field of research that opens up as a result of the increasing availability of data is
that of mathematical models based on genomic data. While this thesis explored both past and current
evolutionary events and showedhow they intersect and influence eachother, the applicationofmathe-
matical models has the potential to inform us about future evolutionary events. Using the knowledge
of past and current events in the form of genomic data will enable us to create mathematical mod-
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els that utilize that data to make predictions about future evolutionary events. These models do not
only rely on high quality genetic data, but also on the data being sampled in a systematic way both
temporally and spatially. The Pf6 MalariaGEN dataset that was analysed as part of Chapters 3 & 4
consisted of exactly suchdata andwith ongoing collections, this resourcewill only continue to become
increasingly valuable and information-rich. It is easy to see how these data could theoretically be used
to construct transmission models that take into account local drug policies and that are trained on
the actual genetic changes in the parasite populations as drug policies change. This is especially true
with our improved understanding of the interactions between different drugs, such as the antagonism
of piperaquine and mefloquine or how chloroquine super-resistance appears to be the genetic back-
bone for artemisinin resistance. Policy-makers want to knowwhat will happen next when they switch
the recommended treatment. While in the past, traditional transmission models were used to inform
these choices, they were always parameterized with assumptions that were often difficult to support
objectively. By supplanting these textbook parameters with proxies that are accurately inferred from
genetic informationwill enablemodels to be parameterized according to the specific scenario and also
allow the parameters to be continually updated as new genetic data comes in from the field.
These future advancements in research will play pivotal roles as we approach near-elimination set-
tings. Bringing together the genomic epidemiological models with the pan-Plasmodium perspective I
outlined earlier is, in my opinion, the holy grail of genomic surveillance for malaria elimination. The
findings that I have presented throughout this thesis have laid in different ways the foundation for
these future breakthroughs. While many of the results contained within this thesis have direct appli-
cations in the field at present, they also pave the way for future discoveries to be made that will have







I aligned the P. malariae (AB354570) and P. ovale (AB354571) mitochondrial genome sequences
against those ofP. falciparum115,P. vivax 51, andP. knowlesi 266 usingMUSCLE94. For each species, I
identified three 15bp stretches within the cox1 gene that contained two ormore species-specific SNPs.
I searched for these 15bp species-specific barcodes within the sequencing reads of all 2,512 samples
from the Pf3K global collection (www.malariagen.net). Samples that contained at least two sequenc-
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ing reads matching one or more of the 15bp barcodes for a specific species were considered to be pos-
itive for that species (Chapter 1: table 1.1). I found good correspondence between the three different
barcodes for each species, with over 80%of positive samples being positive for all three barcodes. I gen-
erated pseudo-barcodes by changing two randomly selected nucleotide bases at a time for 10 randomly
selected 15bp region in the P. vivax 51 mitochondrial genome. I did not detect any positive hits us-
ing these pseudo-barcodes. As an additional negative control, I searched for P. knowlesi co-infections,
but did not find any samples positive for this species. Two samples (PocGH01, PocGH02) had high
numbers for all three P. ovale barcodes and were used for reference genome assembly and SNP calling
respectively.
A.2 ParasiteMaterial
All P. ovale samples were obtained from symptomatic patients diagnosed with a P. falciparum infec-
tion. The two P. o. curtisi samples (PocGH01, PocGH02) identified through co-infection mining
(see above), were from two patients testing positive on a CareStart® (HRP2 based) rapid malaria di-
agnostic test (RDT) kit at the Navrongo War Memorial hospital, Ghana. One P. o. wallikeri sample
(PowCR01) and one P. o. curtisi sample were from uncomplicated malaria patients testing positive
by light microscopy at theMile 16 - BolifambaHealth Centre, Buea, Cameroon. The other P. o. wal-
likeri sample (PowCR02) was obtained from an individual with asymptomatic parasitemia enrolled
through a community survey in Mutengene, Cameroon. For all samples, following consent obtain-
ment, about 2-5mls of venous blood was obtained and then diluted with one volume of PBS. This
was passed through CF11 cellulose powder columns to remove leucocytes prior to parasite DNA ex-
traction.
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The twoP.malariae-like samples, PmlGA01 and PmlGA02, were extracted fromChimpanzee blood
obtained during routine sanitary controls of animals living in a Gabonese sanctuary (Park of La
Lékédi, Gabon). Blood collection was performed following international rules for animal health.
Within six hours after collection, host white blood cell depletion was performed on fresh blood sam-
ples using the CF11 method21. After DNA extraction using the Qiagen blood and Tissue Kit and
detection of P. malariae infections by Cytb PCR and sequencing253, the samples went through a
whole genome amplification step263.
One P. malariae sample, PmMA01, was collected from a patient with uncomplicated malaria in Fal-
adje, Mali. Venous blood (2–5mL) was depleted of leukocytes within 6 hours of collection as previ-
ously described161. The studyprotocolwas approvedby theEthicsCommittee of Faculty ofMedicine
and Odontomatology and Faculty of Pharmacy, Bamako, Mali.
Four samples of P. malariae were obtained from travellers returning to Australia with malaria.
PmUG01 and PmID01 were sourced from patients returning from Uganda and Papua Indonesia re-
spectively, who presented at the Royal DarwinHospital, Darwin, withmicroscopy-positive P.malar-
iae infection. PmMY01 was sourced from a patient presenting at the Queen Elizabeth Hospital,
Sabah, Malaysia, with microscopy-positive P. malariae infection. Patient sample PmGN01 was col-
lected from a patient who presented to Royal Brisbane andWomensHospital in 2013 on return from
Guinea.
Venous blood samples were subject to leukodepletion within 6 hours of collection. PmUG01 was
leukodepleted using a commercial Plasmodipur filter (EuroProxima, The Netherlands); home-made
cellulose-based filters were used for PmID01 and PmMY01, while PmGN01was leukodepleted using
an inline leukodepletion filter present in the venesection pack (Pall Leukotrap;WBT436CEA). DNA
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extraction was undertaken on filtered blood using commercial kits (QIAamp DNA Blood Midi kit,
Qiagen Australia).
For samples PmUG01, PmID01 and PmMY01, ethical approval for the sample collection was ob-
tained from the Human Research Ethics Committee of NT Department of Health and Families
and Menzies School of Health Research (HREC-2010-1396 and HREC-2010-1431) and the Med-
ical Research Ethics Committee, Ministry of Health Malaysia (NMRR-10-754-6684). For sample
PmGN02, ethical approval was obtained from the Royal Brisbane and Womens Hospital Human
Research Ethics Committee (HREC/10/QRBW/379) and the Human Research Ethics Committee
of the Queensland Institute of Medical Research (p1478).
A.3 Sample Preparation and Sequencing
One P. malariae sample, PmUG01, was selected for long read sequencing, using Pacific Biosciences
(PacBio), due to its low host contamination and abundant DNA. Passing through a 25mm blunt-
endedneedle, 6ugofDNAwas sheared to20-25kb. SMRTbell template librarieswere generatedusing
the PacBio issued protocol (20kb Template Preparation using the BluePippin™ Size-Selection Sys-
tem). After a greater than 7kb size-selection using the BluePippin™ Size-Selection System (Sage Sci-
ence, Beverly, MA), the library was sequenced using P6 polymerase and chemistry version 4 (P6/C4)
in 20 SMRT cells (table A.1).
The remaining isolates were sequenced with Illumina Standard libraries of 200-300bp fragments and
amplification-free libraries of 400-600bp fragments were prepared43 and sequenced on the Illumina
HiSeq 2000 v3 or v4 and theMiSeq v2 according to themanufacturer’s standard protocol (table A.1).
































































































































































































































































































































































































































































































































































































































































































The PacBio sequenced P. malariae sample, PmUG01, was assembled using HGAP59 with an esti-
mated genome size of 100Mb to account for the host contamination (≈85% Human). The result-
ing assembly was corrected initially using Quiver59, followed by iCORN260. PmUG01 consisted of
two haplotypes, with the majority haplotype being used for the iCORN260, and a coverage analy-
sis was performed to remove duplicate contigs. Additional duplicated contigs were identified using
a BLASTN5 search, with the shorter contigs being removed if they were fully contained within the
longer contigs or merged with the longer contig if their contig ends overlapped. Host contamina-
tion was removed by manually filtering on GC, coverage, and BLASTN hits to the non-redundant
nucleotide database5.
The Illumina based genome assemblies for P. o. curtisi, P. o. wallikeri, and P. malariae-like were
performed using MaSURCA383 for samples PocGH01, PowCR01, and PmlGA01 respectively. To
confirm that the assemblies were indeed P. ovale, I mapped existing P. ovale capillary reads to the as-
semblies (www.ncbi.nlm.nih.gov/Traces/trace.cgi?view=search). Prior to applying MaSURCA383,
the samples were mapped to the P. falciparum 3D7 reference genome115 to remove contaminating
reads. The draft assemblies were further improved by iterative uses of SSPACE37, GapFiller236 and
IMAGE350. The resulting scaffolds were ordered using ABACAS18 against the P. vivax PVP0120
assembly (both P. ovale) or against the P. malariae PacBio assembly (P. malariae-like). The assem-
blies were manually filtered on GC, coverage, and BLASTN hits to the non-redundant nucleotide
database5. iCORN260 was used to correct frameshifts. Finally, contigs shorter than 1 kilobase (kb)
were removed.
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Table A.2: Accession numbers for the assembled genome sequences
Assembly Name Study ID Sample ID Contig Accession Chromosome Accession
PmUG01 PRJEB2579 ERS1110315 FLRL01000001- LT594622-
FLRL01000047 LT594637
PocGH01 PRJEB2579 ERS013096 FLRI01000001- LT594582-
FLRI01000638 LT594597
PowCR01 PRJEB2579 ERS418894 FLRJ01000001- LT594505-
FLRJ01000771 LT594520
PmlGA01 PRJEB2579 ERS434571 FLRK01000001- LT594489-
FLRK01000035 LT594503
Using two more samples, PocGH02 and PowCR02, additional draft assemblies of both P. ovale
species were produced using MaSURCA383 followed by RATT257 to transfer the gene models from
the high-quality assemblies.
The genome sequences and annotations are currently available onGeneDB (www.genedb.org) and the
genome sequences have been deposited into the European Nucleotide Archive (www.ebi.ac.uk/ena).
Accession numbers for all reads generated for this study can be found in table A.1 . Accession IDs for
the assembled genome sequences can be found in table A.2.
A.5 Gene Annotation
RATT257 was used to transfer gene models based on synteny conserved with other sequenced Plas-
modium species (P. falciparum115, P. vivax 51, P. berghei 256, and P. gallinaceum38). In addition,
genes were predicted ab initio using AUGUSTUS333, trained on a geneset consisting of manually cu-
rated P. malariae and P. ovale genes respectively. Ulrike Boehme from theWellcome Sanger Institute
identfied non-coding RNAs and tRNAs using Rfam 12.0238 and then curated gene models for both
the P. malariae and P. o. curtisi reference genomes, using Artemis300 and the Artemis Comparison
Tool (ACT)55. She also used these tools to manually identify deleted and disrupted genes.
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A.6 Phylogenetics
Following ortholog assignment using BLASTP5 and OrthoMCL194, amino acid sequences of 1,000
core genes from 12 Plasmodium species (P. gallinaceum38, P. falciparum115, P. reichenowi 259, P.
knowlesi 266, P. vivax 20, P. cynomolgi 341, P. chabaudi 256, P. berghei 256, and the four assemblies pro-
duced in this study) were aligned usingMUSCLE94. The alignments were cleaned using GBlocks343
with default parameters to remove non-informative and gapped sites. The cleaned non-zero length
alignments were then concatenated. This resulted in an alignment of 421,988 amino acid sites
per species. The optimal substitution model for each gene partition was determined by running
RAxML332 for each gene separately using all implemented substitution models. The substitution
models that generated the tree with the highest likelihood were used for each gene partition. A maxi-
mum likelihood phylogenetic tree was constructed using RAxML332 with 100 bootstraps331 (Chap-
ter 1: figure 1.1b). To confirmthis tree, I utilizeddifferent phylogenetic tools includingPhyloBayes182
andPhyML128, a number of different substitutionmodelswithinRAxML332, starting the tree search
from the commonly accepted phylogenetic tree, and removing sites in the alignmentwhich supported
significantly different trees. All approaches yielded the final tree reported in Chapter 1 with the high-
est likelihood. Figtree was used to colour the tree (http://tree.bio.ed.ac.uk/software/figtree/).
A phylogenetic tree of four P.malariae (PmID01, PmGN01, PmGN02, PmMY01) and all P.malar-
iae-like samples (PmlGA01, PmlGA02) was generated using PhyML128 based on all P. malariae
genes. For each sample, the raw SNPs as called using the SNP pipeline (see below), were mapped
onto all genes tomorph them into sample specific gene copies using BCFtools192. Amino acids for all
genes were concatenated and cleaned using GBlocks343.
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A.7 Divergence Dating
Species divergence times were estimated using the Bayesian inference tool G-PhoCS125, a software
which uses thousands of unlinked neutrally evolving loci and a given phylogeny to estimate demo-
graphic parameters. One additional sample per assembly (PmGN01 for P. malariae, PocGH02 for
P. o. curtisi, PowCR02 for P. o. wallikeri, and PmlGA02 for P. malariae-like) was used to morph
the respective assembly using iCORN260. Regions in the genomes without mapping were masked,
as iCORN260 would not have morphed them. Unassigned contigs and subtelomeric regions were
removed for this analysis due to the difficulty of alignment. Repetitive regions in the chromosomes
of the four assemblies and the four morphed samples were masked using DUSTmasker227 and then
the chromosomes were aligned using FSA42. The P. o. wallikeri and the P. o. curtisi chromosomes
were aligned against each other, as were the P. malariae and P. malariae-like chromosomes. The
alignments were split into 1kb loci, removing those that contained gaps, masked regions, and coding
regions to conform with the neutral loci assumption of G-PhoCS125. G-PhoCS125 was run for one
million MCMC-iterations with a sample-skip of 1,000 and a burn-in of 10,000 for each of the two
species pairs. Follow-up analyses using Tracer (http://beast.bio.ed.ac.uk/Tracer) confirmed that this
was sufficient for convergence of the MCMC chain in all cases. In the model, I assumed a variable
mutation rate across loci and allowed for on-going gene flow between the populations. The tau values
obtained from this were 0.0049 for P. malariae and 0.0434 for P. ovale.
The tau values were used to calculate the date of the split, using the formula (tau x G)/mu, where
G is the generation time in years and mu is the mutation rate. By assuming a generation time of 65
days77, I estimated a mutation rate of approximately 3.8 x 10−10 SNPs/site/year by optimizing the P.
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falciparum/P. reichenowi split to 4 million years ago, a date that was estimated previously322. For P.
malariae, a generation time of 100 days was used to account for the longer intra-erythrocytic cycle.
A.8 3D Structure Prediction
The I-TASSER380 version 4.4 online web server381 (zhanglab.ccmb.med.umich.edu/I-TASSER) was
used for 3D protein structure prediction. Predicted structures with a TM-score of over 0.5 were con-
sidered reliable as suggested in the I-TASSER user guidelines377. TM-align382, as implemented in
I-TASSER381, was used to overlay the predicted protein structure with existing published protein
structures.
A.9 Hypnozoite Gene Search
Using theOrthoMCL194 clustering between all sequenced Plasmodium species used for the phyloge-
netic analysis (see above), I examined clusters containing only P. vivax P01 genes, P. cynomolgi 341
genes and genes of both of the P. ovale species. Additionally, I examined P. o. curtisi orthologs
of previously published hypnozoite gene candidates341, looking in the 1kb 5’ upstream region for
any of the four ApiAP2 motifs47 involved in sporozoite regulation and expression: GCATGC
(PF3D7_1466400), GCCCCG (PF3D7_1342900), TAAGCC (PF3D7_1342900), and TGTTAC
(PF3D7_0420300).
A.10 Gene Family Analysis
AllP.malariae,P. ovale, andP. vivax P01 geneswere compared in a pairwisemanner usingBLASTP5,
with genes having a minimum local BLAST hit of 50% identity over 150 amino acids or more be-
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ing considered connected. These gene connections were visualized in Gephi27 using a Fruchterman-
Reingold109 layout and with unconnected nodes removed.
P. malariae, P. o. curtisi and P. o. wallikeri protein sequences for Plasmodium interspersed repeat
(pir) genes, excluding pseudogenes, were combined with those from P. vivax P01 , P. knowlesi 266,
P. chabaudi AS v3 (genedb.org/Homepage/Pchabaudi), P. yoelii 17X v2256, and P. berghei v3
(genedb.org/Homepage/Pberghei). Adam Reid from the Wellcome Sanger Institute used these se-
quences to cluster them using tribeMCL96 with blast E-value 0.01 and inflation 2, resulting in 152
subfamilies. He then excluded clusters with onemember and plotted the number of genes per species
in each subfamily in a heatmap using the heatmap.2 function in ggplots in R-3.1.2.
The pir genes from two P. o. curtisi and two P. o. wallikeri assemblies (two high-quality and two
draft assemblies) were compared in a pairwise manner using BLASTP5 with a 99% identity over a
minimum of 150 amino acids cutoff. The gene-gene connections were visualized in Gephi27 using a
Fruchterman-Reingold109 layout after removing unconnected nodes.
A.11 Mirror Tree Analysis
Using Artemis300, 79 fam-m and fam-l doublets that were confidently predicted as being paired-up
were manually selected based on their dispersal throughout the subtelomeres of different chromo-
somes. The Mirrortree248 web server (http://csbg.cnb.csic.es/mtserver/) was used to construct mir-
ror trees for these 79 doublets. Of these, 35 doublets with recent branching from another doublet
were manually selected to enrich for genes under recent selection. To control for chance signals of co-
evolution based on their subtelomeric location, the same methodology was repeated by choosing 79
pir genes in close proximity of fam-m genes as ‘pseudo-doublets’ and paired up in the Mirrortree248
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web server.
A.12 Reticulocyte Binding Protein (RBP) Phylogenetic Plot
Full-length RBP genes were manually inspected using ACT55 and verified to either be functional or
pseudogenized by looking for sequencing reads in other samples that confirmmutations inducing pre-
mature stop codons or frameshifts. All functional RBPs were aligned usingMUSCLE94 and cleaned
usingGBlocks343. PhyML128 was used to construct a phylogenetic tree of the different RBPs. Figtree
was used to colour the tree (http://tree.bio.ed.ac.uk/software/figtree/).
A.13 SNP Calling
Additional P. malariae (PmMY01, PmID01, PmMA01, PmGN01) and P. o. curtisi (PocGH01,
PocGH02, PocCR01) samples were mapped back against the reference genomes using SMALT (-y
0.8, -i 300). As outgroups, P. malariae-like (PmlGA01, PmlGA02) and P. o. wallikeri (PowCR01,
PowCR02) were also mapped against the P. malariae and P. o. curtisi genomes respectively. The
resulting bam format files were merged for either of the two genomes, andGATK’s215 UnifiedGeno-
typer was used to call SNPs from the merged bam format files. Per GATK’s215 best practices, SNPs
were filtered by quality of depth (QD > 2), depth of coverage (DP > 10), mapping quality (MQ >
20), and strand bias (FS < 60). Additionally, all sites with missing data for any of the samples or with
heterozygous calls were filtered away. Finally, I filtered away sites that were masked using DUST-
masker227 to remove repetitive and difficult to map regions. The same methodology was also applied
to two P. vivax samples (SRR3400910 & SRR332566) and two P. falciparum Pf3K field samples
(PF0066-C & PF0038-C) for comparative purposes.
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A.14 Molecular Evolution Analysis
To calculate the nucleotide diversity for the different species, I extracted all filtered SNPs in the
genomes excluding the subtelomeres. I then counted the number of pairwise differences between
the different samples divided by the resulting genome size, comprising three comparisons for species
with three samples (P. malariae, P. o. curtisi, P. vivax, P. falciparum) and one comparison for species
with two samples (P. o. wallikeri, P. malariae-like). These estimates were then averaged by species.
The filtered SNPs were used to morph the reference genomes using BCFtools192 for each sample,
from which sample-specific gene models were obtained. Nucleotide alignments of each gene were
then generated. Codons with alignment positions that were masked using DUSTmasker227 were ex-
cluded. For each alignment (ie. gene), I calculatedHKA152,MK174, andKa/Ks241 values (see below).
Subtelomeric gene families and pseudogenes were excluded from the analysis. The results were anal-
ysed and plotted in RStudio (http://www.rstudio.com/).
The first measure of selection I calculated for each gene was the Hudson-Kreitman-Aguade ratio
(HKAr)152. HKAr is the ratio of interspecific nucleotide divergence to intraspecific polymorphisms,
it is thereby a measure of adaptive evolution, ie. an overrepresentation of recent polymorphisms com-
pared to the expected ‘neutral’ rate implied by the interspecific nucleotide divergence. To calculate
the HKAr, I counted the proportion of pairwise nucleotide differences intra-specifically (ie. within
P. malariae and within P. o. curtisi) and inter-specifically (ie. between P. malariae and P. malariae-
like, between P. o. curtisi and P. o. wallikeri). The intraspecific comparisons were averaged to get
the genes’ nucleotide diversity ‘π’ and these were divided by the average interspecific comparisons, the
nucleotide divergence ‘K’. The HKAr is therefore π/K for each gene.
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The second measure of selection to be calculated was the McDonald Kreitman (MK) skew174. The
MK skew is a measure of maintained polymorphisms, ie. an overrepresentation of polymorphic non-
synonymousmutations compared tofixedones (relative to the ratio polymorphic tofixed synonymous
changes). TheMK skew was calculated for each gene by obtaining the number of fixed and polymor-
phic changes, as well as a corresponding p-value using a previously described software143. Specifically,
the skew was calculated as log2(((Npoly+1)/(Spoly+1))/((Nfix+1)/(Sfix+1))) where Npoly and Nfix are
polymorphic and fixed non-synonymous substitutions respectively, while Spoly and Sfix refer to the
polymorphic and fixed synonymous substitutions respectively.
The final measure of selection I calculated was the average Ka/Ks ratio241 for each gene. The Ka/Ks
ratio, also known as the dn/ds ratio, is the ratio of nonsynonymous to synonymous changes, thereby
being a measure of positive (or negative) selection if there is an over- (or under)-representation of
nonsynonymous changes. I took the cleaned alignments of the above MK skew, extracting the pair-
wise sequences of P. malariae and P. malariae-like (and of P. o. curtisi and P. o. wallikeri). The
Ka/Ks values for each pair were calculated as per the method introduced in240 as implemented in
the Bio::Align::DNAStatistics module, averaging across samples within a species. Briefly, in the240
method, for a set of r codons in a gene, the proportion of synonymous (ps) and nonsynonymous(pn)
mutations are calculated as Sd/S andNd/N respectively, where Sd andNd are the sums of the number
of respective differences per codon (represented as the probability of the different mutational path-
ways that could result in the codon change), while S and N are the average number of synonymous
and nonsynonymous sites compared. Finally, from ps and pn we can calculate ds and dn (which give
the dn/ds ratio) using the formula: d = -(3/4) * loge(1-(4/3) * p).
Using existing RNA-Seq data from seven different life-cycle stages in P. falciparum203, sequencing
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reads were mapped against spliced gene sequences (exons, but not UTRs) from the P. falciparum
3D7 reference genome115 using Bowtie2179 v2.1.0 (-a -X 800 –x). Read counts per transcript were
estimated using eXpress v1.3.0294. Genes with an effective length cutoff below 10 in any sample were
removed. Summing over transcripts generated read counts per gene. Numbers were averaged for all
gametocyte stages and for all blood stages. Genes with no stage having 10 ormore reads were classified
as being expressed elsewhere. Genes in P. malariae and P. ovale were classified by their P. falciparum
ortholog’s maximum expression stage if the difference between the maximum expression stage and
the second highest stage was larger than the difference between the second and third highest stage,
otherwise the gene was classified as having no peak expression.
The GO term enrichment analysis was performed in R, using TopGO3. As a GO-database, the pre-
dicted GO terms from the P. falciparum 3D7 genes orthologous to the P. malariae and P. o. curtisi





B.1 Tree Sensitivity Testing
A number of conflicting phylogenetic trees of the Plasmodium genus have been published that differ
in their placement of P. ovale and P. malariae. The two most commonly reported topologies either
place P. ovale as a sister taxon to the rodentmalaria parasites14 (Tree A) or as an outgroup to P.malar-
iae andP. vivax 339,308,10 (Tree B). The same studies also placeP.malariae as either a distant outgroup
toboth the rodentmalaria parasites and theP. vivax clade14, or as beingmore closely related toP. vivax
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than P. ovale, with P. malariae thereby being a close outgroup to the primate infective clade308,10. A
recent study using draft genome sequences supported Tree B10, while the phylogenetic tree presented
here supports the Tree A topology (Chapter 1: figure 1.1 b).
To better understand the origin of these conflicting reports and to showcase how robust my present
analysis is, it is important to delve into the specifics of building the phylogenetic trees. As de-
scribed in the methods section in Appendix A, following orthologue assignment using BLASTP5
and OrthoMCL194, amino acid sequences of 1,000 core genes from 12 Plasmodium species (P.
gallinaceum38, P. falciparum115, P. reichenowi 259, P. knowlesi 266, P. vivax 20, P. cynomolgi 341, P.
chabaudi 256, P. berghei 106, and the four assemblies produced here) were aligned using MUSCLE94.
The alignments were cleaned using GBlocks343 with default parameters to remove non-informative
and gapped alignment columns. The cleaned non-zero length alignments were then concatenated.
This resulted in an alignment of 421,988 amino acid sites per species, the largest such alignment in-
cluding P. malariae and P. ovale used to date.
I determined the sensitivity of the tree topology to different parameters and tree-building algorithms,
I analysed the 1,000 core gene alignment used for the tree reported in Chapter 1 using a number of
different algorithms for phylogenetic inference. I utilized different tree-building softwares, includ-
ing RAxML332 (see below), PhyloBayes182 (using ratecat, cat, and uni models), and PhyML128 (LG
model with optimized site rates), all resulting in Tree A. I also used a number of different amino
acid substitutionmodels implementedwithinRAxML332 version 8.2.4., including JTT, LG, LG4M,
LG4X, GTR_unlinked, GTR, and DAYHOFF. All these models were tested with both CAT and
GAMMA site distribution rates. All substitutionmodels resulted in Tree A. In addition to this, I cal-
culated the optimal substitution model for each gene partition by running RAxML332 for each gene
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separately using all implemented substitutionmodels (minimumAIC).Using this substitutionmodel
optimized partitioned alignment I still generated Tree A. In order to determine whether the conflict-
ing topology would be a local optimum and was therefore not found using my other approaches, I
used Tree B as the starting tree using RAxML332 with a PROTGAMMAJTT substitution model.
This approach still converged on Tree A, indicating that my alignment does not support the Tree B
topology.
I performed bootstrapping as implemented within RAxML331, obtaining very good bootstrap sup-
port for all nodes (Chapter 1: figure 1.1 b). I also tested the RAxML ‘-f S’ parameter with a window
size of 10 and Tree A as the reference tree. This computes phylogenetic signal strengths for each site
in the alignment using a leave-one-out approach29. I used this output to filter away the top 5% of sites
that either strongly supported or strongly did not support Tree A. Using this trimmed alignment,
RAxML still produced Tree A, indicating that the phylogenetic signal is not driven by a small subset
of sites. Finally, I generated maximum likelihood trees using RAxML332 with an LG4X model for
additional GBlocks343 trimmed alignments consisting of 200, 500, and 3,298 orthologous genes (the
latter being all genes with 1-1 orthologs across all 12 species). All alignments resulted in Tree A with
good bootstrap support331.
I generated separate phylogenetic trees using RAxML for each gene in the 1,000 orthologous gene
alignment using their optimal substitutionmodels (see above). The consensus tree, as calculated using
RAxML332, of these gene-specific trees was Tree A. Most nodes were supported by the majority of
gene trees (>50%). The two nodes that differ between Tree A andTree B are less well supported. Only
25% of genes support the placement of P. malariae as the distant outgroup, while 38% support P.
ovale branching off with the rodent malaria parasites. While these percentages may seem low, a lower
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Table B.1: Effects of Different FilteringMethods on Resulting Phylogenetic Tree
TrimmingMethod Retained Amino Acids Phylogenetic Tree
Untrimmed 1,012,857 Tree C
GBlocks (default param.) 421,988 Tree A
GBlocks (liberal param.) 480,453 Tree C
TrimAl (nogap) 569,568 Tree C
TrimAl (strict) 450,571 Tree A
TrimAl (strictplus) 418,240 Tree A
proportion of genes support Tree B, namely only 19% of genes support the placement of P. ovale as
an outgroup to P. malariae and P. vivax, while 24% place P. malariae between P. ovale and P. vivax.
This shows that there is significant heterogeneity in the phylogenetic signal present and that these
particular nodes are difficult to resolve. I however show that a larger proportion of genes- and the
strongest signals when alignments of all genes are concatenated- support Tree A than support Tree B.
B.2 Alignment Effect on Tree Topology
In order to determine the effect of alignment filtering on the resulting tree, I constructed phylogenetic
trees usingRAxML,with the JTTamino acid substitutionmodel as inAnsari et al. 10 , using a number
of different alignment trimming strategies. This included no trimming, trimming using GBlocks343
default parameters (as above), loosening the GBlocks343 parameters by allowing some gapped sites (if
in less than 50% of sequences) and allowing smaller synteny blocks (down to 2 sites), as well as all three
TrimAl49 preset options (nogap, strict, strictplus), as used in Ansari et al. 10 (table B.1).
Of the six trimming methods, the three most stringent filtering methods all resulted in Tree A. The
other three trees labeled as ‘Tree C’ were identical to each other, not placing P. ovale as a sister taxon
with the rodent malaria parasites but still differing from Tree B by placing P. malariae in the same
position as Tree A. I was therefore unable to generate Tree B using my alignment. I show however
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Table B.2: Correlations of molecular evolution coef cients with number of sites discarded (Absolute) and proportion
retained (Retained)
HKAr HKAr Ka/Ks Ka/Ks MK (p-value) MK (p-value)
Comparison Absolute Retained Absolute Retained Absolute Retained
P. o. curtisi/ P. o. wallikeri 0.099* -0.066 0.324*** -0.478*** -0.179*** 0.025
P. malariae/ P. malariae-like 0.139** -0.088 0.312*** -0.365*** -0.178*** 0.090
P. falciparum/ P. reichenowi 259 0.094 -0.115* 0.454*** -0.554*** -0.194*** 0.107*
* p < 0.1, ** p < 0.01, *** p < 0.001
that the stringency of the alignment filtering can severely impact the placement of P. ovale. The more
stringent the filtering, the more likely P. ovale is placed as a sister taxon to the rodent malaria species.
Due to the impact that filtering has on determining the topology, I investigated whether the filtering
performed using GBlocks343 with default parameters is appropriate. I correlated (Pearson’s correla-
tion coefficient, r) the absolute number of sites removed (Absolute) and the proportion of the gene
sequence retained (Retained) with a number of molecular evolution selection coefficients (HKAr,
Ka/Ks, MK p-value) calculated for three species-species comparisons (Appendix A) for each gene.
Note that these statistics were calculated using variant calls directly frommapped reads, and so should
be relatively robust to alignment quality itself. Table B.2 shows the Pearson’s correlation coefficient
(r) and Bonferroni adjusted p-values for those correlations.
The table shows that there is a strong correlation between Ka/Ks and MK for all three comparisons
with the number of sites removed from each gene. The strong positive correlation for Ka/Ks indicates
that Ka/Ks is higher in genes where more of the gene sequence is removed. The strong negative corre-
lation for MK (p-value) indicates that the p-values tend to be lower (i.e. more likely to be significant)
in genes where more of the gene sequence is removed. Hence, genes that seem to be under significant
selective pressures tend to be filtered more heavily using GBlocks343. This is as expected, as Ka/Ks
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measures are increased by bad alignments. This means that the filtered alignment consists of a larger
proportion of neutrally evolving sites, which are more informative for phylogenetic inference.
I performed a GO term enrichment analysis3 by looking at the top 10% of genes that were filtered
either themost or the least byGBlocks343. I found a very strong enrichment for ‘GO:0006412: trans-
lation’ (p < 6 x 10−7) in the highly filtered genes, in addition to a number of ribosomal GO terms:
‘GO:0022625: cytosolic large ribosomal subunit’ (p <0.001) and ‘GO:0022627: cytosolic small ri-
bosomal subunit’ (p <0.001). I did not see enriched GO terms in the genes that were not filtered
much. Ribosomal genes are often either extremely conserved or highly variable, making them dif-
ficult to align and they were therefore filtered away by GBlocks343. Many of the genes that I filtered
awayusingGBlocks343, including ribosomal genes and surface antigens such asama1, were previously
included in a manually selected genelist that generated Tree B10.
The genes chosen by Ansari et al. 10 are enriched for those with poorer-quality sequence alignments
and showing signals of selection. My alignment filtering approach reveals a more robust signal for an
alternative topology (Tree A). In any case, I note that even without filtering, a comprehensive analysis
of one-to-one orthologs between Plasmodium species does not support Tree B, but agrees with our





The protocol used to collect human blood samples for patients with malaria attending Royal Dar-
win Hospital was approved by the Health Research Ethics Committee of Menzies School of Health
Research (HREC 09/83). Written informed consent was obtained from the patient.
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C.2 Sample Collection
Plasmodium malariae DNA used in this study was isolated from a symptomatic patient who pre-
sented to the Royal Darwin Hospital, Australia in March and April 2015 with a P. malariae para-
sitemia detected by blood film examination. At each episode, 5ml of EDTA blood was collected from
the patient for routine confirmation of malaria by microscopy, full blood count, urea and electrolytes
and liver function tests. An additional 10ml of EDTA blood was collected and leukodepleted by pas-
sage through aPlasmodipur filter (Euro-diagnostica)within 6 hours of collection. DNAwas extracted
from a 2ml aliquot of the filtered red blood cell pellet using the QIAampDNABloodMidi Kit (Qia-
gen) as per themanufacturer’s instructions, and stored at≈20◦C.Plasmodium species was confirmed
by PCR for P. vivax, P. falciparum, P.malariae and P. ovale parasites using amodified version of that
described by Padley et al. 265 so that each species was identified in a separate (non-multiplex) assay.
PCR for P. knowlesi parasites was undertaken using the method of Imwong et al. 151 .
C.3 Genome Sequencing
Whole genome sequencing was performed on both parasite isolates (PmUG01 and PmUG02) using
Illumina Standard libraries of 200–300bp fragments and amplification-free libraries of 400–600bp
fragments were prepared43 and sequenced on the Illumina HiSeq 2000 v4, the MiSeq v2, and the
X Ten according to the manufacturer’s standard protocol. Raw sequence data were deposited in the
European Nucleotide Archive (table C.1).
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Table C.1: Sequencing Information and Statistics
Characteristic PmUG01 PmUG02
Accession Number ERS1110316 ERS1110319
Origin Uganda Uganda
Infection Initial Recrudescence
Mean Coverage Depth 407x 136x
Coverage Range (Min-Max) 0x-7499x 0x-3519x
%Genome Covered at 1x 99.9% 99.9%
Sequencing Platform Illumina HiSeq X Ten, Illumina HiSeq X Ten,
IlluminaMiSeq v2 IlluminaMiSeq v2
Library Type Amplification Free Amplification Free
C.4 Genotyping of Single Nucleotide Variants
The two P. malariae samples (PmUG01, PmUG02) were mapped against the P. malariae reference
genome301 using SMALT(-y 0.8, -i 500). The resultingbamformatfilesweremerged, andGATK’s215
UnifiedGenotyper was used to call SNPs from the merged bam format files (table C.2). According to
GATK’s215 best practices, SNPs were filtered by quality of depth (QD >2), depth of coverage (DP
>20), mapping quality (MQ >30), and strand bias (FS <60). SNPs in low-complexity regions, as
determined by DUSTmasker227, were removed, as were sites with missing data in either of the two
samples, and SNPs within 50bp of each other to avoid SNPs in repetitive regions. Finally, only exonic
SNPs were retained. We performed the same SNP calling procedure by also including additional pre-
viously published samples301. Heterozygous sites were filtered out, while SNPs in non-coding regions
were retained (table C.3). Raw SNPs for PmUG01 and PmUG02 differ between table C.2 and table
C.3 due to calling SNPs from a merged bam format file instead of individually. Samples are therefore
pooled and SNP calling is performed on the population rather than on the individual. The conse-
quence of this is that if an individual sample has insufficient reads at a particular locus to reliably call
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Table C.2: SNPCalling Results speci cally for both PmUG01 and PmUG02
Sample ID PmUG01 PmUG02








*Sites atwhich the sample has no coverage. SNPcalling results as permapping the twoP.malariae
samples from the present clinical case against the PmUG01 reference genome 301. The raw SNPs
are the total number of SNPs that we called using GATK’s UnifiedGenotyper default parameters
in the different samples. Of these raw SNPs, some are exclusive to a certain sample (Private), are
identical to the reference genome (Ref), or there is no coverage and therefore no SNP call could
be made (Missing). The same information is also shown for the filtered SNPs, which were filtered
according to several different parameters.
a SNP there, that SNP might still be called if other samples in the population also have SNPs at that
location, as this increases the likelihood of a SNP at that position. The number of SNPs therefore
differs for identical samples depending on the population on which the SNP calling was performed.
C.5 Abundance Calculations
Using the relative SNP frequencies of the three haplotypes (R1, H1 andH2), the relative abundances
of the different haplotypes were calculated, assuming that the number of sequencing reads is propor-
tional to the abundance of the specific haplotype in the blood. Manually inspecting the SNP frequen-
cies by eye, H1 and R1 are approximately in a ratio of 35:65 and H2 to R1 is in a ratio of 15:85. In
both cases I ignore the third haplotype because I cannot ascertain its genotype. Ratio multiplication
yields a joint ratio of 975:2975:5525 for H2:H1:R1, simplifying to approximately 10:30:60. Explic-
itly, multiplying 85 by 65 (the R1 terms in both ratios) gives 5525 for the above joint ratio. We know
thatH1 is in a 35:65 ratio toR1, so the joint ratio term forH1 is 5525 x (35/65) resulting in 2975, and
198
Table C.3: SNPCalling Results for all P. malariae samples
Sample ID PmUG01 PmUG02 PmMY01 PmID01 PmMA01 PmGN01
Origin Uganda Uganda Malaysia Papua Indonesia Mali Guinea
Raw SNPs 200,679 191,766 252,172 187,327 198,029 503,175
Private 13,300 10,462 48,632 19,396 26,637 73,208
Ref 531,180 479,142 367,672 347,257 360,155 398,393
Missing* 5,468 23,064 65,361 107,355 95,973 38,609
Filtered SNPs 1,375 2,707 22,696 17,564 16,057 21,329
Private 0 414 8,816 5,939 6,079 10,343
Ref 49,647 47,868 27,521 32,762 34,205 29,021
Missing* 0 0 0 0 0 0
*Sites at which the sample has no coverage. SNP calling results as per mapping all P. malariae samples against the PmUG01 reference genome 301.
The raw SNPs are the total number of SNPs that we called using GATK’s UnifiedGenotyper default parameters in the different samples. Of these raw
SNPs, some are exclusive to a certain sample (Private), are identical to the reference genome (Ref), or there is no coverage and therefore no SNP call
could be made (Missing). The same information is also shown for the filtered SNPs, which were filtered according to several different parameters.
the same logic holds forH2 giving 975. The joint ratio is a way of representing the relative abundances
of the haplotypes but do not inform us on their absolute abundances in the infection.
Tri-allelic sites offer themost straightforward way of observing the ratio of the three haplotypes, how-
ever their number is low. Following SNP filtering (see above), the retained 13 tri-allelic sites were
spread evenly across the genome (table C.4). Assuming that the allele with the highest depth is R1,
the intermediate depth is H1, and lowest depth is H2, I calculated the mean depth for all three. This
yielded a ratio of ≈9:22:69 for H2:H1:R1 (table C.4). The ratio for PmUG02 was also calculated
(table C.5).
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Table C.4: Sequencing reads for the three haplotypes in tri-allelic sites in PmUG01
Genomic Location H2 haplotype reads H1 haplotype reads R1 haplotype reads
Chr1: 704,003 6 21 202
Chr2: 437,291 43 71 130
Chr7: 1,580,127 12 18 75
Chr9: 1,429,882 21 82 140
Chr10: 873,165 9 31 209
Chr11: 987,107 17 60 173
Chr11: 2,535,419 47 84 113
Chr12: 2,746,074 9 44 192
Chr12: 2,855,999 11 36 176
Chr12: 3,047,435 11 34 204
Chr13: 1,061,473 13 16 221
Chr14: 1,118,313 27 62 139
Total (Proportion) 265 (0.09) 650 (0.22) 2,091 (0.69)
Assuming that the lower-level genotype is H2, intermediate-level genotype is H1, and higher-level genotype is R1, the tri-allelic sites
have a certain number of sequencing reads confirming each of these three genotypes.
Table C.5: Sequencing reads for the three haplotypes in tri-allelic sites in PmUG02
Genomic Location H2 haplotype reads H1 haplotype reads R1 haplotype reads
Chr1: 704,003 16 0 7
Chr2: 437,291 20 4 0
Chr7: 1,580,127 18 0 9
Chr9: 1,429,882 25 0 0
Chr10: 873,165 23 0 0
Chr11: 987,107 19 8 1
Chr11: 2,535,419 11 0 7
Chr12: 2,746,074 15 0 1
Chr12: 2,855,999 9 0 1
Chr12: 3,047,435 6 4 4
Chr13: 1,061,473 8 0 5
Chr14: 1,118,313 26 0 0
Total (Proportion) 212 (0.81) 16 (0.06) 35 (0.13)




D.1 Sample Collection and Preparation
From 2010 to 2013, patients with uncomplicated P. falciparum malaria were enrolled in a parasite
clearance rate studies6,7,15 in three provinces in Cambodia. The three provinces were selected based
on the level of artemisinin and piperaquine resistance in the local parasite population: Pursat (com-
mon), Preah Vihear (emerging), and Ratanakiri (uncommon)8. Informed consent was obtained in
writing from adult patients or by a guardian in the case of child patients. Protocols were approved
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by the Cambodian National Ethics Committee for Health Research and the National Institute of
Allergy and Infectious Diseases Institutional Review Boards. The protocols are registered with Clin-
icalTrials.gov, under the numbers NCT00341003, NCT01240603, and NCT01736319.
Whole blood samples were obtained from patients at enrolment. The samples were then leukocyte-
depleted using theCF11 filtrationmethod355, followed byDNA extraction using theQIAampDNA
Blood Kit (Qiagen, Valencia, CA). Relative ratios of human to Plasmodium DNA were ascertained
using a Qubit instrument (Invitrogen, Carlsbad, CA) based fluorescence analysis, as well as through
the use of a multi-species quantitative PCR run on the Roche Lightcycler 480 II system209.
D.2 In-vitroDrug Assays
The in-vitro drug assays using a standard 72hr SYBR Green I-based stain-based method209 were per-
formed for chloroquine and mefloquine on parasites freshly obtained from patients. The IVART
software198 was used to determine IC50 values by fitting the drug concentration-growth inhibition
data. Throughout these assays, the P. falciparum 3D7 line was used as a quality control.
D.3 Whole Genome Sequencing
Samples with low levels of human contamination (<80% human) and sufficient DNA (>50ng) were
selected for whole genome sequencing. Sequencing was performed on the Illumina HiSeq platform
following the manufacturer’s standard protocols28, producing 100bp paired-end sequencing reads.
Approximately 1Gbp of read data was generated per sample.
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D.4 SNP Calling and Filtering
Single nucleotide polymorphisms (SNPs) were typed across the P. falciparum genome in positions in-
cluded in thehigh-quality SNP set established via theMalariaGENcommunityprojectV6. SNPswere
extracted for samples with mefloquine IC50 values and filtered as follows. In addition to the filtering
criteria defined in the MalariaGEN community project V6 (flag: “PASS”), the following filtering cri-
teria were used to remove alignment artefacts and low-confidence genotype calls: insertions/deletions;
non-coding SNPs; SNPs with >2 alleles; SNPs with >20% missingness; SNPs with minor allele fre-
quency less than 3%; SNPs in plastids. Prior to the filtering, heterozygous calls weremanually recoded
as missing genotype calls.
D.5 Genome-Wide Association Study (GWAS)
The GWAS analyses were performed using a linear mixed model implemented in FaST-LMM199 ver-
sion 2.06. I performed the GWAS with the log base 10 transformed mefloquine IC50 values as the
continuous dependent variable. I corrected for population structure using a relationship matrix221,
calculated froma subset of unlinked SNPs (inwindows of 100 SNPs, shifted forward by 10 SNPs each
time, removing one from each pair of SNPs with linkage disequilibrium >0.3) using PLINK version
256,287 (option: –indep-pairwise 100 10 0.3). I also always included the province of origin for each
sample as a covariate (encoded as 1, 2 and 3 for Pursat, Preah Vihear, andRatanakiri, respectively). To
correct for multiple testing, I corrected the p-value threshold for genome-wide significance using the
Bonferroni method, yielding a threshold of p < 4 x10−6 for both phenotype datasets. I also utilized
a second, less stringent, suggestive threshold of p < 1 x10−4 to look at other SNPs highly associated
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with the phenotype. Depending on theGWAS, additional covariates were included, CNVor F1068L
mdr1 SNP presence/absence, in each case, I encoded the wild type as ‘1’, the alternate as ‘2’ and miss-
ing data as ‘0’.
D.6 Copy Number Amplification Calling
Copy number amplification calling was performed by Richard Pearson from the Wellcome Sanger
Institute. Two orthogonal methods were used to determine presence/absence of mdr1 and plas-
mepsin 2/3CNVs: a coverage-basedmethod and amethod based on position and orientation of reads
near discovered duplication breakpoints. Briefly, a coverage-based hidden Markov model was used
to identify potential copy number amplifications and their boundaries. Breakpoints of duplications
around mdr1 and plasmepsin 2/3 were manually inspected by identifying face-away read pairs span-
ning the supposedbreakpoints. If face-away readpairs confirmed the predictionof the hiddenMarkov
coverage-basedmodel, then aCNVwas called as present. If no coverage was present in the breakpoint
region, then the CNV genotype was called ‘missing’.
D.7 Miscellaneous
All the SNP filtering and GWAS analyses were run in the Juptyer notebook suite169. Downstream
analysis was performed using R version 3.3.2 within RStudio271. The beeswarmR package was used




E.1 Spatial & Geographical Trends in Chloroquine Resistance
Originating from three Cambodian provinces (Pursat, Preah Vihear, and Ratanakiri), 391 clinical
P. falciparum isolates collected between 2010 and 2013 were phenotyped for chloroquine (CQ) 50%
inhibitory concentration (IC50) (table E.1). I observed significant differences inCQ IC50 between the
different provinces, with Pursat having a significantly highermeanCQ IC50 of 456 nmol/L compared
to 355 nmol/L in PreahVihear (t-test: p < 0.005) and 213 nmol/L inRatanakiri (p < 5 x10−16) (figure
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Table E.1: Sample Origin Information
Year Pursat Preah Vihear Ratanakiri Total
2010 48 0 39 87
2011 79 59 49 187
2012 22 33 22 77
2013 14 14 12 40
Total 163 106 122 391
E.1 a). The mean CQ IC50 value in Preah Vihear is also significantly higher than in Ratanakiri (p <
5 x10−9). I also noticed significant increases in CQ IC50 in all provinces from the start of collection
to the end of the collection (figure E.1 b). In Pursat, the mean CQ IC50 increased from 447 nmol/L
in 2010 to 703 nmol/L in 2013 (t-test: p < 0.05). In Preah Vihear, it increased from 294 nmol/L in
2011 to 621 nmol/L in 2013 (p < 0.0005), while in Ratanakiri it went from 202 nmol/L in 2010 to
409 nmol/L in 2013 (p < 0.05).
E.2 GWAS of Chloroquine Resistance
To better understand the genetic basis underpinning the differences in CQ levels, whole genome se-
quencing was performed on all samples with CQ IC50 values. In order to identify genetic markers
that may be associated with the different levels of CQ and MQ resistance, I performed a GWAS for
the 391 P. falciparum samples with CQ IC50 values.
Beginning with the samples with CQ IC50 values, following a variety of filtering steps (Appendix D),
I identified 12,603 high confidence SNPs in coding regions that had a non-reference genotype call in
at least 12 samples (3% of all samples). I associated these 12,603 SNPs with CQ log(IC50) values as a
continuous dependent variable using the fastLMM software199, which employs a linear mixedmodel
algorithm. I controlled for confounding effects by treating the province of origin as a covariate and
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Figure E.1: Differences in chloroquine CQ IC50 between different provinces in Cambodia (a) and across the years of
collection within each province (b). Each point represents one clinical P. falciparum isolate, colored either by province
of origin (a) (seemap) or by pfcrt K76 genotype (b) (see legend). The number of samples per province is indicated above
(a). Themap shows the respective geographical location of the three provinces within Cambodia. The horizontal lines
indicate themedian (bold) and interquartile range (thin) of the respective distributions. Blue bars indicateWelch two-
sample t-tests performed between two distributions, with stars indicating the level of signi cance of that comparison (see
legend).
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population structure (as measured by genetic similarity across samples) as a random effect.
TheGWAS yielded a very strong signal onChromosome 7, with all the SNPs that passed the genome-
wide threshold for significance (Bonferroni-adjusted p-value < 4 x10−6) lying within the pfcrt gene
(PF3D7_0709000) (figure E.2 a)(table E.2). The SNPmost strongly associated with CQ log(IC50) is
theK76Tmutation, currently used as themost sensitivemarker ofCQ resistance81. Two other signif-
icant SNPs (Q271E andA220S) are known to be commonly associatedwith theK76Tmutation103,90
and are thought to be required in the mutational pathway to achieve chloroquine resistance337. I ob-
served a significant difference in CQ IC50 between K76 wild type and mutant parasites (t-test: p <
1.4 x10−9) (figure E.2 b), but still note a striking level of variance in the CQ IC50 values of K76T car-
rying parasites (figure E.2 b). Indeed, the differences in the level of CQ resistance between the three
provinces and across time seem to be independent of the K76Tmutation (figure E.1 b).
The second and third most significant SNPs in the GWAS analysis code for amino acid changes just
upstream of the K76Tmutation (N75D,M74I) (figure E.2 a& table E.2). These SNPs encode a hap-
lotype unique to Cambodia known as CVIDT (from amino acid positions 72-76)197, distinguishing
it from the wild type CVMNK haplotype. The most common haplotype besides CVMNK is the
CVIET haplotype375, which is the CQ resistant haplotype that initially spread from Southeast Asia
toAfrica12. TheCVIEThaplotype is formed bymultiplemutations in the 74 and 75 codon positions
that are called as an indel using automated genotype callers, resulting in missing genotype calls for the
SNPs at these positions due to filtering out indels. Encoding this CVIET haplotype as a biallelic SNP,
I find that it also passes the suggestive threshold I employed (figure E.2 a & table E.2). Comparing the
CQ IC50 values of CVIDT and CVIET samples, I find a significantly higher level of CQ IC50 in











































































































































































































































































































































































































































































































































































Figure E.2: a) GWAS analysis using chloroquine log(IC50) as the dependent variable. Each point corresponds to a SNP,
coloured by the chromosome it is located on and they are ordered by their position on the chromosome. The dotted red
line indicates the genome-wide threshold for signi cance (4 x10−6) and the dotted green line is a more lenient suggestive
threshold (1 x10−4). The SNPs exceeding the signi cance threshold are labeled by the gene they are found in and the
amino acid alteration they code for. b) Difference in CQ IC50 between parasites without (black) andwith (grey) the K76T
mutation in pfcrt. c) Difference in CQ IC50 between parasites with a CVIDT (magenta) and a CVIET (blue) haplotype
for pfcrt. The horizontal lines indicate themedian (bold) and interquartile range (thin) of the respective distributions.
Blue bars indicateWelch two-sample t-tests performed between two distributions, with stars indicating the level of
signi cance of that comparison (see legend). d) Pie charts of the differential distribution of CVIET (blue) and CVIDT
(magenta) pfcrt haplotypes between the three different provinces. Number of samples shown below the pie charts.
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tionally, the relative ratio of these two haplotypes to each other differs substantially between the three
sampled provinces (figure E.2 d), with Pursat having an overrepresentation of CVIET parasites and
Ratanakiri having a comparatively high proportion of CVIDT samples. This therefore mirrors the
overall differences in chloroquine resistance between the different provinces.
E.3 Additional GWAS Analysis Identifies NovelMarker
Following the observation that only SNPswithin pfcrt passed the genome-wide significance threshold,
I wanted to investigate whether there are any novel markers of chloroquine resistance in other parts of
the genome. I redid the GWAS using the K76T SNP genotype as an additional covariate. Doing this
however, the signal obtained in the original GWAS disappears, with no SNPpassing the genome-wide
significance threshold (figure E.3 a).
Differences in high-end CQ IC50 values being more pronounced on a linear scale compared to a log
scale, I performed a GWAS with CQ IC50 as the dependent variable, instead of CQ log(IC50). Inter-
estingly, I do not observe a significant SNP in the pfcrt gene, showing that the significance of theK76T
mutation is visible onlywhen looking on a log-transformed scale (table E.3&figure E.3 b). I identified
three potential SNPs of interest, one of which passes the genome-wide threshold for significance. It is
a nonsynonymous SNP (D2658Y) in a dynein heavy chain protein gene (PF3D7_1202300). Samples
with this particular mutation and K76T seem to have a significantly higher CQ IC50 than samples
that only have K76T (figure E.4 a). It is found in samples from all three Cambodian provinces, but
has increased dramatically in frequency across the four years of samples, with almost a quarter of sam-
ples possessing this SNP in 2013 (figure E.4 b). This doesn’t seem to be due to a clonal expansion, as
the 19 samples with this mutation do not seem to be related genetically (figure E.4 c), and the flanking
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Figure E.3: GWAS analyses using (a) the K76T genotype in pfcrt as a covariate and (b) the linear CQ IC50 as the dependent
variable. In both analyses, I controlled for population structure and sample origin. Each point corresponds to a SNP,
coloured by the chromosome it is located on and they are ordered by their position on the chromosome. The dotted
red line indicates the genome-wide threshold for signi cance ( p < 4 x10−6) and the dotted green line is a more lenient
suggestive threshold ( p < 1 x10−4).
212
Table E.3: SNPsmost strongly associated with linear CQ IC50
Chromosome Position Gene ID Gene Description N or S Alteration p-value
12 129,899 PF3D7_1202300 Dynein heavy chain N D2658Y 3.5 x10−6
5 202,752 PF3D7_0504800 Conserved Plasmodium protein N G661R 1.2 x10−5
10 372,716 PF3D7_1009100 Conserved membrane protein N L66F 2.0 x10−5
Table E.4: SNPs that pass either the Bonferroni-adjusted p-value threshold (p < 4 x10−6) or themore lenient suggestive
threshold (p < 1 x10−4) are listed in order of increasing p-value. The table shows chromosome and nucleotide position of
the SNP, the ID and description of the gene in which the SNP occurs, whether it is a synonymous (S) or nonsynonymous
(N) mutation, what amino acid alteration it encodes if it is nonsynonymous, and the p-value associated with the SNP.
regions around the SNP are quite diverged between the samples (figure E.4 d). This therefore seems
like an interesting candidate SNP to look further into, though it is unclear how a SNP in a dynein
heavy chain protein gene would increase a parasite’s CQ resistance from a functional perspective.
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Figure E.4: a) Difference in CQ IC50 betweenwild type parasites (black), those with the K76Tmutation in pfcrt (grey)
and those with both the K76Tmutation and the D2658Y SNP in the dynein heavy chain gene (PF3D7_1202300) (yel-
low). Numbers above plot indicate sample numbers. The horizontal lines indicate themedian (bold) and interquartile
range (thin) of the respective distributions. Blue bars indicateWelch two-sample t-tests performed between two distri-
butions, with stars indicating the level of signi cance of that comparison (*** = p < 0.0005). b) Percentage of samples with
the D2658Y SNP in PF3D7_1202300 across the four years of sampling. Numbers above the plot indicate the number
of samples. c) Amultidimensional scaling plot for all 391 samples with CQ IC50 values, based on all 12,603 SNPs called
genome-wide. Yellow dots represent samples with the D2658Ymutation. d) Flanking regions around PF3D7_1202300,
showing the genotype of the 391 samples (rows) for all SNPs within 100kb of either side of PF3D7_1202300. The geno-
types are either reference (blue), alternate (red), or missing (white). The position of PF3D7_1202300 is indicated with a




F.1 Data and Filtering
The MalariaGEN community project V6 (Pf6) dataset was harnessed for this analysis. Single nu-
cleotide polymorphisms (SNPs) were typed across the P. falciparum genome in positions included
in the high-quality SNP set established via the MalariaGEN community project V6. In addition to
the filtering criteria defined in the MalariaGEN community project V6 (flag: ‘PASS’), the following
filtering criteria were used to remove alignment artefacts and low-confidence genotype calls: inser-
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tions/deletions; non-coding SNPs; SNPs with >2 alleles; SNPs with >20% missingness; SNPs with
minor allele frequency less than 3%; SNPs in plastids. Prior to the filtering, heterozygous calls were
manually recoded as missing genotype calls.
F.2 Antimalarial Drug Resistance Phenotype Data
The in-vitro drug assays using a standard 72hr SYBR Green I-based stain-based method209 were per-
formed for chloroquine, piperaquine, and mefloquine on parasites freshly obtained from patients.
The IVART software198 was used to determine IC50 values by fitting the drug concentration-growth
inhibition data. Throughout these assays, the P. falciparum 3D7 line was used as a quality control.
The artemisinin parasite clearance half-life (PCt1/2) phenotype data was obtained from the TRAC
study (NCT01350856) and the US National Institutes of Health study (NCT00341003 and
NCT01240603). In brief, during treatment, parasite densities were estimated by counting parasitized
erythrocytes in blood smears from peripheral blood samples taken at 0, 4, 6, 8 and 12 h after patient
admission and then every 6h until two consecutive counts were negative. PCt1/2 estimates were com-
puted from these parasite counts, by fitting a statistical model104 using the Parasite Clearance Estima-
tor developed byWWARN.
F.3 Haplogroup Classification
Haplogroup classificationwas performed by JacobAlmagroGarcia from the BigData Institute inOx-
ford. Both pfcrt andmdr1 genes were classified into haplogroups using the filtered Pf6 MalariaGEN
data set (www.malariagen.net). Samples with amissing genotype call in either gene were not classified
for that gene respectively. Haplogroups were then determined using all nonsynonymous mutations
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in the coding regions of the genes. Thus, genes differing by one or more nonsynonymous mutations
were categorized into separate haplogroups.
F.4 Copy Number Variation Calling
Copy number amplification calling was performed by Richard Pearson from the Wellcome Sanger
Institute. Two orthogonal methods were used to determine presence/absence of mdr1 and plas-
mepsin 2/3CNVs: a coverage-basedmethod and amethod based on position and orientation of reads
near discovered duplication breakpoints. Briefly, a coverage-based hidden Markov model was used
to identify potential copy number amplifications and their boundaries. Breakpoints of duplications
around mdr1 and plasmepsin 2/3 were manually inspected by identifying face-away read pairs span-
ning the supposedbreakpoints. If face-away readpairs confirmed the predictionof the hiddenMarkov
coverage-basedmodel, then aCNVwas called as present. If no coverage was present in the breakpoint
region, then the CNV genotype was called ‘missing’.
F.5 Miscellaneous
All the SNP filtering was performed in the Juptyer notebook suite126. Downstream analysis was per-
formed using R version 3.3.2 within RStudio271. The beeswarmR package was used for plotting the
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